2018 DIRECTORY OF KOREAN PHARMACEUTICAL … · capabilities of Korean drug manufacturers, and has improved export conditions, including inspection exemptions of local drug manufacturing

2018 DIRECTORY OF KOREAN PHARMACEUTICAL INDUSTRY

2018

No Company Page

28 Elyson Pharmaceutical Co. Ltd. 06829 GC Pharma 07030 Green Cross Cell Corporation 07431 GUJU PHARM. CO. LTD. 077

H~K32 Hana Pharm Co., Ltd 07933 HanAll Bio Pharma 08134 HANDOK Inc. 08335 Hankooksinyak Pharm. Co., Ltd. 08636 HANLIM PHARM. CO., LTD. 08837 Hanmi Pharm. Co., Ltd 09038 Han Wha Pharma Co., Ltd. 09239 Hawon Pharmaceutical Corporation 09440 Humedix Co., Ltd 09641 HUONS CO., LTD. 09842 Hyundai Pharm 10043 ICURE Pharmaceutical Inc 10244 IKSU PHARMACEUTICAL CO., LTD. 10445 ILDONG Pharmaceutical 10746 Ilsung Pharmaceuticals 10947 IL-YANG PHARM. CO., LTD. 11148 ISU Abxis Co., Ltd. 11549 JEIL Pharmaceutical Co., Ltd. 11750 JINYANG PHARM. Co., Ltd. 11951 JW Pharmaceutical Corporation 12152 KMS Pharm Co., Ltd. 12353 Kolmar Korea Co.,Ltd. 12554 Kolon Pharma 12755 Korea Arlico Pharm Co.,Ltd. 129

No Company Page

Regular Members

A~G1 Ahngook Pharmaceuticals Co., Ltd. 0102 AJU PHARM CO., LTD. 0123 Astellas Pharma Korea 0144 BC World Pharm. Co., LTD. 0165 Binex Co., Ltd. 0186 Boryung Pharmaceutical Co., Ltd. 0207 CHO-A PHARM.CO.,LTD. 0228 Chong Kun Dang Pharmaceutical Co. 0249 CJHealthCare Corp. 027

10 CMG Pharmaceutical Co., Ltd. 03011 CORESTEM Inc. 03212 CTCBIO, Inc 03413 Daewoo Pharmaceutical Co., LTD 03614 Daebong LS Co., Ltd 03815 DAE HWA PHARMACEUTICAL CO., LTD. 04016 DAEWON Pharm. Co., Ltd 04217 Daewoong Pharmaceutical Co., Ltd. 04418 DAI HAN PHARM. CO., LTD. 04619 Daiichi Sankyo Korea 04820 Dalim BioTech Co., Ltd. 05021 DHP KOREA CO.,LTD. 05222 DongKoo Bio&Pharma Co., Ltd. 05523 Dongkook Pharmaceutical Co., Ltd. 05724 Dongkwang Pharm. Co., Ltd. 05925 DONGWHA PHARM 06126 Dong-A ST(Science & Technology) 06327 Dongsung Bio Pharm 066

No Company Page

56 Korea Otsuka Pharmaceutical Co.,Ltd. 13157 KOREA PHARMA CO., LTD. 13358 Korea Prime Pharm. Co., Ltd. 13559 KOREA UNITED PHARM.INC. 13760 Korea Vaccine 13961 KOREAN DRUG CO., LTD. 14162 KUKBO SCIENCE 14363 Kukje Pharma Co., Ltd. 14564 Kwang Dong Pharmaceutical Co.,Ltd. 14765 Kyongbo Pharmaceutical Co., Ltd. 14966 Kyowa Hakko Kirin Korea Co., Ltd. 15167 Kyung Dong Pharm. Co., Ltd. 15468 Kyung Nam Pharm. Co, Ltd 156

M~Y69 Medica Korea Co., Ltd. 15870 MG Co., Ltd. 16071 MOTHER'S PHARMACEUTICAL CO., LTD. 16272 Myung In Pharm. Co., Ltd. 16473 Myung Moon Pharm. Co., Ltd. 16674 Pharmbio Korea Co., Ltd 16875 PMG Pharm 17076 Richwood Pharmaceutical Co., Ltd. 17277 RP Bio 17478 SamChunDang Pharm. Co., Ltd. 17679 SAMA PHARM CO.,LTD. 17880 Samik Pharm. Co., Ltd. 18081 Samil Pharm. Co., Ltd. 18282 Samjin Pharmaceutical Co., Ltd. 18483 Samyang Biopharmaceuticals Corporation 186

No Company Page

84 Seoul Pharma Co.,Ltd. 18885 SHIN POONG PHARM. CO., LTD. 19086 SINSIN Pharmaceutical Cp., Ltd. 19287 SK Chemicals Co., Ltd. 19488 SS Pharm.Co.,Ltd. 19689 Suheung Capsule. Co., Ltd. 19890 Taejoon Pharmaceutical 20091 Taiguk Pharm. co., Ltd. 20392 THERAGEN ETEX CO., LTD. 20593 Union Korea Pharma Co., Ltd. 20794 WHITE LIFE SCIENCE 20995 WhanIn Pharm Co., Ltd. 21196 Won Kwang Pharm. Co., Ltd 21397 WOORIDUL PHARMACEUTICAL LTD. 21598 YOOYOUNG PHARMACEUTICAL 21799 Yuhan Corporation 219

100 Yuyu Pharma., Inc. 221

Associated Members

101 C&R Research Inc. 223102 CrystalGenomics, Inc. 225103 GL PharmTech 227104 Medi Help line 230105 Pharmicell Co., Ltd. 231

Table of Contents

Greetings .................................................................................................................................................................... 004

Overview of the Korean Pharmaceutical Industry ........................................................................................... 005

Information of Pharmaceutical Companies ....................................................................................................... 009

- Regular Members

- Associated Members

KPBMA Member Company List ............................................................................................................................ 233

2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY2 3

Greetings

Greetings from Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA). This is Jung-Hee Lee, Chairman of the Directors Board.

Representing about 200 KPBMA member companies, I would like to express my sincere gratitude to all the relevant readers who have interest in Korean pharmaceutical industry.

Korean pharmaceutical companies are manufacturing quality medicines in compliance with ICH guidelines as well as Pharmaceutical Affairs Act in Korea, in order to provide consumers with safe medicines.

As a result, the Ministry of Food and Drug Safety in Korea was able to join PIC/S in 2014, and became the regular member of ICH in 2016.

Even with short history of 120 years, the Korean pharma industry was able to develop 29 new drugs(NCEs) and as of the end of 2016, 82 incrementally modified drugs was developed by Korean pharma companies. As for clinical trials, Seoul is the best city of all city level in terms of the number of clinical trials. Biopharmaceuticals are other area that Korea is making real result. Following the recent trend, efforts to combine the advanced IT technology with new drug development is being made to usher in the 4th industrial revolution.

The purpose of KPBMA Directory is to provide all related people from government, international organization and companies oversea with precise information regarding Korean pharma companies, thus to facilitate co-operation. Following the 2016 version, the KPBMA spared no efforts to list precise and recent information of each Korean company to highlight the strength of KPBMA member companies.

I hope that this directory can be helpful to promote the cooperation between Korean companies and readers. As for the KPBMA, we will make a promise to continue to update the information of the directory.

Thank you.

Jung-Hee Lee, Chairman of the Directors Board, KPBMA

Overview of Korea’s Pharmaceutical IndustryThe market size of Korea’s pharmaceutical industry was USD 18.7 billion (as of 2016), making up 1.8% of

approximately USD 1.1 trillion of the global pharmaceutical market, 1.2% of domestic GDP, and 4.3% of domestic manufacturing GDP. During the same period, domestic pharmaceutical production was USD 16.2 billion with export and import volumes accounting for USD 3.1 billion and USD 5.6 billion respectively, while domestic biopharmaceutical production was USD 1.73 billion, composing 9.2% of the domestic pharmaceutical market. As of 2016, there were 737 pharmaceutical companies who manufactured drug products. Of these, 367 manufactured finished drug products, 204 manufactured drug substance, and 379 manufactured quasi drugs. Average revenue for publicly-traded pharmaceutical companies was USD 143 million, while 45 drug manufacturers generated USD 100 million or more in revenue and two manufacturers (Yuhan Corporation and Green Cross) recorded USD 1 billion or more (as of 2016).

Market Size (Unit: USD million, %)

2012 2013 2014 2015 2016

Market size (yearly growth rate) 17,060 (0.32) 17,648 (0.51) 18,395 (0.24) 16,992 (-0.69) 18,729 (12.94)

Production 13,943 14,955 15,593 15,004 16,212

Export 2,077 2,128 2,416 2,946 3,121

Import 5,194 4,821 5,219 4,948 5,638

Trade balance -3,117 -2,693 -2,803 -2,002 -2,517

Pharmaceutical Production and Quality Management Capacities

Equipped with advanced production and quality management capacities, Korean pharmaceutical manufacturers are producing high quality pharmaceutical products. Additionally, efforts by domestic drug manufacturers to improve Good Manufacturing Practice since the mid-2000’s, have allowed them to build cGMP facilities compliant with what are required by major countries such as the U.S.

As regulatory and quality management systems for drugs have improved with the sincere efforts of regulatory and private agencies, Korean drugs are now receiving great confidence as quality drugs not only from countries in Southeast Asia, Central and South America, but also from those in Europe and the U.S.. Furthermore, recent efforts by the Ministry of Food and Drug Safety (MFDS) to introduce Quality by Design (QbD) are leading Korea’s pharmaceutical industry to establish a production infrastructure that will meet the requirements that are expected of advanced countries.

Korea also boasts world-class drug regulatory systems. The MFDS having joined the Pharmaceutical Inspection Cooperation Scheme (PIC/s) in May, 2014, is an international testament to the quality and management


capabilities of Korean drug manufacturers, and has improved export conditions, including inspection exemptions of local drug manufacturing plants located in the PIC/s member nations. In addition, gaining Membership to the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) in November, 2016, has proved that the level of drug regulatory systems in Korea is on par with that of advanced countries, including the U.S., Japan and the EU, and has earned Korea elevated standing as one of the countries that is leading drug regulatory policies. This is expected to be a great stepping stone for Korea to advance in the global market as it will create favorable circumstances conducive to signing mutual agreements with other national regulatory authorities and discussing exemptions required for gaining marketing approvals.

Investments in R&DDomestic drug manufactures are well aware that the pharmaceutical industry is technology-intense, thus they

have been making greater investments to develop new drugs.

The average spending on R&D in 2016 by drug manufacturers was 6.0% of sales revenues, and that figure reached 8.9% in publicly-traded drug manufacturers. In particular, Innovative Pharmaceutical Companies (selected by the Ministry of Health and Welfare) spent 11.7% of revenue, far exceeding the 3.7%-mark recorded in the manufacturing sector. The R&D budget of drug manufacturers in 2016 hit USD 1.156 billion with an annual average increase of 6.7% over the previous five years.

Development of New DrugsSince the development of Korea’s first drug product “Sunpla Injection (cancer treatment)” in 1999, 29 new drugs

have been developed in Korea as of March, 2018. With an average annual roll-out of 1.7 new drugs from 1999 to 2017, Korea is gradually becoming a global pharmaceutical powerhouse. Furthermore, there are close to 20 drug products that have established a foothold in major global pharmaceutical markets including the U.S. and Europe. And starting with Amosartan (hypertension treatment) in 2009, 83 Incrementally Modified Drugs (IMD) had been developed as of the end of 2016.

BiopharmaceuticalsFour out of the seven globally commercialized stem cell therapy products were developed in Korea and they

include the world’s first stem cell therapy, Hearticellgram-AMI (Pharmicell). Additionally, a hemophilia treatment NBP601 (AFSTYLA) developed by SK Chemical, became the first new domestically-developed biopharmaceutical

product that obtained a marketing authorization from the US FDA in 2016. And it only took the world’s first antibody biosimilar Remsima by Celltrion four years to exceed the USD 1 billion mark in aggregate export revenues since its launch in 2013.

Vigorous Global Market EntryKorean drug manufacturers equipped with a global competitive edge in new drug development and drug

formulation technologies, production management facilities and quality control practices are successfully entering markets around the world.

In 2016, Korean-manufactured drug products reached markets in 188 countries, and total export volume was USD 3.121 billion which was an 8.6% increase from the year before. Thus, the Korean pharmaceutical industry had embarked on a high growth trajectory with an annual average growth rate of 13.6% between 2011 and 2016.

Furthermore, 27 drug manufacturers opened 69 local offices, and 18 pharmaceutical companies conducted 64 clinical trials overseas (as of 2014).

In 2015 and 2016, when technology exports occurred in earnest, Korean drug manufacturers signed 25 technology export contracts with multinational pharmaceutical companies, and in 2017 alone, eight technology export contracts were concluded with their total volume reaching close to USD 1.23 billion.

Drug Export Volume by Export Destination (Unit: USD 1,000, %)

Ranking Export destination2016

ChangeFinished drug product Source material Sum

1 Japan 158,180 304,626 462,806 -6.6

2 Croatia 397,830 28 397,858 356.1

3 Ireland 2,771 228,835 231,606 75.1

4 China 112,084 95,938 208,022 23.8

5 Vietnam 158,980 23,472 182,452 31.6

Total 1,711,325 1,409,072 3,120,397 5.9

Government’s Policies to Promote and Support the Pharmaceutical Industry

In December 2017, the government announced the Second Comprehensive Plans to Promote and Support the Pharmaceutical Industry (Second Comprehensive Plans) to help make the pharmaceutical and healthcare sectors as a whole, leading industries that will drive innovative growth.


2018 DIRECTORY OF KOREAN PHARMACEUTICAL INDUSTRY

Information of Pharmaceutical

Companies

When the new administration took office in May 2017, it identified pharmaceuticals as a future-oriented new industry in its National Initiatives that can create high added value, and presented the Second Comprehensive Plans in which a blue print detailed how to further grow the pharmaceutical industry in the future.

The Second Comprehensive Plans, with their vision of “Catapulting into a Pharmaceutical Powerhouse that Offers Health and Jobs to the Public,” are composed of four specific areas, namely, R&D, employment opportunities, export support measures and streamlining of rules and regulations.

1. Ways to strengthen R&D efforts to improve new drug development capacities

- Foster promising areas for the next generation that will lead the Fourth Industrial Revolution, and sophisticate support mechanisms that will improve new drug development success rates while increasing pharmaceutical R&D investments that are designed to benefit the public

2. Ways to foster professional talent and help start businesses aimed at securing future growth engines in the pharmaceutical industry

- Build a pool of pharmaceutical talent in different disciplines, create quality jobs, and lay the foundation for new businesses that will help increase the number of pharmaceutical and biopharmaceutical growth drivers.

3. Seek ways to reinforce export support systems based on field demands

- Lay the foundation to help domestically-manufactured drug products enter global markets, help domestic pharmaceutical companies strengthen export capacities, and support domestic drug manufacturers in order to overcome entry barriers to respective markets.

4. Find ways to lay the foundation for the domestic pharmaceutical industry to help Korea become a leading pharmaceutical country.

- Help boost private investments by offering policy loans, tax cuts, and strengthening institutional foundations to help develop more new drugs, while simultaneously implementing rules and regulations that can improve the pharmaceutical ecosystem.

2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY8

RepresentativeJIN AUH(President & CEO)

Headquarter Address613 Siheung-daero, Yeongdeungpo-gu, Seoul 07445, Korea

Foundation DateSep. 03. 1959

Research FocusIMDs, NCEs and Bio drugs

Total Staff510 persons

Representative Phone82-2-3289-4200

Webwww.ahn-gook.com

Contact PersonJay Kim

Contact Phone82-2-3289-4359

Contact [email protected]

Summary (1 Million Won)

Fiscal Year 2015 2016 2017

Sales 180,435 100,529 175,000

R&D Expenditure 15,875 15,467 13,282

Capital 175,667 144,554 176,178

Financial Figures

Ahngook is a fully integrated pharmaceutical company dedicating to development, manufacture, marketing, and sales of good medicines in Korea since 1959. And currently Ahngook has a strong presence in Respiratory, Gastroenterology, and Cardiovascular. For the future growth Ahngook is concentrating its R&D efforts on Bio products as well as various chemical products.

Ahngook is dreaming to be a global company. It has its own entity in China and is trying to expand its presence outside Korea. Ahngook has entered several out-license agreements and a number of export agreements with many overseas partners. Ahngook has many differentiated products and it is flexible for collaboration and business models to ensure for mutual benefits with its partners.

Company Profile

Ahngook Pharmaceuticals Co., Ltd.Main Products

Product (Ingredient) Use Exporting Countries Remarks

1. Synatura Syrup (Ivy leaf 30% Ethanol Ext. 2.625mg/mL + Coptis Rhizoma Butanol Ext. 0.875mg/mL)

Antitussive and Expectorant

Iran, South Africa, Mexico, Colombia, Vietnam, Kuwait

New herbal medicine with new composition

2. Valkyrie OD!FS (Tadalafil 5mg, 10mg, 20mg)10mg&20mg: Treatment of

erectile dysfunction5mg: Treatment of ED, BHP

-New formulation

Orally Dissolving in a Few Seconds

3. Letopra Tab.(S-Pantoprazole 10/20mg) Treatment of GERD, PPI Kuwait, Vietnam 1st chirally pure S-pantoprazole

4. Anycough Cap.(Theobromine 300mg) Relief of cough symptom KuwaitNew and non-opioid

antitussive

5. Levotension Tab.(S-amlodipine 2.5/5mg) Hypertension Philippines, Vietnam1st chirally pure

S-amlodipine

6. Anytin SR tab. (Trimebutine maleate 300mg)Functional dyspepsia.

Irritable Bowel Syndrome- -

7. Sustar Tab.(Rosuvastatin 5/10/20mg)Primary Hyperlipidemia and mixed dyslipidemia

Guatemala -

8. Xaltrin XL Tab.(Alfuzosine HCL 10mg)Benign Prostatic

HyperplasiaPhilippines, Vietnam,

Guatemala, Peru-

9. Curost Granules (Montelukast Sodium 4.16mg)

Prevention and continuos therapy of asthma

Philippines, Vietnam -

New Active Substances

Product (Ingredient) Use Approval Date/Country

Anycough cap. (Theobromine 300mg) Antitussive Jun. 2008, Korea

Synatura Syrup (Ivy leaf 30% Ethanol Ext. 2.625mg/mL+ Coptis Rhizoma Butanol Ext. 0.875mg/mL)

Antitussive & ExpectorantMar. 2011, Korea, Iran, Kuwait, South Africa

Rupafin Tab. (Rupatadine 10mg) AntihistamineApr. 2017, Korea

(In-licensed product)

R&D Pipeline

Ingredient Code Use Stage of Development

AG-1301 Naturalsubstance new drug Respiratory Therapeutics Non-clinical

AK903 Natural substance new drug Periodontal disease treatment Phase 2 Clinical Study

AG-1502 IMD Circulatory system treatment Research

AGB-P1 IMD Musculoskeletal Therapeutics Research

UAI-101 Compound drug Metabolic disease treatment Non-clinical

AG-B1511 Bio better (long acting) Neutropenia Non-clinical

AG-B1512 Bio better (long acting) Human Growth Hormone Deficiency Non-clinical completed

AG-B1622 Bio Drug Immune anticancer agent Research

Others

We welcome inquiries about our products export or R&D collaboration. Also we are specialized in the development of NCE and IMD drugs for domestic development. If you are interested in Korean market, please feel free to contact us.


RepresentativeJoong-Kil KIM

Headquarter Address#600 Gyeongin ro, Guro-gu, Seoul, Korea

Foundation Date1953.

Research FocusAntibiotics, Cardiovascular

Total StaffAbout 400


Representative Fax 82-2-849-4123

Webwww.ajupharm.co.kr

Contact PersonJeeyoun Sung


Contact [email protected] Summary (1 Million Won)

Fiscal Year 2015 2016 2017

Sales 85,504 104,029 118,700

R&D Expenditure 2,401 2,226 -

Capital 4,200 4,200 4,200

Financial Figures

Founded in 1953, Aju Pharm has been well know as a quality-oriented pharmaceutical company. 120+ pharmaceutical products comprised of in-licensed products, our own value-added products, generics. medical devices, and consumer health products.

Exporting products to more than 15 countries, always developing new opportunities around the world.

Company Profile

AJU PHARM CO., LTD.Main Products


1. Ceftriaxone Sod 0.25, 0.5, 1.0g Injection Antibiotics Georgia etc. -

2. Cefotaxime Sod 0.25, 0.5, 1.0g Injection Antibiotics Mongolia etc. -

3. Ezetimibe+Rosuvastatin 10/5, 10/10, 10/20mg Tablet

Cardiovascular Peru etc. -

4. Eperison HCl 75mg SR Tablet Neuro-Muscular Azerbaijan etc. -

5. Omeperazole+NaHCO3 20/1100, 40/1100mg Tablet

Gastro-Intestinal - -

6. Candesartan 8, 16mg Tablet Circulatory Philippines etc. -

7. Pregabalin 75mg, 150mg Capsule CNS Peru etc. -

8. Bisoprolol fumarate+Hydrochlorothiazide 10/6,25, 5/6.25, 2.5/6.25mg Tablet

Circulatory Philippines etc. -

9. Thiotic acid 25mg Injection Antioxidant Vietnam etc. -

10. Olive leaf extract Spray Daily throat care Saudi Arabia etc. Food Item

R&D Pipeline

Ingredient Use Stage of Development

Esomeprazole+ NaHCO3 Tablet Gastro-Intestinal Under clinical trial

Others

Olea, our consumer health brand, aspires to help people live healthier lives by offering dietary supplements and other consumer health products made with the highest quality olive leaf extract.

Medical device(Soft tissue repairs and reconstruction).

Biocomposite and bioabsorbable suture anchors for rotator cuff repair(First biocomposite suture anchor developed in Korea) and Disposable cannula with dual silicone seal system


RepresentativeJeong Hai Do

Headquarter Address6F, Kumha Bldg.41-2, Chungdam-Dong, Kangnam-Ku, Seoul, Korea

Foundation Date2005.04.01.




Webwww.astellas.com/kr


Fiscal Year 2008 2009 2010

Sales 105,800 132,300 150,400

R&D Expenditure - - -

Capital 11,500 11,500 11,500

Financial Figures

Astellas Pharma Korea., Inc. is alocal subsidiary of Japanese pharmaceutical corporate with superior R&D and worldwide sales network. It was founded in April 1st 2005 by merging of Fujisawa pharma Korea.,Co.and Yamanouchi pharma Korea.,Co,with 100% Japanese ownership.

Company Profile

Astellas Pharma KoreaMain Products

Product (Ingredient) Use Exporting Countries

1. Harnal D(Tamsulosin HCI) benign prostatic hyperplasia Japan

2. Vesicare(Solifenacin Succinate) Overactive Bladder Netherland

3. Oldeca(Barnidipine HCl) Hypertension Japan

4. Berasil(Beraprost sodium) Peripheral Arterial Disease Japan

5. Protopic(Tacrolimus) Atopic Dermatitis Japan

6. Nasea(Ramosetron HCI) Nausea and Vomiting Japan

7. Prograf(Tacrolimus) Post-transplant rejection Ireland

8. Irribow(Ramosetron HCI) Irritable Bowel Syndrome Japan

9. Rapamune(Sirolimus) Post-transplant rejection -

10. Perdipine(Nicardipine HCI) Hypertension -


Headquarter AddressGyung Building, 78, Gaepo-ro, 22-gil, Gangnam-gu, Seoul, 139-961, Korea


Research FocusDDS (Drug delivery system)



Webwww.bcwp.co.kr

Contact PersonDavid Kim




Fiscal Year 2015 2016 2017

Sales 41,414 45,657 50,207

R&D Expenditure 5,794 6,556 6,649

Capital 1,335 1,335 1,461

Financial Figures

We are a pharmaceutical company that discovers, develops, produces and markets formulations. We are actively engaged in R&D, including depot injectables, liposomes, and fast dissolving tablets.

We are certified as Korea Innovative Pharmacetical Company (KIPC) by Korea Ministiry of Health & welfare and designated as Advanced Technology Center (ATC) by Korea Ministry of Knowledge Economy.

Our newly facility constructed will be approved according to EU GMP standards by 2018. The manufacturing site construction dedicated for Carbapenem injection started in this year.

Company Profile

BC World Pharm. Co., LTD.Main Products


1.Meropenem 500mg, 1g, 2g / Injection AntibioticsVietnam,

Philippines and etc.

2. Imipenem 500mg+Cilastatin Sodium 500mg / Injection

AntibioticsVietnam, Philippines,

Nigeria,Mongolia and etc.

3.Citicoline sodium 500mg/2ml / Injection Central nervous systemAzerbaijan,

Dominica and etc.4. Nicardipine HCl

10mg/10ml, 2mg/2ml / InjectionCirculatory system Taiwan and etc.

5. Vancomycin HCl 1g / Injection Antibiotics Yemen and etc.

6. Methylprednisolon Sodium Succinate 40mg/ Injection

Adrenal gland hormone Vietnam and etc.

7. Piroxicam 20mg/1ml / Injection Anti-inflammatory Vietnam and etc.

8. Acetaminophen 325mg+Tramadol HCl 37.5mg / Tablet

Anti-inflammatory Myanmar and etc.

9. Glibenclamide 5mg+Metformin HCl 500mg, Glibenclamide 2.5mg +Metformin HCl 500mg/ Tablet

Anti-Diabetes Bolivia and etc.

10. Acetazolamide 500mg/ Injection Circulatory system Iran and etc.

R&D Pipeline

Classification Code Use Stage of Development

Long-acting Microsphere Injection

BCWP-D001 Anti-cancer Formulation

BCWP-D004 Anti-cancer Formulation

BCWP-D006 Anti-cancer Non-Clinical

BCWP-D007 Parkinson's disease Formulation

BCWP-D008 Alzheimer's disease Formulation

BCWP-D009 Anti-schizophrenia IND

BCWP-D010 Anti-schizophrenia Formulation

Liposomal Injection

BCWP-Y001 Anti-cancer Tech transfer

BCWP-Y002 Anti-fungal Pre-Clinical

BCWP-Y004 Analgesia Formulation

GastroretentiveBCWP-A001 Antibiotics Pre-Clinical

BCWP-C003 Hyperlipidemia/DM Clinical

Fast-dissolving Tab.

BCWP-E001 Anti-emetic Launching

BCWP-E003 ADHD Formulation

BCWP-E004 Antiulcerant PIII


RepresentativeMyoung-Ho Jeong

Headquarter Address#368-3 Dadae-ro, Saha-gu, Busan, 604-846, Republic of Korea


Research Focusbiosimilar




Webhttp://www.bi-nex.com


Fiscal Year 2009 2010 2011

Sales 32,252 47,243 53,458

R&D Expenditure 4,349 706 4,663

Capital 7,800 8,357 9,379

Financial Figures

Binex is currently comprised of three main business sectors: biologics, chemicals, and cell therapy. As the only biologics CDMO in Korea, Binex plays the key role in solving the manufacturing bottleneck of biopharmaceutical industry with accumulated experience and US and EU-GMP facility.

Company Profile

Binex Co., Ltd.Main Products


1. Contract Development and Manufacturing Service - Binex manufactures client's products both in API and finished form based on clients' need. Products are manufactured at GMP quality with proficiency at reduced time and cost.

- -

2. Human Growth Hormone Growth Hormone Deficiency -

3. Small molecule products digestion, ophthalmic solution, etc. -

R&D Pipeline


Infliximab (Remicade biosimilar)

Rheumatoid Arthritis and other inflammatory conditions

Phase 1 in Korea and Japan for Rheumatoid Arthritis


RepresentativeTae-Hong, Choi

Headquarter Address#136, Changgyeonggung-ro, Jongno-gu, Seoul, Korea


Research FocusCardiovascular, Oncology

Total Staff1,100 persons



Webwww.boryung.co.kr

Contact PersonMicheal park Jay Kim

Contact Phone82-2-708-803282-2-708-8051

Contact [email protected]@boryung.co.kr


Fiscal Year 2012 2013 2014

Sales 312,075 327,279 359,491

R&D Expenditure 9% 7.4% 7.2%

Capital 17,440 18,283 19.170

Financial Figures

Boryung Pharmaceutical Co., Ltd has put a strong presence as TOP leading company in Korean pharmaceutical market since its foundation in 1963. Boryung has made its continuous efforts and investment on R&D to produce high-quality products in its specialty areas such as cardiovascular, gastrointestinal, antineoplastic, antibiotics drugs and API. Boryung has devoted itself to achieve the aspiration of company, “Dedicating to the health of mankind.”

In particular, Kanarb (Fimasartan, 8th ARB NCE for anti- hypertension) has been already licensed out to 14 Latin countries including Mexico & Brazil, Russia and China (16 countries in total). Following the launch of Kanarb in Mexico in Sept. 2014, further global market development has been accelerated. In 2015, Kanarb is going to be licensed to APAC & MENA regions and be launched in Russia, Brazil, and China in a few years. Also, the projects heading to the reference countries such as EU & Japan have been carried out.

Following the remarkable success in Kanarb, Boryung is confident to make another success story with its next key pipeline, Lafutidine(new generation H2RA), Cilnidipine (4th generation CCB), and Gelfos (Top antacid in East Asia), with its best clinical values in class.

Focus Area : Cardiovascular, Gastro-ntestinal, Antibiotics, Oncology, API synthesis

Company Profile

Boryung Pharmaceutical Co., Ltd.Main Products


1. Kanarb Tab. (Fimasartan) Anti hypertensionMexico, Brazil,Russia, China,

NCE(New chemical entity)

2. Cilnidipine Tab. Anti hypertension - 4th generation CCB

3. Lafutidine Tab. Gastric Ulcer, Gastritis - new generation H2RA

4. Gelfos Susp. (ALPO4) Antacid China, Taiwan Top Antacid in East Asaia.

5. Pitavastatin Hyperlipimedia Japan API

6. Oncology Injectable Anticancer Chemotherapy ASEAN, MENA -

7. Cephalosporin Injectable Antibiotics Japan PMDA approved

R&D Pipeline

Compound Name Code Use Stage of Development

Kanarb + CCB combo BKC002 Hypertension P3

Kanarb + Statin combo BKC003Hypertension

HyperlipimediaP3

Kanarb + CCB + Statin combo BKC004Hypertension

HyperlipimediaP1

Incrementally modified drugs BNT002 Dementia P1

New Chemical Entity BNT001Hypertension

Diabetes mellitusDiscovery

Gene therapy BCB002 Liver cancer P1

Vaccine BVN002 Vaccine P3

Vaccine BVN003 Vaccine PC



Fimasartan Anti-hypertension Korea / 2011

- - Mexico / 2014

- - Ecuador / 2014


RepresentativeMr. Sung-Hwan Cho(CEO)

Headquarter Address1F Ace-Techno Tower, 55-7 Mullea-dong 3ga, Youngduengpo-gu, Seoul, Korea





Webwww.choa.co.kr


Fiscal Year 2008 2009 2010

Sales 24,709 29,567 34,943

R&D Expenditure 1,623 1,502 1,296

Capital 39,514 39,875 42,237

Financial Figures

CHO-A PHARM.CO.,LTD. has put all efforts to develop and supply excellent medicine under a corporate slogan, "Keep People Healthy and Happy Away from Diseases" since establishment in 1988. With fast growth over the last 20 years, CHO-A PHARM, is one of the leading pharmaceutical company in Korea producing about 300kinds of drugs especially OTC products and health foods. CHO-A PHARM. began producing drinkable double-neck ampoule under technical cooperation with Laphal of France in 1994 and currently has 30kinds of proudcts and exports them to Vietnam, Yemen and Guatemala.

After establishing a manufacturing factory in 1994, CHO-A has invested to improve quantity and maximize production capacity by obtaining an approval of KGMP in 1995 as well as ISO 9001 for the first time in the pharmaceutical industry in 1996. Through the CHO-A Bio technical R&D center, CHO-A succeeded producing a somatic-cell cloned pig for the first time in Korea and cloned a pig with EPO gene character coverted in 2005. Thereby CHO-A is expected to be a prominent biotech company of the next generation.

Company Profile

CHO-A PHARM.CO.,LTD.Main Products


1. Uratonyl (L-Ornithine-L-Aspartate) Acute,Chronic Vietnam

2. Hemopoly (Ferric hydroxide polymaltose complex)

Iron deficiencya anemia Vietnam

3. Calcitonic (Calcium Lactate) Calcium deficiency Vietnam

4. Elemmen (Adenosine, Thymidine) Acute, chronic, hepatitis anemia Vietnam

5. New Hem (Ferrous gluconate hydrate, Manganese gluconate, Copper gluconate)

Iron deficiencya anemia Yemen

6. Lyvitol (L-Lysine HCl, Inositol, Cyanocobalamin)

Nutrition disorder Vietnam

7. Ronalamin (Calcium Lactate) Calcium deficiency Vietnam

8. Manpos (L-Arginine-L-Aspartate) Physical mental asthemia Guatemala

9. Babycolcol Reduction of symptoms resulting from the cold Mongolia

10. Ginseng Korea (Korean Ginseng Ex.) Reduces fatigue, improve mental conditions. Vietnam


RepresentativeYoung-Joo Kim

Headquarter Address#8, Chungjeong-ro, Seodaemun-gu Seoul 120-756, Korea


Research FocusOncology, Immunology, Metabolism, Cardiovascular



Webhttp://www.ckdpharm.com

Contact PersonKi-Su Lee(Head of Global Business Division)



Fiscal Year 2014 2015 2016

Sales 544,130 544,130 831,986

R&D Expenditure 74,727 91,359 102,178

Capital 23,523 23,523 23,523

Financial Figures

Chong Kun Dang Pharmaceutical Corporaiton (CKD) was spin-off from CKD Holdings on November 2, 2013. CKD is a new organization to manufacture, sales and market the pharmaceutical products, and has the excellent capabilities to develop new chemical entities (NCEs), incrementally modified drugs and generics. CKD has invested over 12.3% of annual revenues for R&D (2016), and succeded to develop NCEs such as CAMTOBELL®, anti-cancer drug and DUVIE®, anti-diabetic drug.

Camtobell® was launched in 2004, as the first CKD new drug developed by its own technology. Based upon this successful experience, Duvie® (Lobeglitazone) which is a thiazolidinedione (TZD) derivative for type 2 diabetes has been launched on February 2014.

CKD has the capacity to research and develop drugs in broad areas: New Chemical Entity (NCE), Incrementally Modified Drug (IMD), and Biologics with a focus on antineoplastic, metabolic, immune and cardiovascular diseases.

Company Profile

Chong Kun Dang Pharmaceutical Co.Main Products


1. Lipilou (atorvastatin calcium anhydrous) Hyperlipidemia Asia

2. Dilatrend (carvedilol) Hypertension -

3. Cipol-N (cyclosporine) Immunosuppressant Asia, S. America

4. Tacrobell (tacrolimus) Immunosuppressant Japan, Asia

5. Candemore plus (candesartan + HCTZ) Hypertension Asia

6. Sarlotan (losartan potassium) Hypertension -

7. Imotun (avocado-soya) Arthritis -

8. Pregrel (clopidogrel resinate) Myocardial infarction -

9. Avelox (moxifloxacin hydrochloride) Antibiotics -

10. Telminuvo (telmisartan, S-amlodipine) Hypertension -

R&D Pipeline


CKD-351 Glaucoma Phase II

CKD-337 Dyslipidemia Phase I/III

CKD-333 Hypertension & Hyperlipidemia Pre-Clinical

CKD-391 Dyslipidemia Phase III

CKD-11101 Anemia Phase III

CKD-396 Type 2 Diabetes Phase I

CKD-393 Type 2 Diabetes Pre-Clinical

CKD-516 Colorectal cancer Phase I/II

CKD-381 Peptic ulcer Phase I

CKD-394 Anti-coagulant Phase I

CKD-519 Dyslipidemia Phase II

CKD-581 Multiple myeloma Phase I/II

CKD-841 Cancer Phase I

CKD-495 Gastritis Phase II

CKD-506 Autoimmune disease Phase I

CKD-504 Huntington’s disease Phase I

CKD-12101 Neutropenia Pre-Clinical

CKD-508 Dyslipidemia Pre-Clinical



CKD-509 Oncology Pre-Clinical

CKD-701 AMD Pre-Clinical

CKD-702 NSCLC Pre-Clinical


Product (Ingredient) Use Approval Date

Camtobell (belotecan) Ovarian cancer, SCLC October 22, 2003 / South Korea

Duvie(lobeglitazone sulfate) Type II diabetes July 4, 2013 / South Korea

R&D Pipeline

RepresentativeSeok Hee KANG

Headquarter AddressCJ CheilJedang Center, 330, Dongho-ro, Jung-gu, Seoul 04560, Republic of Korea

Foundation Date1.April 2014.

Research Focusdigestive disorders, anti-cancer, and immune diseases



Webwww.cjp.co.kr

Contact PersonHeadquaters


Contact [email protected] (Global Business)[email protected] (R&D Business Development)


Fiscal Year 2015 2016 2017

Sales 463,100 520,800 -


Capital - - -

Financial Figures

CJ HealthCare, which launched as a professional pharmaceutical subsidiary of CJ Group on April 1, 2014, is preparing for the future through its active investment in R&D and Open Innovation.

CJ Healthcare has concentrated on developing innovative new drugs, biopharmaceuticals, and Incrementally Modified Drug in a variety of therapeutic groups.

The new drug for gastroesophageal reflux disease (CJ-12420/ingredient name: Tegoprazan), which is currently being developed, is now attracting attention as a drug that can shake the market for digestive system drugs in the near future.

Tegoprazan has been recognized for its competitiveness both domestically and internationally, and has achieved technology export of 100 billion won to China < Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.> in 2015.

Company Profile

CJHealthCare Corp.


Main Products


1. Epokine Inj. (rh-EPO)Treatment of anemia of hemodialysispatients with end-stage renal disease

Southeast Asia, Africa, The Middle East, North

Africa and CIS, Latin America

2. Leukokine Inj. (rh- G-CSF)Chemotherapy in advanced cancer patientsand Neutropenia caused by acute Leukemia

Southeast Asia, Africa, The Middle East, North

Africa and CIS, Latin America

3. Vancorin Inj.(Vancomycin)Treatment of serious, life-threateninginfections by gram-positive bacteria

China

4. Tapocin Inj.(Teicoplanin)Treatment of serious infections

by gram-positive bacteriaSoutheast Asia,Latin America

5. Moveloxin I.V. solution bag (Moxifloxacin)Treatment of acute bacterial sinusitis, acutebacterial exacerbation of chronic bronchitis,community acquired pneumonia and so on

Southeast Asia

6. Cinezolid I.V. solution bag (Linezolid)Treatment of Vancomycin-resistant

Enterococcus faecium infectionsSoutheast Asia

7. Calmtop Inj.(Irinotecan) Treatment of colorectal cancer Southeast Asia

8. Pemta RTU Inj.(Pemetrexed)Treatment of pleural mesothelioma

and non-small cell lung cancerSoutheast Asia

9. OmapOne Lipid Inj. (Soybean oil, MCT, olive oil and fish oil)

Lipid emulsion for intravenous nutrition Southeast Asia

10. OmapOne Peripheral Inj. (Lipid, Amino acids and Glucose)

Emulsion for infusion Southeast Asia

11. Machkhan Tab. (Candesartan, Amlodipine) Treatment of hypertension -

12. Vogmet (Voglibose, Metformin) Treatment of diabetes -

13. CONDITION CONDITION LADY (Hyaluronic acid)

Anti-hangover drink China, Japan, Vietnam

14. HONGSAMJIN (4 years old red ginseng extract) HONGSAMJIN GOLD (6 years old red ginseng extract)

Red Ginseng drink Vietnam

15. HUTGAESOO (Oriental raisin tree fruit extract concentrate)

Natural oriental raisin tea with zero caloriesand caffein

-

R&D Pipeline


Tegoprazan CJ-12420 Gastric Acid-Related Disorders NDA

UNDISCLOSED CJ-14199 NASH PC

JAK-1 inhibitor CJ-15314 Rheumatoid Arthritis PC

Atorvastatin, Metformin CJ-30056 Type 2 Diabetes / Hyperlipidemia NDA

Valsartan, Amlodipine, Rosuvastatin CJ-30060 Hypertension / Hyperlipidemia P3

Valsartan, Amlodipine, Atorvastatin CJ-30061 Hypertension / Hyperlipidemia P3

Tegoprazan, Clopidogrel CJ-30064Gastric Acid-Related Disorders /

AntithromboticsDC

Tegoprazan CJ-30065 Gastric Acid-Related Disorders DC

- CJ-30066 Type 2 diabetes DC

- CJ-30067 Type 2 diabetes DC

Darbepoetin alfa biosimilar CJ-40001 Renal Anemia P3

- CJ-40010 Hand, Foot & Mouth Disease PC

Ranibizumab biosimilar CJ-40012 Macular edema PC


RepresentativeJoohyung Lee

Headquarter AddressCHA Bio Complex, Pangyo-ro 335, Bundang-gu, Seongnam, Gyeonggi-do 13488, Republic of Korea

Foundation DateAugust 1, 2001.

Research FocusNCE, IMD, Oral Soluble Film



Webhttp://cmgpharma.com/

Contact PersonHaekwan Eo




Fiscal Year 2015 2016 2017(E)

Sales 27,042 32,970 41,535

R&D Expenditure 6,009 2,404 2,799

Capital 44,149 54,354 54,431

Financial Figures

CMG Pharmaceutical is a fast growing mid-cap company listed in KOSDAQ stock market in Korea. R&D focus area includes development of targeted cancer therapeutics (NCE), IMDs including Oral Soluble Film and fixed-dose combinations of established drugs with therapeutic areas in cancer, CNS and cardiovascular disease.

CMG is seeking Open Innovation partnership in various areas including licensing, marketing/sales, R&D collaboration and Joint Venture investment in healthcare industry.

Company Profile

CMG Pharmaceutical Co., Ltd.Main Products


1. Kanarb Tab. (Fimasartan) Erectile dysfunction Taiwan, Hongkong 20, 10, 5mg

2. Amlodipine/Valsartan Tab. Hypertension - 5/80, 5/160, 10/160mg

3. Mosapride Tab. Acid reflux, IBS - 5mg

4. Rebamipide Tab. Gastric ulcer - 100mg

5. Loxoprofen Tab. Anti-inflammation - 60mg

6. Rosuvastatin Tab. Hyperlipidemia - 5, 10, 20mg

7. Multi-Vitamin Tab.Fatigue recovery,

inflammation- Vit B1, B2, B6, C, E

8. Hyaluronic acid micro needle Cosmetic Mexico, Ukraine -

9. Hyaluronic acid injectable Skin filler - -

10. Vitamin C solution Hair loss, scalp care - -

R&D Pipeline


Aripiprazole ODF - Schizophrenia, Bipolar I disease US Pre-NDA, 505(b)(2)

NCE CHC-2014 Solid cancer Phase 1 Study Candidate

NCE CCN-002 Lung/stomach cancer Pre-clinical

NCE CCN-006 Prostate/bladder cancer Pre-clinical

NCE CNN-006 Alzheimer's disease Pre-clinical

NCE CCN-007 Solid cancer Hit selection

Orlistat - Obesity Reformulation

Others

CMG, part of CHA Hospital Group, is open to discuss business collaborations including open innovation, M&A, JV, R&D, and investment with foreign companies and investors.


RepresentativeKyung Suk Kim

Headquarter Address24, Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea


Research FocusPersonalized stem cell therapy for incurable diseases



Webhttp://corestem.com/en/

Contact PersonYon Hui Sarah Kim




Fiscal Year 2015 2016 2017 (~Sep.)

Sales 18,571 17,953 50,037

R&D Expenditure 740 2,003 1,530

Capital 67,092 77,761 83,096

Financial Figures

CORESTEM is a bio-pharmaceutical company specializing in research and development of personalized stem cell therapies for incurable disease.

We developed the world’s first stem cell therapeutic product for ALS (Amyotrophic Lateral Sclerosis) name of NEURONATA-R, received the permission of medicines by Korea’s Ministry of Food and Drug Safety in July 2014 and began commercialized medication to patients in February 2015.

CORESTEM, a global stem cell biotechnology company, leads the market in meeting patient expectations beyond national, ethical and economic limitations through ongoing research into incurable diseases.

Company Profile

CORESTEM Inc. Main Products

Product (Ingredient) Use Exporting Countries Remark

1. NEURONATA-R Amyotrophic Lateral Sclerosis (ALS) All MFDA approval in 2015

R&D Pipeline


Allogenic Stem Cell CS20AT04 Systemic Lupus Erythematosus Phase I

Autologous Stem Cell CS10BR05 Multiple System Atrophy Phase I

Allogenic Stem Cell HYNR-CS-Allo Amyotrophic Lateral Sclerosis IIT

Autologous Stem Cell NEURONATA-R Anoxic Brain Injury IIT

Cartilage-derived Precursors CS30MS02 Osteoarthritis Preclinical


RepresentativeHo Yeon Cho

Headquarter Address13, 40-gil, Jungdae-ro, Songpa-gu, Seoul, Rep. of Korea

Foundation DateJune. 1993.

Research FocusFinished Formulations


Representative Phone82-1661-8800


Webwww.ctcbio.com

Contact PersonChae Young Ban




Fiscal Year 2012 2013 2014

Sales 129,800 123,400 -


Capital 125,400 150,500 -

Financial Figures

CTCBIO is a Korean pharmaceutical company which holds top 50 domestic pharmaceutical companies as solid clients and is involved in co-operative partnership with international pharmaceutical companies. Its pharmaceutical business covers development and production of super-generics with drug formulation and delivery technology. We are specialized in micro-encapsulation using fluid bed and OSF formulation. CTCBIO is capable of manufacturing various types of oral dosage forms and has business capabilities starting from formulation development and all the way to commercial production.

Company Profile

CTCBIO, IncMain Products


1. Sildenafil treatment of erectile dysfunctionLebanon, Iraque,

Taiwan, Japan etc.

R&D Pipeline


Donepezil free base CDFF0212 Treatment of Alzheimer's disease NDA applied

Desmopressin CDFF0612Treatment of primary enuresis, nocturnal

enuresis

bioequivalence test / review of specification and

test method completed

Entecavir CDFF0511 Treatment of chronic hepatitis B virus NDA applied

Tadalafil CDFF0213 Treatment of erectile dysfunction20mg: approved

5mg, 10mg : NDA applied

Clomipramine/sildenafil CDFR0812 Treatment of premature ejaculation IND (phase II) applied

omeprazole/sodium hydrogen caronate CDFR0209Treatment of duodenal and gastric ulcer,

GERD and symptoms of gastroesophageal reflux disease

NDA applied

sodium picosulfate etc. CDFR0613eathartic for colonology and preoperatic

treatmentPhase I


RepresentativeDr. Yong-Hoon Ji MD

Headquarter Address153 Dadae-ro, Saha-guBusan, Republic of Korea

Foundation DateApril. 1976.

Research FocusOphthalmic product formula modification & customization, Development of targeted cancer drugs with inhibition of angiogenesis




Webhttp://www.daewoopharm.co.kr

Contact PersonJi-Hoon Suh




Fiscal Year 2012 2013 2014

Sales 36,025 41,479 46,448

R&D Expenditure 1,414 1,547 1,180

Capital 24,141 27,205 24,246

Financial Figures

Since its founding in 1976, Daewoo Pharmaceutical has endeavored to promote the public health with 3 business principles-sincerity, correctness, research.

We have focused on the business of ethical drugs in the past 30 years in Korea. With the business experience, Daewoo has effort on continuous research, development and investment about facilities and human resources.

Now, Deawoo is preparing to become a global pharmaceutical company with new-drugs pipline, particularly anti-angiogenesis and anticancer drug for the next 10 years. We are investing for world class product facilities to increase oversea business and accomplish R&D projects in Daewoo R&D institute. Daewoo has committed Contract Manufacturing Organization(CMO) business with sufficient technical and marketing resources.

Even in challenging internal and external enviroment, Daewoo will be a competent global pharmaceutical company with recognized ability.

Focus Area : Opthalmic Products / Cancer Drugs / Generic Drugs

Company Profile

Daewoo Pharmaceutical Co., LTDMain Products

R&D Pipeline


Rivaroxaban

Int. CL.: A61K 31/335 :A61K 35/74: C12P 7/62 :A61P 29/00Application number: 10-2010-0029016

Anti-inflammatory Non-clinical

Macrolactin A and its derivatives

Int. CL.: A61K 31/335 :A61K 31/335: A61P 19/02 :A61P 19/00Application number: 10-2011-0012707

Anti-angiogenesis Non-clinical

Macrolactin Compounds

Int. CL.: A61K 31/335 :A61K 31/365: A61P 1/00 :A61P 29/00Application number: 10-2012-0011924

The prevention or treatment of inflammatory bowel disease

Non-clinical

Macrolactin Compounds

Int. CL.: A61K 31/335 :A61K 31/365: A61P 35/00Application number: 10-2013-0089955

Anticancer Drug Non-clinical


1. Original Relief Eye Drops (Tetrahydrozoline HCl 0.5mg/Ophthalmic Eye Drops)

Relieves red, Irritated eyes USAOTC

(USA OEM)2. Advanced Relief Eye Drops

(Tetrahydrozoline HCl 0.5mg + Dextran 70 1mg + Polyethylene glycol 400 10mg + Povidone 10 mg/Ophthalmic Eye Drops)

Relieves red, Irritated eyes, Hydrating moisturizer

USAOTC

(USA OEM)

3. Hyalsan Eye Drops 1) Single-use disposable type 0.8 mL (Sodium hyaluronate 0.8mg/Ophthalmic Eye Drops) 2) Multi-use type (Sodium hyaluronate 1mg/Ophthalmic Eye Drops)

Keratoconjunctival epithelial disorder

Vietnam -

4. Tobeson Eye Drops (Tobramycin 3mg, Dexamethason 1mg/Ophthalmic Eye Drops)

Eye steroids, Antiallergics Vietnam -

5. Taspen-ER Tablet (Acetaminophen 650mg/Tablet, Extended Release)

Other Analgesics, Antipyretics

- -

6. Eperisone Tablet (Eperisone HCl 50mg/Tablet) Skeletal muscle relaxants Vietnam, Thailand -

7. Simvasterol Tablet (Simvastatin 20mg/Tablet) Antilipidemic agents - -

8. Pantezol Tablet (Pantoprazole sodium sesquihydrate 45.1mg, as Pantoprazole 40mg/Tablet)

H+ Pump inhibitors - -

9. Pseudoephedrine Tablet (Pseudoephedrine HCl 30mg/Tablet)

Decongestants, Nasal prep - -

10. Romicin Tablet (Roxithromycin 150mg/Tablet) Macrolide antibiotics Vietnam -


RepresentativeJin Oh Park

Headquarter Address123, Neungheodae-ro 649 beon-gil Namdong-gu, Incheon, Korea


Research FocusAPI




Webwww.daebongls.co.kr

Contact PersonHyun Cheol Kim




Fiscal Year 2014 2015 2016

Sales 47,696 53,414 63,362

R&D Expenditure 1,524 1,856 2,422

Capital 5,543 5,543 5,543

Financial Figures

Daebong LS specializes in pharmaceutical raw materials and cosmetics and is committed to our mission to be “a company that providesthe best solutions to enable people to live healthier and more beautiful lives” Through our “Total Solutions for Human Better-Being”, we work to improve the Quality of Life (QoL) for all human beings.

We develop the API of major anti-aging, respiratory, hypertension and digestive-system treatments and medicines and supply excipients to domestic companies as an agent for global companies. We are also able to meet the demands of our customers as we provide a Total Service by supplying the pharmaceutical technologies we have developed through our collaboration with top Formulation ventures to our client companies.

Focus Area : Erdosteine, Olmesatan medoxomil, Valsatan, Amlodipine besylate

Company Profile

Daebong LS Co., LtdMain Products


1. Erdosteine Expoctorant - API

2. Olmesatan medoxomil Hypotensive Agent - API

3. Valsatan Hypotensive Agent - API

4. Amlodipine besylate Hypotensive AgentMexico,Latin America

and the CaribbeanAPI



Pro Multi White Cysteine Whitening/Antiinflammatory AgentsLaunched in 4Q

2015(Korea)

R&D Pipeline

Compound Name CAS No Use Stage of Development

Rivaroxaban 366789-02-8Anticoglurant

Pilot scale process development

Apixaban 503612-47-3 Lab scale process development

Sitagliptin phosphate · H2O 654771-77-9

Antidiabetics

Pilot scale process development

Vildagliptin 274901-16-5 Pilot scale process development

Linagliptin 668270-12-0 Lab scale process development

Sarpogrelate HCl 135159-51-2 Antithromboticantiplatelet

Lab scale process development

Cilostazol 73963-72-1 Lab scale process development

Acetyl L-carnitine HCl 5080-50-2 Amino Acids Derivatives

Lab scale process development

L-carnitine 541-15-1 Lab scale process development

Rosuvastatine Ca 147098-20-2 Antiarteriosclerotic Lab scale process development

Etoricoxib 202409-33-4 NSAIDs Lab scale process development

Tobramycin sulfate 49842-07-1 Antibiotics Lab scale process development

Choline fenofibrate 856676-23-8 Dyslipidemia Plant scale process development

Linoleamide Seriol - Pseudo Ceramide Lab scale process development

Linoleneamide Serinol - Pseudo Ceramide Lab scale process development

Cetyl ethylhexanoate 59130-69-7 Emollient Lab scale process development

Pentaerythritol tetra(2-ethylhexanoate)

7299-99-2 Emollient Lab scale process development

Hydrogenated Natural Oil - Skin Conditioning Lab scale process development


RepresentativeEun-Seok, Kim

Headquarter Address495, Hanu-ro, Hoengseong-eup, Hoengseong-gun, Gangwon-do, Republic of Korea

Foundation Date1984.01.19

Research FocusAPI, TDDS, Finished product, etc.



Webwww.dhpharm.co.kr

Contact PersonHan-Woong, Seo




Fiscal Year 2015 2016 2017

Sales 72,191 81,960 86,204

R&D Expenditure 3,710 5,074 5,470

Capital 30,960 30,960 30,960

Financial Figures

Company Profile

DAE HWA PHARMACEUTICAL CO., LTD.

DAEHWA Pharmaceutical Co., Ltd., was established in the spirit of “contribute to society by providing a more human-centered pharmaceutical business.” Its main goal is to improve National health and people’s life.

Since its foundation in 1984, DAEHWA continuously seeks new paths for its business development with a consistent progress-oriented core-target.

With its own platform technologies, DAEHWA produces APIs and finished products. Some of them are: Cephametyl, which is ranked third in the oral cephalosporin antibiotic market; Flospan, ranked first in the antispasmodic market; and Liporaxel Solution, which is the result of DAEHWA’s 17 year-study and which achieved astonishing results proving its efficacy, safety and convenience. DAEHWA’s DH-LASED technology created this first oral Paclitaxel anticancer drug in the world.

DAEHWA also developed DH-HERBAL Technology specialized for elderly people, and represents the biggest unique CMO Company for transdermal drug delivery system (TDDS) product in Korea.

DAEHWA invests more than 10% of its sales into R&D and focuses most of its company resources into the development of QoL products. DAEHWA currently exports more than 60 products to 20 countries in the world. DAEHWA runs a representative office in Vietnam, and took over Redoxbio Inc. as well as a German cosmetics & medical device manufacturing and distribution company. Consequently, DAEHWA has grown from a middle-sized Korean company into a global company specialized in pharmaceutical products.

Main Products


1. Liporaxel solution (paclitaxel 10mg/mL) Gastric cancer -New

formulation as oral solution

2. PROTASE Tab. (Bromelain 40mg, Crystallized Trypsin 1mg)

Relieve of inflammatory

symptoms

Myanmar, Vietnam, Cambodia

-

3. Top-Roll Soft capsules (Korea Ginseng 100mg with multivitamins)

Tonic, nutritive supplement

Myanmar, Cambodia, Bolivia, Ghana and others

-

4. ALMETAMIN Tab. (Betamethasone 0.25mg, Dexchlorpheniramine maleate 2mg)

Acute rash, allergic rhinitis

Ethiopia, Cambodia -

5. DEMACOT Cream (Batamethasone dipropionate 0.64mg, Clotrimazole 10mg, Gentamicin sulfate 1.0mg)

Allergic dermatitisVietnam, Bolivia,

Cambodia, Ghana, Mongolia

-

6. KEBANON Plaster (Ketoprofen 30mg)Relief of symptoms of

muscular painBolivia, Cambodia, Hongkong, Vietnam

-

7. LOXONA Plaster (Loxoprofen 56.7mg)Relief of symptoms of

muscular painCambodia, Hongkong -

8. RESNALIN Patch (Tulobuterol 0.5/1/2mg)

Respiratory distress caused by airway

obstruction of bronchial asthma

Myanmar, China -

9. BARATIS ODF (Entecavir 0.5/1mg)Treatment of chronic

hepatitis B virus infection

- -

10. Amalian Filler (Hyaluronic acid)Wrinkle

improvementWorldwide

Made in Germany

R&D Pipeline


Paclitaxel DHP107Breast cancer, Gastric cancer, Non-small cell lung cancer,

Ovarian cancerClinical Study Phase II & III

Jujube extract DHP1401 Dementia Clinical Study Phase II

Ramosetron DHP26002 Antiemetics New formulation

DHP23007 DHP23007 Antiviral agent New formulation

DHP32002 DHP32002 Rare disease Pre-Clinical Study


RepresentativeSeung Ho Baek, Seung Ryel Baek

Headquarter AddressCheonhodaero 386, Sungdong-gu, Seoul, Korea.

Foundation DateJanuary 7, 1958.

Research FocusDDS Research, New Drug Chronic diseases, Improving dosage forms




Webwww.daewonpharm.com

Contact PersonJunggun Park




Fiscal Year 2015 2016 2017(E)

Sales 216,187 240,722 270,000

R&D Expenditure 16,713 18,978 20,000

Capital 194,749 214,682 230,426

Financial Figures

Since the establishment in 1958 with a founding idea of “Realization of human health”, Daewon Pharm has produced reliable and safe medicines by securing world-class manufacturing facilities and superior R&D capabilities.

We, Daewon Pharm is a capable company that has developed new drugs using excellent technological basis and manufacturing facility. We are devoting ourselves to develop numerous new products to improve the quality of life, and trying our best to become the representative pharmaceutical company of the Republic of Korea.

We, Daewon Pharm has developed Pelubi, Pelubi CR Tab. (pelubiprofen 30mg, 45mg), the first NSID-class antiphlogistic/analgesic drug in Korea.

Hyangnam factory is a new GMP standard applied high-tech facility equipped with excellent infrastructures, and manufactures internal solid dosage forms, injections, sex hormone drugs, and other various products.

Starting from sales expansion to Vietnam in 1994, we are currently exporting our products to China and 40 other countries in Asia, South America, Middle-East, Africa, and further. By licensing-out new drugs, incrementally modified drugs, and high-value original drugs such as Pelubi Tab, Megex-I Suspension(anti-cancer supplement), and Privituss Suspension(antitussive) to large pharmaceutical markets like China, Daewon Pharm is preparing another rapid growth. We are also moving forward to export medical devices such as hearing aids.

Delight, a subsidiary company specialized in hearing aid business, produces hearing aids using 3D scanner and patented technology called 'standarized hearing aid.' We provide worldwide customers high performance hearing aids with reasonable price, delivering joy and happiness of hearing.

Focus Area : Ethical Drug, Over-the-Counter Drug, Contract Manufacturing, Medical Instrument

Company Profile

DAEWON Pharm. Co., LtdMain Products



Pelubi/Pelubi CR Tab. (Pelubiprofen 30/45 mg)Anti-inflammatory, analgesic

(RA, OA, BP, Fever)-


1. Pelubi/Pelubi CR Tab. (Pelubiprofen 30/45 mg)Anti-inflammatory,

analgesic(RA, OA, BP, Fever)

Mongolia, Georgia*12th Korean

New Drug

2. Oramin Soft Capsule (Ginseng, Multi Vitamin) Supplementation of

vitamins and mineralsPhilippines, Nigeria, Myanmar, Iran, etc

Export Over 30 Countries

3. Trigel Susp. (Aluminum hydroxide gel, Magnesium, Oxethazaine)

High-potency antacidVietnam, Cambodia,

Taiwan, Peru, etc Export Over 10 Countries

4. Megex-I Susp.(Megestrol acetate) Anorexia and cachexiaGuatemala, Iran, Colombia, Taiwan

Export Over 10 Countries

5. Codaewon Tab. /Syrup (Dihydrocodeine, Guaifenesin, Methylephedrine, etc)

Potent Antitussives, Expectorants

Hongkong,MongoliaCambodia

-

6. Renamezin Cap.(Oral adsorptive charcoal) Renal failure Taiwan -

7. Freefol MCT Inj. (Propofol Inj.) Anesthesia, sedation Ukraine, Syria, Georgia -

8. Wontran ER Tab.(Acetaminophen, Tramadol) Pure analgesicTaiwan, Guatemala,

Hongkong*IND Drug

R&D Pipeline


NCE DW-325 Hyperlipidemia -

NCE BAL-110 Prostate, Cervical Cancer -

NCE DW-4301 Hyperlipidemia -

BIO (TERROSA™) Osteoporosis -

IMD DW-1404 RHINITIS -

IMD DW-1501 Hypertension/Hyperlipidemia -

IMD DW-1502 Neuropathic Pain -

IMD DW-1601 Acute Bronchitis -

IMD DW-1606 Osteoporosis -


RepresentativeJongwook Lee

Headquarter Address12, Bongeunsa-ro 114-gil, Gangnam-gu, Seoul, Republic of Korea


Research FocusGI, CV, Neuroscience & Pain, Fibrotic Disease, Immuno-Oncology, Autoimmune Disease



Webwww.daewoong.com

Contact PersonDoyoung (Brian) Kim



Fiscal Year 2015 2016 2017

Sales 800,517 797,010 861,500

R&D Expenditure 99,924 107,993 92,000

Capital 492,694 517,660 563,642

Financial Figures

Daewoong Pharmaceutical was established in 1945 and has become one of the leading pharmaceutical companies in Korea with approximately 800 million USD in annual revenues.

As it is our vision to become a global healthcare group, Daewoong Pharmaceutical has established 3 manufacturing sites in Indonesia and China and 8 branch offices in China, Japan, Indonesia, Thailand, Vietnam, Philippines, India and USA. Thus, we are actively striving to export our high value added portfolio to the world.

As it is our mission to provide the most beneficial total solutions in pharmaceuticals and services that contribute to improving the quality of life of valued consumers, we have been reinforcing R&D capacities through the establishment of R&D centers globally in Korea, China, India and Indonesia and focusing on developing new chemical entities, biologics, incrementally modified drugs and high-value added APIs. Our most recent R&D achievements include the initiation of Phase II trials for our reversible acid pump antagonist, DWP14012, an NCE expected to become the best in its class based on its potent acid suppressive effect. Furthermore, we foresee great potential for DWP17011, a PRS inhibiting anti-fibrosis NCE that has demonstrated both anti-fibrotic and anti-inflammatory effects with a novel MOA, which have been demonstrated in the pre-clinical studies that have been conducted.

Company Profile

Daewoong Pharmaceutical Co., Ltd.Main Products


1. Nabota (Botulinum toxin type A / Injectable)Glabellar lines, Post stroke,

Upper limb spasticity

Australia, Canada, CIS 12 countries, EU 28 countries, Hong Kong, Macao,

LATAM 15countries, Macao, Middle East 10 countries, Philippines, South Africa, Taiwan, Thailand, Turkey, USA, Vietnam

2. Novosis (rhBMP-2 / Lyophilized Powder)Dental sinus lifting,

Spinal fusion

Chile, Columbia, Hong Kong,Indonesia, Malaysia, Peru,

Philippines, Thailand, Vietnam

3. Easyef (rhEGF / Topical Solution, Ointment)Diabetic foot ulcer,

Oral mucositis, Acute wound healing

Algeria, Armenia, Azerbaijan, Egypt, Georgia, Iraq, Jordan, Russia, Syria,

Turkey, Uruguay

4. Caretropin (Somatropin /Injectable) Growth hormone deficiencyBelarus, Ecuador, Georgia, Hong Kong,

Iran, Kazakhstan, Peru, Ukraine, Uruguay

5. Eposis (rhEPO / Injectable)Anemia in end stage renal

diseases

Algeria, Azerbaijan, Georgia, Indonesia, Iraq, Kazakhstan, Mongolia, Sri Lanka,

Syria, Thailand, Turkey, Vietnam

6. Olostar (Olmesartan, Rosuvastatin / Tablet)Concomitant hypertension

and dyslipidemiaAustralia, Canada, Japan, Taiwan, USA

7. Ursa (Ursodeoxycholic acid / Tablet, Capsule)Liver & bile disease including cholestasis, Gallstone, etc.

Azerbaijan, China, Georgia, Iraq, Jordan, Kazakhstan, Malaysia, Mongolia,

Philippines, Ukraine, Uruguay, Vietnam

8. Albis (Ranitidine, Bismuth, Sucralfate / Tablet)Gastric & duodenal ulcer,

GastritisAzerbaijan, Ecuador, Georgia, Vietnam

9. Luphere depot (Leuprorelin Acetate / Injectable)

Prostate cancer, Endometriosis,

Precocious pubertyJapan, Malaysia, Myanmar, Russia

10. Meropenem (Meropenem / Injectable)

Complicated skin and skin structure infections,

Complicated intra-abdominal infections,

Bacterial meningitis

USA

R&D Pipeline


APA (Reversible) DWP14012 Gastrointestinal Disease Phase II

SGLT-2 inhibitor DWP16001 Diabetes Phase I

PRS Inhibitor DWP17011 Fibrotic disease Pre-clinical

Ion channel blocker DWJ208 Neuropathic pain, cancer pain Pre-clinical

Dual Target Inhibitor DWJ212, 213 Autoimmune disease (RA) Research

Long acting insulin DWP457 Diabetes Research

Undisclosed Protein DWJ815 Osteoarthritis Research


RepresentativeYoonwoo Lee

Headquarter Address3 Seonyu-ro 45-Gil Yeongdeungpo-gu Seoul

Foundation DateOct. 14, 1945.

Research FocusInjections and Infusions




Webwww.daihan.com

Contact PersonGeorge Kim




Fiscal Year 2015 2016 2017

Sales 124,276 139,437 150,000


Capital - - -

Financial Figures

DAI HAN PHARM. Co., Ltd. makes Good Pharmaceutical Products in the GMP plant, We make Infusions (Bag, Glass bottles), Injections (PE, PP Ampoules), Solutions for external use and Contrast Media products. We have exported the product since 2005.

Focus Area : Infusion, Injection, Contrast Media, and Solutions for external uses.

Company Profile

DAI HAN PHARM. CO., LTD.Main Products


1. Iohexol Inj. 300 (Iohexol 300mg/50mL)Myelography, angiography, urography, Computerized-

tomography(CT)-contrast enhancementVietnam, Costa Rica,

Philippines

2. Iohexol Inj. 350 (Iohexol 350mg/50mL)Myelography, angiography, urography, Computerized-

tomography(CT)-contrast enhancementVietnam

3. Luminal 10% Inj. (Phenobarbital sodium 100mg/ml)

Sedation (if urgently required), epilepsy and status epilepticus

Vietnam

4. Lefquin Infusion (Levofloxacin 500mg)pneumonia, acute pyelonephritis, multiple urinary tract infection, acute sinusitis, infection of skin and tissue,

etc.Philippines, Vietnam

5. Lidocaine HCL 2% (Lidocaine HCL 2%)1. Anesthesia: epidural anesthesia, nerve block, infiltration anesthesia and surface anesthesia.2. Internal medical use: ventricular arrhythmia.

Hong Kong, Philippines, Myanmar, Mongolia,

Costa Rica

6. Pan-B-Comp Inj. (Vitamin B complex)Supply of vitamins and prophylaxis of deficiency of

vitamin B seriesCambodia, Vietnam,

Philippines

7. Vitamin K1 Inj. (Phytonadione 10mg/ml)1.Prophylaxia and treatment of hemorrhage disease for

a newborn2.Hypoprothrombinemia

Iran, Vietnam, Philippines, Myanmar

8. Orni Inj. (L-Ornithin L-Aspartate 500mg/1ml)

Hepatic coma, Treatment of precomaVietnam, Azerbaijan, Uzbekistan, Mongolia

9. Heparogen Inj. (L-Ornithin L-Aspartate 100mg/1ml)

Detoxication of liver disease(hepatitis and sequela, tissue damage, hepatic cirrhosis)

Vietnam, Azerbaijan, Mongolia

10. Tranexamin Inj. 500mg (Tranexamic acid 500mg/5ml)

Hemorrhage(by leukimia, aplastic anemia, purpura, cancer, pulmonary hemorrhage, renal hemorrhage,

genital bleeding, etc.)

Vietnam, Philippines, Myanmar

11. Bidoxin inj. (Pyridoxine HCl 100mg/ml)Treatment and prophylaxis of vitamin B6 deficiency

symptomCosta Rica, Mongolia

12. Ketorolac Inj. (Ketorolac tromethamine 30mg/mL)

Severe pain Philippines, Panama

13. Sod. Bicarbonate Inj. (Sod. Bicarbonate 8.4%)

Acidosis, Acute pruritusIraq, Philippines,

Costa Rica

14. Piroxicam Inj. (Piroxicam 20mg/ml)Rheumatic arthritis, osteoarthritis,

ankylosing spondylitis etc.Vietnam

15. Statirin Inj. (Citicoline 500mg/2ml)Disturbance of consciousness by head trauma and

surgery of brain etc.Vietnam, Myanmar

16. Ciprofloxacin Inj. (Ciprofloxacin 2mg/mL)

Respiratory tract, ENT infections, renal or urinary tract infections, genital infection including gonorrhoea, GI

infections, bone or joint infections, etc.Philippines

17. Aminohex Inj. (Aminoacid Infusion)Supply of amino acids in following cases

(Hypoproteinemia, hypoalimentation, and before/after surgery)

Vietnam, Mongolia

18. Amicomplex Inj. (Aminoacid Infusion)Supply of amino acids in following cases

(Hypoproteinemia, hypoalimentation, and before/after surgery)

Mongolia

19. Hepavia Inj. (Aminoacid Infusion)Improvement of encephalopathy due to acute/chronic hepatic impairment, supply of amino acids to a patient

with hepatic impairmentVietnam, Mongolia

20. Epinephrine Inj. (Epinephrine 1mg/ml)Relief of bronchial asthmatic paroxysm, symptoms by

serum disease, hives and angioneurotic edema.Costa Rica, Philippines,

Mongolia


RepresentativeMr. Dae Jung Kim / CEO

Headquarter AddressPosco Center west wing 3rd floor, Daechi4-dong 892, Kangnam gu. Seoul

Foundation DateJuly 16, 1990.




Webwww.daiichisankyo.co.kr


Fiscal Year 2008 2009 2010

Sales 36,300 50,200 56,700


Capital - - -

Financial Figures

Daiichi Sankyo Korea.,Ltd. is the Korean subsidiary of Daiichi Sankyo Japan, a global Pharmaceutical enterprise. Consolidation of the Daiichi Pharmaceuticals Co.,Ltd. and Sankyo Co. Ltd., gave birth to Daiichi Sankyo Korea Co.,Ltd. in April 2007, which since its launch has expanded its domain of expertise from anti-inflammatory area to cardiovascular area. Daiichi Sankyo Korea offers a fluoroquinolone antibacterial agent named Cravit, an anti-hypertension agent Olmetec and sevikar as well as an anti-dyslipidemia agent Mevalotin. The company will continue to make strides forward to secure a leading status in the pharmaceutical industry by leveraging and further diversifying its product offerings.

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging market. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabloic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model" which will respond to market and customer diversity and growth opportunities across the value chain. For more information, please www.daiichisankyo.com

Company Profile

Daiichi Sankyo KoreaMain Products


1. Olmetec (Olmesartan) Anti Hypertension Imported

2. Olmetec plus (Omesartan + Hydrothiazide) Anti Hypertension Imported

3. Mevalotin (Pravastatin) Anti dislipidemia Imported

4. Sevikar (Olmesartan+amlodipine) Anti Hypertension Imported

5. Cravit (Levofloxacin) Antibiotics Imported

6. Sunrythm (Pilsicainide HCI) Antiarrhythmic agent Imported

7. Effient (Prasugrel) Antiplatelet agent Imported


RepresentativeJong sup Chung

Headquarter Address107, Jeyakgongdan 3-gil, Hyangnam-eup, Hwasung-si, Gyeonggi-do, Korea,


Research FocusEndocrinology(Diabetes, Thyroid, Sex hormone), Vitamin D (Finished Pharmaceutical Products)



Webwww.dalimpharm.co.kr

Contact PersonMr. Mark Choi



Fiscal Year 2015 2016 2017

Sales 29,345,548 31,469,565 35,00,000

R&D Expenditure 1,746,84 1,416,375 2,000,000

Capital 500,000 500,000 500,000

Financial Figures

Dalim Biotech is a family company of Dalim Corporation Co., Ltd, started to produce the medicines at first hand that were released by importation or production partnership after it was established in 2001, and concentrated on the area of endocrinology led by diabetes to affirm its position as the best company specializing in the area of diabetes despite a short time. Moreover, it came to produce and apply hormone preparations at first hand which have depended on importation only by completing the construction of building to exclusively produce sex hormone site in 2006.

Company Profile

Dalim BioTech Co., Ltd. Main Products

Product (Ingredient) Use Exporting Countries Remark

1. Metformin hydrochloride 500mg + Gliclazide 80mg Tab

Oral hypo-glycemics Azerbaijan, Uzbekistan

World 1st combination of Metformin HCl + Gliclazide

2. Repaglinide 0.5mg/1mg/2mg Tab Oral hypo-glycemics - World 1st generics

3. Repaglinide 1mg/2mg + Metformin HCl 500mg Tab

Oral hypo-glycemics - World 1st generics

4. Norepinephrine bitartrate 2mg/1ml Amp (Norepinephrine 4mg/10mg/20mg)

Acute hypotension, Shock

Thailand -

5. Conjugated equine estrogens 0.3/0.625mg Tab

Postmenopausal syndrome

- World 1st generics

6. Tibolone 2.5mg TabPostmenopausal

syndrome-

Produced by Dalim BioTech’s facility (Dedicated sex

hormonal premiss)

7. Desogestrel 0.15mg + Ethinyl Estradiol 0.02mg Tab

Contraceptive -

8. Levonorgestrel 1.5mg TabEmergency

contraceptive -

9.Carbimazole 5/10mg Tab Hyperthyroidism -Solely produced by Dalim

BioTech in Korea

10. Cholecalciferol concentrate powder 10mg Tab.(Cholecalciferol 1,000IU) Cholecalciferol concentrate powder 70mg Tab (Cholecalciferol 7,000IU) Cholecalciferol concentrate powder 300mg Tab (Cholecalciferol 30,000IU)

Vitamin D deficiency -Highest strength of Vitamin D (Cholecalciferol 30,000IU) in

Korea

11. Evening primrose oil 450mg Soft cap. ( -linolenic acid 40mg)

Diabetic neuropathy, Atopic eczema,

Breast pain - Developed 1st in the world


RepresentativeYoeu Daehoon

Headquarter Address1106 starvalley, 99, Digital-ro 9-gil, Geumcheon-gu, Seoul, Korea

Foundation DateAugust. 30, 2005.

Research FocusOphthalmic Drugs (Dry eye, Anti-glaucoma, Anti-allergy/inflammatory/infective, etc)




Webhttp://www.dhpkorea.co.kr

Contact PersonKo Jin-Sook




Fiscal Year 2012 2013 2014

Sales 21,870 26,850 32,566

R&D Expenditure 181 245 342

Capital 7,490 44,914 56,716

Financial Figures

DHP KOREA was created for the purpose of being an special company in the field of ophthalmic drugs. As the leading ophthalmic drugs company in Korea, DHP KOREA seeks to be a world-class that continuously tries to meet customer’s need by offering safe and stable drugs. Also, we make constantly effort to comfort demand of various customers, through ceaseless produce and offer more developed products.

Focus Area : Ophthalmic Drugs

Company Profile

DHP KOREA CO.,LTD.Main Products

Product (Ingredient) Use Remarks

1. Tearinfree EYE DROPS (Sodium Hyaluronate 0.1%)

Keratoconjuntival epithelial disorder with symptoms following :1. Endogenous disease: Sjogren syndrome,

Dry eye syndrome.2. Enthetic disease: Drug-induced trauma

after operation, Enthetic disease due to wearing contact lenses.

· Preservative-free, 30 Single Dose Units per Box

· 6 mL Multi Dose Bottle

2. TearinS EYE DROPS (Sodium Hyaluronate 0.18%)


3. TearinF EYE DROPS (Sodium Hyaluronate 0.3%)


4. Dr.Fresh EYE DROPS (Sodium Carboxymethylcellulose 0.5%)

· For the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun.

· May be used as a protectant against further irritation.


5. DryFree EYE DROPS (Cyclosporine 200ug)

· For the increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.


6. Tearsopt Free EYE DROPS (Dorzolamide HCl 22.26mg Timolol Maleate 6.83mg)

· Open angle glaucoma. For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blocker.


7. Floson EYE DROPS (Fluorometholone 1mg) . To treat eye inflammation· Preservative-free, 10 Single Dose Units per Box

8. Flotera EYE DROPS (Fluorometholone 1mg, Tetrahydrozoline HCl 250ug)

. For the allergic, noninfectious conjunctivitis & keratitis, severe swelling & hyperaemia, noninfectious inflammation of the anterior segment of the eye (including anterior uveitis, episcleritis & scleritis) and post-operative conditions.

. Inflammation after operation (glaucoma, cataract)


9. LevoFresh EYE DROPS (Levofloxacin 0.5%). To treat by helping to kill the bacteria which are causing the infection.


10. SmileO2Tears EYE DROPS (Sodium Chloride 5.5mg, Potassium Chloride 1.5mg)

· Tired Eyes· Dryness· Contact Lens Discomfort· Dimed Eyes



11. Allervid EYE DROPS (Olopatadine HCl 1.11mg)

· To treat itching associated with allergic conjunctivitis.



12. KetofinFree EYE DROPS (Ketotifen Fumarate 552ug)

· To treat itching associated with allergic conjunctivitis.



Product (Ingredient) Use Remarks

13. FINECLE EYE DROPS (Chondroitin Sodium Sulfate 2mg, Cyanocobalamin 100ug , Dipotassium Glycyrrhizinate 1.5mg, Naphazoline HCl 20ug, Panthenol(pantothenol) 500ug, Pyridoxine HCl 500ug)

· Dryness· Redness· Gritty Feeling/Foreign Body Sensations· Photophobia (sensitivity to light)· Itching· Blear Eyes/Dimed Eye· Hard Contact Lens Discomfort


14. one&day FRESH EYE DROPS (Chondroitin Sodium Sulfate 5mg, Hydroxypropylmethylcellulose(hypromellose) 2910 3mg, Potassium Chloride 800ug, Sodium Chloride 4.4mg)

· Tired Eyes· Dryness· Hard Contact Lens Discomfort· Dimed Eyes


15. Eyemarine EYE DROPS (Aminocaproic acid 10mg, Dipotassium Glycyrrhizinate 2mg, Sulfamethoxazole Sodium 40mg, Taurine(aminoethylsulfonic acid) 2mg)

· Epidemic[contagious] Conjunctivitis a stye· Itching· Blear Eyes/Dimed Eye


16. Predia EYE DROPS (Phenylephrine HCl 5mg, Tropicamide 5mg)

· Mydriasis required treatment or Accommodative


R&D Pipeline

Code Use Stage of Development

DHPNP01 Dry Eye Plant scale process development

DHPNP02 Dry Eye Plant scale process development

DHPNP03 Glaucoma Lab-scale process development

DHPNP04 Glaucoma Formulation development

DHPNP05 Allergic conjunctivitis Formulation development

DHPNP06 Cataract Formulation development

RepresentativeYong Joon, CHO

Headquarter AddressB-14F, Mstate, 114, Beobwon-ro, Songpa-gu, Seoul, South Korea

Foundation DateMay 1st, 1970.



Webwww.dongkoo.co.kr

Contact PersonJi-Yong, Park

Contact Phone82-2-2684-5421 (Ext:387)



Fiscal Year 2015 2016 2017

Sales 80,369 87,363 102,500

R&D Expenditure 3,929 4,116 6,125

Capital 2,409 3,414 3,811

Financial Figures

Since 1970, DongKoo Bio&Pharma Co., Ltd. has been evolving into a global healthcare leader. DongKoo Bio&Pharma, consolidated with world-class research centers and PIC/s fulfilled GMP facilities, is in vigor expanding its commercial territories to global markets in the field of generic drugs and contract manufacturing. The company is also growing its influence in stem cell technology, developing world 1st SVF extraction kit (SmartX) and stem cell conditioned media cosmeceutical (CELL BLOOM). With synergy between bio technology and pharmaceutical, DongKoo Bio&Pharma pursues a total healthcare solution that contributes in improving people’s quality of life.

Company Profile

DongKoo Bio&Pharma Co., Ltd.


Main Products


1. Dermotasone MLE Cream (Mometasone Furoate1mg/g)

Inflammation reacting to corticoide ASEAN

2. Uropa SR Tablet 0.2 mg| (Tamsulosin HCl 0.2mg)

BPH ASEAN

3. Heparos Soft Capsule (L-cystine 250mg, Choline Bitartrate 250mg)

Hepatic function supplement ASEAN

4. Cernilton Tablet (Cernitin T60 60mg, Cernitin GBX 3mg)

BPH, CP/CPPS ASEAN

5. A-Clo Cream (Acyclovir 50mg, Hydrocortisone 10mg)

Herpes Labialis ASEAN

6. A.C. Cure MLE Gel (Benzoyl Peroxide 33.3mg/g, Adapalene 1mg/g)

Acne ASEAN

7. Amepox Soft Capsule (L-Cystine 500mg) Acne ASEAN

8. Betatriol Ointment (Betamethasone Dipropionate 0.643mg/g, Calcipotriol 50ug/g)

Psoriasis ASEAN

9. Priga Capsule (Pregabalin) Central, peripheral neuropathic pain ASEAN

10. Caverlactin Tablet (Cabergoline 0.5mg)Lactation prevention and inhibition,

hyperprolactinemia ASEAN

R&D Pipeline


- DKB15001 BPH Completed non-clinical study

Omega3+ Atorvastatin DKB15003 Hyperlipidemia DDI


Fiscal Year 2016 2017 2018

Sales 304,408 323,496 356,829

R&D Expenditure 10,414 12,271 17,049

Capital 22,230 22,230 22,230

Financial Figures

Dongkook Pharmaceutical was founded in 1968 and from the early stage since its foundation, Dongkook has concentrated on R&D and technology innovation.

We, Dongkook Pharmaceutical is well known for its OTC products boasting of high brand values in Korea. Besides OTC products, Dongkook has developed and produced outstanding therapeutic products through various clinical trials, e.g. Pofol Injection, intravenous anesthetic agent, and Lorelin Depot, an anti-cancer agent, earning raves in both domestic and overseas markets.

Dongkook completed its registration in PMDA of Japan regarding GMP approval and product registration for the finished product such as Antibiotic agent, and anesthetic agent. Teicoplanin acquired COS(Certificate of Suitability) in 2009 from EDQM, and also completed the GMP approval in TGA of Australia in 2010.

Currently, Dongkook Pharmaceutical exports finished pharmaceutical products and API to over 50 countries around the world. It seeks to grow into a global leading pharmaceutical company that is trusted and loved by all domestic and overseas customers backed by the greatest global competitiveness.

Focus Area : Nano-emulsions, Long-acting release, Liposomal drug, HA dermal filler, Antibiotics, etc.

Company Profile

Dongkook Pharmaceutical Co., Ltd.

RepresentativeHung Joo, Oh

Headquarter Address7, Teheran-ro 108-gil, Gangnam-gu, Seoul, Korea

Foundation DateOct, 1968.

Research FocusNano-emulsions, Long-acting release, Liposomal drug, HA dermal filler, Antibiotics, etc.




Webwww.dkpharm.co.kr/english

Contact PersonMs. Eugene Jang




Main Products

Product (Ingredient/Formulation)) Use Exporting Countries

1. Profofol Injection General AnaesthesiaJapan, Brazil, Uruguay, Russia,

Georgia, Iran, UAE, Iraq, Philippines, Thailand, etc.

2. Leuprolide Acetate Injection Prostatic Cancer EndometriosisMexico, Peru, Uruguay, India,

Iran, Pakistan, Kazakhstan, etc.

3. Octreotide LAR lnjection Acromegaly Carcinoid Tumors Chile, Peru, etc.

4. Cross-linked Hyaluronic Acid InjectionInjectable implant for filling wrinkles

and folds in skinPeru, Mexico, Georgia,

Indonesia, Philippines, Syria, etc.

5. Sodium Hyaluronate Injection Osteoarthiritis Under registration

6. Teicoplanin(API) AntibioticsAustrailia, Japan, Spain, France,

UK, Begium, Brazil, Greece, Turkey, Tunisia, Ukraine, etc.

7. Liposomal Amphotericin B Injection Antibiotics Ready to launch

8. Daptomycin(API) Antibiotics Ready to launch

R&D Pipeline


Daptomycin Injection DKF3152 Antibiotics Process validation

Liposomal doxorubicin DKF3151 Ovarian cancer treatment Formulation

Donepezil Depot Injection DKF310 Alzheimer treatment Formulation

Aripiprazole Depot Injection DKF002F Major tranquilizer Formulation

Dutasteride + Tadalafil Combo DKF331 Protestitis treatment Formulation

Risedronate + Vit D3 solution DKF335Nonsteroidal anti-inflammatory

Ulcer treatment drug Formulation

Long acting cross-linked hyaluronic acid injection

DKF352Injectable implant for filling wrinkles and folds in skin

Formulation

RepresentativeByungGil Yoo

Foundation DateSep. 1952

Research FocusInjectable production line




Webwww.dkpco.co.kr

Contact PersonJunku Shim

Contact Phone82-2-776-7641 (ext.153)



Fiscal Year 2015 2016 2017

Sales 83,458 93,194 -


Capital 15,000 15,000 -

Financial Figures

Dongkwang has been contributing to advancement of pharmaceutical industry by developing pharmaceutical products for over the past 60 years since its establishment in 1952. We are always striving for 'Fulfillment of Human Health and Human Happiness' with 3 ideas of its philosophy.

One of the 3 ideas is, leading the pharmaceutical industry with a clear sense of duty. Dongkwang is committed to be the leading company based on the values of sincerity, passion and creativity.

The second is, making efforts to realize a welfare society for the public. We are constantly manufacturing high-quality medicines to make human life healthy and happy with a sense of duty.

Lastly, enabling the growth of individuals and the company with outstanding creativity. It means all members of the company maximize their abilities to contribute to not only growth of the company, but also national development.

With this philosophy, we have been investing in the production facilities and focusing on the R&D to supply excellent pharmaceutical products for people. And Dongkwang has various product line-ups, in total approximately 170 kinds of products. Moreover, we are exporting good-quality medicines to over 10 countries and fulfilling the values of Dongkwang around the world.

Based on all these mentioned above, we will accomplish the vision of 'first or best' and pioneer the future.

Focus Area : Injectables production line * Equipped with prefilled syringe system * Equipped with freeze-drying line

Company Profile

Dongkwang Pharm. Co., Ltd.


Main Products

Product (Ingredient/Formulation) Use Exporting Countries Remarks

1. Aragan Injection (sodium hyaluronate 25mg/2.5mL)

Osteoarthritis 6 countriesPre-filled syringe2. Aragan Plus Injection

(sodium hyaluronate 20mg/2mL)

3. Silkron Cream (Betametasone dipropionate 0.64mg, Clotrimazole 10mg, Gentamycin sulfate 1mg)

Corticoid reactive skin disease where infection is

concerned, bacterial or fungal infection

2 countries Ointment


Research FocusAntibiotic, Cancer, New Herbal Drug

Total Staff687


Webhttp://www.dong-wha.co.kr

Contact PersonYoon Kyung Kim, Director, Global Business Team




Fiscal Year 2015 2016 2017

Sales 223,201 237,470 257,200

R&D Expenditure 13,329 13,717 14,000

Capital 27,931 27,931 27,931

Financial Figures

DONGWHA PHARM, as Korea’s first and oldest pharmaceutical company, is pursuing the ultimate goal of pharmaceutical industry, which is the development of new drugs.

Whal Myung Su, Korea’s first western-style medicine, by integrating the advantages of Western medicine into the royal court’s secret recipe in 1897, the first year of The Great Korean Empire. Furthermore, many pharmaceutical products such as Fucidin ointment and Pancold A etc., have been developed after DONGWHA PHARM. Research Institute was founded in 1973. Since present state-of-the-art laboratory building was built in 2010, it is now set to become a global hub for new drug development. The DONGWHA Chungju Plant (established in 2009) is equipped with equipment and facilities that satisfy Current Good Manufacturing Practice (cGMP) Regulations of US F. D. A. In addition, the plant has been evaluated as a world-class pharmaceutical company by the installment of high-tech plant automation system. Utilizing multi-component resources, DONGWHA strategizes to develop numerous superior medicines, the most advanced drugs and new pharmaceutical products.

Company Profile

DONGWHA PHARM


Main Products

Product (Ingredient/Formulation) Use Exporting Countries

1. Ambroxol Hydrochloride APIJapan, Indonesia, Mexico,

Philippines

2. Pantoprazol Sodium Sesquihydrate API Portugal, Indonesia

3. Levosulpiride API Spain

4. Whal Myung Su Alimentary System USA, Mongolia

5. M-Cobal 500 90C (mecobalamin/Capsule) peripheral neuropathy Vietnam

6. Pan Cold-S(Oral Solution)The relief of common cold

symptomsMongolia, Cambodia

7. Silmazin1%Cream (silver sulfadiazine) burn, bedsore, skin ulcers Mongolia



ZabofloxacinAcute Exacerbations of Chronic Obstructive Pulmonary Disease

2015.03.20./Korea

R&D Pipeline


Zabofloxacin(Quinolones Antibiotics)

DW224Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Launched in Korea.Signed Agreement in MENA and China.

Zabofloxacin(Quinolones Antibiotics)

- Community acquired pneumonia Clinical preparation

DW1018 DW1018 breast cancer Phase I

DW1017 DW1017 AML Candidate

DW2005 DW2005 Overactive bladder Preclinical completed

DW2007 DW2007 ulcerative colitis Phase II

DW2008 DW2008 asthma Preclinical completed

DW6008 DW6008 pain Phase I

DW6009 DW6009 antiplatelet Phase I

DW6010 DW6010 dementia Phase I

DW2009 DW2009 Mild cognitive impairment Clinical study

DW2010 DW2009 Anti-Obesity Clinical study

RepresentativeChan-il Park

Headquarter Address64, Cheonho-daero, Dongdaemun-gu, Seoul, Korea

Foundation DateMarch. 2013

Research FocusNew drugs

Total Staff1,582 persons (R&D Personnel : 212)



Webhttp://en.donga-st.com

Contact PersonGeunsung Kim



Summary ((1 Billion Won)

Fiscal Year 2012 2013 2014

Sales - 594.6 568.1

R&D Expenditure - 525 627

Capital - 925.7 1,077.9

Financial Figures

Dong-A ST focuses on drugs, such as domestically developed new drugs like Stillen, Zydena, and Motilitone, medical devices, diagnosis, and overseas businesses.

With its optimized research infrastructures such as its world-class, sophisticated research center completed in 2011, as well as its excellent researchers, Dong-A ST is furthering its efforts to develop global new drugs. Also, with the backing of these infrastructures, Dong-A ST vows to positively explore overseas markets, to expand its overseas exports, and to establish itself as a global pharmaceutical 0company, operating beyond the domestic market.

Focus Area : Manufacture of ETC drug, overseas business, medical equipments and diagnostics

Company Profile

Dong-A ST(Science & Technology)


Main Products


1. Growtropin II ®inj/AQ/cartridge (somatropin/injection)

Human growth hormoneBrazil, Iran, Peru, Colombia, Mexico

Bio- pharmaceutical

2. Eporon®inj./PFS (erythropoietin/injection) Renal anemia treatmentTurkey, Thailand, Chile, vietnam,

Pakistan

Bio- pharmaceutical

3. Atorvastatin Hyperlipidemia treatment Japan APIs

4. Cycloserine Tuberculosis treatment India APIs

5. Terizidone Tuberculosis treatment South Africa APIs

6. Closerin® (Cycloserine/Capsule) Tuberculosis treatment Europe Ethical drug

7. Zydena® (Udenafil/Tablet) Erectile DysfunctionBrazil, Turkey,

Russia, Malaysia, India

NCE

8. Monotaxel®inj. (Docetaxel anhydrous/Injection)

Anti-Malignant tumor Drug EU approval Ethical drug

9. Bacchus® (Taurine, Royal Jelly and others/Drink)

Energy Drink Cambodia -

R&D Pipeline


Udenafil DA-8159 Erectile DysfunctionLaunched(Korea)

Ready to NDA(USA)

Udenafil DA-8159 Benign Prostatic Hyperplasia Ph II completed(USA)

Udenafil DA-8159 Pulmonary Arterial Hypertension Ph II (Korea)

Tedizolid DA-7218 Infection: ABSSSILaunched(USA)

NDA approved (EU)

Tedizolid DA-7218 Pneumonia: HA/VAP Ph III (Global)

Evogliptin DA-1229 Type2 diabetes NDA submitted(Korea)

5-Hydroxytryptamine4 agonist

DA-6886Irritable Bowel Syndrome-

ConstipationPh I completde(Korea)

M3 receptor antagonist DA-8010 Overactive bladder Non-clinical(Korea)

SARM(selective androgen receptor modulators)

DA-4210 Sarcopenia Non-clinical(Korea)

GPR119 agonist DA-1241 Type 2 diabetes Non-clinical(Korea)

Herbal extract DA-9701 Functional dyspepsiaLaunched(Korea)

Ph II planned(USA)



Zydena(Udenafil) Erectile Dysfunction Dec. 2005/Korea

Sivextro(Tedizolid) Infection: ABSSSIJun. 2014/USAApr. 2015/Korea


Herbal extract DA-9801 Diabetic neuropathyPh II completed(Korea)Ph II completed(USA)

Herbal extract DA-9803 Alzheimer's disease Non-clinical(Korea)

Herbal extract DA-9805 Parkinson's disease Non-clinical(Korea)

Recombinant Follicle Stimulating Hormone

DA-3801Controlled Ovarian Hyper-stimulation in Assisted Reproductive Technology

Launched(Korea)

Recombinant Follicle Stimulating Hormone

DA-3801Ovulation induction in anovulatory

womenNDA submitted(Korea)

Recombinant human Chorionic Gonadotropin

DA-3803 Infertility Ph III completed(Korea)

PEG-G-CSF(Pegylated-Granulocyte-Colony Stimulating Factor)

DA-3031 Neutropenia NDA approved(Korea)

G-CSF(Granulocyte-Colony-Stimulating Factor)

DA-3030 Diabetic neuropathy Ph II completed(Korea)

Interferon- DA-3051 Multiple sclerosis Ph III planned(Brazil)

Trastuzumab biosimilar DMB-3111 Breast cancer Ph I completde(Japan)

Recombinant Factor biosimilar

DA-3808 Hemophilia A Non-clinical(Korea)

Etanercept biosimila DMB-3853 Rheumatoid arthritis Non-clinical(Korea)

Adalimumab biosimilar DMB-3113 Rheumatoid arthritis Non-clinical completed(UK)

Glyco-engineered Darbepoetin- biosimilar

DA-3880 Anemia of chronic renal failure Ph I completde(EU)

New anti-VEGF mAb DA-3131 Age-related macular degeneration Non-clinical completed(Korea)


RepresentativeLee Yang-Gu

Headquarter Address683, Dobong-ro, Dobong-gu, Seoul, Republic of Korea

Foundation DateNovember. 25,1957

Research FocusOTC



Webdongsung-pharm.com

Contact PersonJi Sun Na




Fiscal Year 2015 2016 2017

Sales 74,660 79,720 84,700

R&D Expenditure 4,078 3,201 4,000

Capital 124,116 125,386 126,000

Financial Figures

Company Profile

Dongsung Bio Pharm

Company introduction

Founded in 1957, Dongsung pharmaceutical has led 60 years to be a mid-size pharmaceutical. We have taken the lead for the modernization of pharmaceutical industry by establishing KGMP factory and central research center with high end facility in Asan, Chungnam. We have international competitiveness by producing high quality medical product through strict quality control and the high quality hair dye through accumulated new technology.

Company philosophy

'Health from Nature', the health and beauty searched in the nature, means the realization of health and beauty through value discovery from nature and coexistence with nature.

Dongsung pharmaceutical are dedicating to nature friendly products development in the various fields of pharmaceuticals, cosmetics, hair dye and photodynamic therapy under the corporate philosophy 'Health from Nature'.

We will realize the product which can contribute the national health with the vision orienting 100 years corporate and the material founded in the nature as a future growth engine.

Corporate motto

Dongsung pharmaceutical makes harmony, sincerity and creativity as corporate mottos which have been the foundation of corporate management by progressively succeeding them up to now from the company foundation.

Main Products


1. Dong Sung Cheong Ro Hwan (In 1 pill Creosote 44.4mg, Cyperus rhizome powdered 16.6mg, Coptidis rhizoma powder 22.2mg, Glycyrrhiza powder 22.2mg, Citrus unshii pericarpium 22.2mg)

Dyspepsia, watery stool, vomiting and diarrhea

U.S.A

2. Dong Sung Cheong Ro Hwan (Sugar Coated Tablet) (In 1 tab. Creosote 22.5mg, Pulvis phellondendri corticis 33.75mg, Pulvis geranil herbae 25mg)

Dyspepsia, watery stool, vomiting and diarrhea

U.S.A

3. Teethrol (In 1 tab. Zea mays L. extract 35mg)Parodontopathy,

Gingivitis, ParodontosisU.S.A

4. Teethran (In 1 cap. Tocopherol acetate 50% 10mg, Carbazochrome 2.0mg, Lysozyme chloride 30.0mg, Ascorbic acid coated 96% Type SC 156.3mg )

periodontal disease, pyorrhea alveolaris(erythema, swelling,

hemorrhage, pus etc.)

U.S.A

5. Livermarine (In 1 cap. Carduus marianus L. seeds extract 200mg, Calcium pantothenate 8mg, Cyanocobalamin 1.2 , Nicotinamide 12mg, Pyridoxine hydrochloride 4mg, Thiamine nitrate 4mg )

chronic liver disease, fatty liver, liver cirrhosis, toxic liver

diseaseU.S.A

6. EMG (In 1 cap. Tocopherol acetate 500mg, Magnesium oxide 250mg)

Improvement of muscle spasm that runs out of

magnesiumU.S.A

7. GinKolin (In 1 cap. Ginko leaf extract 120mg)

Organic brain dysfunction accompanying athymia

symptoms such as tinnitus, headzche, memory

impairment, attention impairment, depression,

vertigo

U.S.A

8. You Green F (In 1g, Urea 250mg)

keratodermia tylodes palmaris progressive

(housewife`s eczema),keratodermia, ichthyosis, senile xeroderma, lichen pilaris, atopic dermatitis

U.S.A

9. Syan (In 1 Cap. Retinol palmitate 2mg, Ergocalciferol 200IU, Copper Chlorophyll 0.3mg, Snake oil 296.7mg)

Construction feeling of eye,Bone defectiveness,

Night blindness,Rickets prevention,

Vitamin A and D supplies

U.S.A

10. Vaso-Q (In 1 cap. Crataegus oxyacantha fruit dried extract 50mg, Garlic oil 150mg, Ginkgo Biloba Leaf Extract 5mg, Melissa leaf extract 10mg )

Problems with the circulation of the blood : decreasing

of memory, enervation, and concentration becomes

worse, dizziness, chronicity tiredness

U.S.A


RepresentativeEul Won Dhong

Headquarter Address2F Kyungpoong building, 18, Nonhyeon-ro 64-gil, Gangnam-gu, Seoul, Korea

Foundation DateOct. 2011

Research FocusCardiovascular disease



Webwww.elyson.co.kr

Contact PersonJae Jin Jung




Fiscal Year 2015 2016 2017

Sales 8,601 9,544 14,000


Capital 1,000 1,000 1,000

Financial Figures

Elyson Pharm was founded in 2011 as thinking patient very first and conducting research and development for improvement of national health and the quality of life.

Elyson Pharm as a company specialized in cardiovascular disorders, strives to develop new global medicine by constant investment to R&D, and we do our best for national health with all of one heart of passion.

Company Profile

Elyson Pharmaceutical Co. Ltd.Main Products


1. Niferon CR tablet 40mg (Nifedipine) Hypertension - -

2. Molsiton tablet 2mg/4mg (Molsidomine) Anti-anginal Drug - -

3. Oxiklorin tablet 100mg/150mg/200mg/300mg (Hydroxychloroquine sulfate)

Rheumatoid arthritis, Malaria and malaria prophylaxis

- -

4. Conbloc tablet 1.25mg/2.5mg/5mg/10mg (Bisoprolol fumarate)

Hypertension, angina, Treatment of stable chronic heart failure with reduced

systolic left ventricular function

- -

5. Nebistol tablet 2.5mg/5mg (Nebivolol hydrochloride)

Essential Hypertension, Chronic heart failure

- -

R&D Pipeline


Nebivolol+Rosuvastatin EL-1401 Hypertension+Hyperlipidemia phase III


RepresentativeEun-Chul Huh

Headquarter Address107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, Republic of Korea

Foundation Date1967

Research FocusBiological Products



Webhttp://www.globalgreencross.comhttp://www.greencross.com

Contact PersonByung Lim Lee

Contact Phone82-31-260-9300 / 0848

Contact [email protected]@greencross.com Summary (1 Million Won)

Fiscal Year 2015 2016 2017

Sales 912,911 1,033,114 1,098,479

R&D Expenditure 92,509 101,893 96,814

Capital 58,433 58,433 58,433

Financial Figures

GC Pharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name.

1971 Korea’s First Human Plasma Fractionation

GC Pharma is the first company in Korea to begin fractionating plasma proteins from human plasma on an industrial scale.

1974 Pioneering Haematology

GC Pharma starts to produce Antihaemophilic factor (AHF) and the resulting therapies are provided free to Korean patients.

1982 First IV Immunoglobulin

GC pharma launches IV-Globulin in Korea, the county’s first purifies immunoglobulin product for intravenous infusion

1983 Hepatitis B Triumph

After a 12 year research and development, GC Pharma launches Hepatitis B vaccine, HEPAVAX.

1993 New Varicella Vaccine Introduced

SUDUVAX is introduced as the world’s second varicella vaccine option.

Company Profile

GC Pharma

1995 China Growth

GC China is established to support increased demand for albumin and future growth in China.

2008 GreenGene Approved

GreenGene, GC Pharma’s first recombinant factor VIII product for haemophilia A was granted marketing authorisation in Korea.

2012 Rare Treatment Option

The KFDA granted marketing approval for HUNTERASE, the world’s second therapy for the treatment of Hunter syndrome.

2014 Another Flu Vaccine Milestone : Green Cross’s manufacturing site in Hwasun, Korea reaches 100 million doses of cumulative GCFLU, flujab, production in only five years of operation.

2015 Expanding Plasma Business

To support global demand of plasma products, Green Cross establishes a manufacturing site in Thailand for the Thai Red Cross.

New Flu Vaccine

GCFLU QUARDRIVALENT, the only locally produced seasonal influenza vaccine in Korea, achieves MFDS approval.

2017 Capacity for the Future

GC Pharma announces major global business expansion plans in Canada. A new biotech facility will help meet future demand for plasma-derived products.


Main Products


1. Human Intravenous Immunoglobulin

· A-/Hypogammaglobulinemia· Combined therapy with antibiotics

for severe bacterial or viral infections · Idiopathic thrombocytopenic purpura· Guillain-Barre syndrome · Kawasaki syndrome

Asia, Middle-East, Central & South

America

Plasma Derivatives

2. Human Albumin Solution

For hypoalbuminemia and shock in acute hemorrhage from loss of albumin (burns, nephrotic syndrome, etc.) and low synthesis of albumin (hepatic cirrhosis, etc.)


America

Plasma Derivatives

3. Human Blood Coagulation Factor VIIIFor the treatment of hemophilia A with supplies of blood coagulation factor VIII


America

Plasma Derivatives

4. Recombinant Coagulation Factor VIIIFor the prevention and control of bleeding episodes and preoperative management in hemophilia A


America

Recombinant Product

5. Human Hepatitis B Immunoglobulin

· For prophylaxis of hepatitis B after exposure to HBsAg

· For prophylaxis of hepatitis B in neonates

· For prevention of recurrence of hepatitis B in patients with liver transplants


America

Plasma Derivatives

6. Human Tetanus Immunoglobulin

For the prophylaxis of tetanus and the reduction of tetanus symptoms by providing passive immunization against infection caused by Clostridium tetani


America

Plasma Derivatives

7. Split Virion Inactivated Influenza Vaccine

For the prophylaxis against influenzaAsia, Middle-East,

Central & South America

Vaccines

8. Live Attenuated Varicella Vaccine For the prophylaxis against varicellaAsia, Middle-East,

Central & South America

Vaccines

9. Idursulfase betaFor treatment (Enzyme Replacement Therapy) of Hunter Syndrome (Mucopolysaccharidosis II)


America

Recombinant Product

10. PEG-GCSF

For decrease the duration of severe neutropenia for patients receiving cytotoxic chemotherapy for solid tumor and malignant lymphoma


America

Recombinant Product

R&D Pipeline


Fibrinogen (Factor I) GC5112A Congenital fibrinogen deficiency Pre-clinical

Plasma-derived Factor VIII GC5111A Hemophilia A Pre-clinical

Anti-TFPI antibody MG1113A Hemophilia A & B Pre-clinical

Tuberculosis vaccine GC3107A Tuberculosis Clinical Phase I

Factor Xa inhibitor GC2107 Anti-thrombotics Clinical Phase I

EGFR target anti-cancer GC1118A Colon Cancer Clinical Phase I

Anthrax vaccine GC1109 Anthrax Clnical Phase II

Tetanus, diphteria and pertussis vaccine GC3111A Tetanus, diphteria and pertussis Clnical Phase II

Hunter Syndrome treatment GC1111B Hunter Syndrome Clnical Phase II

Hepariris B Immunoglobulin GC1102Prevention of HBV recurrence after

liver transplantationClnical Phase II

Allogenic NK cell MG4101 Hepatocellular Carcinoma Clnical Phase II

IVIG GC5101B Severe infection/PID Clinical Phase III

IVIG GC5107B Severe infection/PID Clinical Phase III

Seasonal influenza vaccine GC3106A Seasonal influenza Clinical Phase III

Recombinant Factor VIII GC1101D Hemophilia A Clinical Phase III

Varicella vaccine MG1111 Varicella Clinical Phase III

Fc-optimized monoclonal antibody MGAH22 Breast cancer Clinical Phase III


RepresentativeDuckjoo Lee, President & CEO

Headquarter Address153-769, 6th floor, 278, Beotkkot-ro, Geumcheon-gu, Seoul, Korea

Foundation DateSep. 17, 1992

Research FocusManufacture and distribute Anti-Cancer cell-therapy products

Total Staff160 FTE


Webhttp://eng.greencrosscell.com

Contact Persondaehwan kim




Fiscal Year 2015 2016 2017

Sales 10,418 11,909 19,539


Capital $5,400,000 $5,400,000 $5,400,000

Financial Figures

1. Business

R&D, manufactures and distributes cell therapy products, licensing business for cell therapy products, research services, cell cryopreservation, etc.

1) Cancer Immunotherapy Business- The company developed "Immuncell-LC" which is one of the most

effective cancer immunotherapy.- The products has been approved by KFDA(Korea Food and Drug

Administration) in 2007 for the indication of the reduction in the recurrence of Liver cancer.

2) Cell Bank Business- Future resource with high potential as a cell therapy.

3) Entrusted Business (CMO service) - Various services based on superior technologies and know-how

as a leader in the cell therapy market.- A company specialized in cell therapies with boundless potential

in this area.- Advanced technologies for the development and production of

cell therapy products.

2. Competitive Edge

1) Industry Leader- Cell expansive Technology.- Leader of personalized medicine through the development of safe

cancer immunotherapy.- Disastrous medical expenses for serious diseases (2013-2014).

2) Continuous R&D Investment, Commercialization- 2006: Awarded a patent on immune cell cryopreservation

Company Profile

Green Cross Cell Corporation

Main Products

Product (Ingredient/Formulation) Use Remarks

Immuncell-LC

Adjuvant therapy for patients whose tumor has been removed

after curative resection for Hepatocellular Carcinoma (Surgical resection, Radio

Frequency Ablation, Percutaneous Ethanol Injection

Therapy)

Clinical Trial Results Publications of our clinical results in global top-tier oncology journals

1. Liver cancerGastroenterology(May 27, 2015)Results of phase 3 clinical trial• Recurrence Free Survival increased by 1.5 times• Risk of recurrence decreased by 37%• Risk of death decreased by 79%

technology.- 2007: Received approval for the HCC immunotherapy “Immuncell-LC” from MFDS.- 2012: Completed phase III clinical trials for HCC and glioblastoma.

3) Diverse Pipelines of Business- Build infrastructure through networking with major university hospitals and cancer-related research centers.- Green Cross - linked synergies expected.

Executives Profile

Duckjoo Lee, President & CEO.

• MD, Ph.D.• Studied for Master’s degree from Public Health, University of Minnesota.• Former Doctor, Ajou University Hospital Family Physician.

Joon Hee Han, CFO.

• MBA.• Former Managing Director, Green Cross BT, CANADA.• Former Director Corporate Strategy, Green Cross Holdings Corp.

Jong Seong Ahn, Director, Operations.

• Ph.D in Biotechnology.• Former Director, the production sector of Green Cross LabCell.

Gyouchul Jung, Director, R&D.

• MD.• Former Vice President, Green-Cross Lab. Medical Center.

Kiwon Kang, Director of Commercial Operations.

• Former Director, Marketing, Green Cross Corp.

Hee-jung Wang, BOD member.

• MD, Ph.D. Liver Transplantation Specialist.• Current President, Ajou University

Hospital Cancer Center/Transplant Center.




Immuncell-LC Liver cancer Aug, 2007

R&D Pipeline

Compound Name Code (ClinicalTrials.gov Identifier) Use Stage of Development

CIK(Cytokine-Induced Killer cell)

+ aTc(CTL)(Activated Tc cell)

NCT01890291 Liver cancer Launch

NCT00807027 Glioblastoma Phase III

NCT02856815 Liver cancer, Mid stage Phase II (IIT)

NCT01897610 Liver cancer, Terminal stage Phase II (IIT)

- Liver cancer, Liver Transplantation Phase II (IIT)

NCT03220984 Colorectal cancer Phase II (IIT)

NCT01802138 Neuroblastoma Phase I (IIT)


Immuncell-LC

Adjuvant therapy for patients whose tumor has been removed

after curative resection for Hepatocellular Carcinoma (Surgical resection, Radio

Frequency Ablation, Percutaneous Ethanol Injection

Therapy)

2. Brain tumorImmunotherapy(March 30, 2017)Review of phase 3 clinical trial• Progression Free Survival increased by 1.5 times• Disease control rate increased by 30%

3. Pancreatic cancerCancer Immunology, Immunotherapy(Jun 12, 2014)Results of phase 2 clinical trial led by researchers• Disease control rate increased by 25%• Improvement of Quality of Life

Others

Business Strategy

- Target Indication (Liver cancer)

• Market Exclusivity -> To maximize Profit & MKT Share

• Fast Track Pathway -> To sustain minimized Payback Period

• CMO Utilization -> Risk mitigation

- Other applications (Various cancers)

• Continuous R&D and Addition of new Indications (Brain tumor, Pancreatic cancer)

• Other Collaboration with Partners

RepresentativeKim Woo Tae

Headquarter AddressRiver Tower officetel 12F, 50, Beodeunaru-ro, Yeongdeungpo-gu, Seoul, South Korea

Foundation Date23rd of Dec. 1974

Research FocusFinal Product (Medicine)




Webhttp://www.gujup.co.kr/

Contact PersonKim Jeoung Seob

Contact Phone82-2-2672-1122, Ext. 400



Fiscal Year 2012 2013 2014

Sales 56,592 59,253 57,137

R&D Expenditure 1,795 1,856 2,091

Capital 13,189 14,788 15,960

Financial Figures

GUJU PHARM. CO. LTD. is a specialized pharmaceutical manufacturer considering human life the most important value in the world.

Focus Area : Chronic metabolic disease

Company Profile

GUJU PHARM. CO. LTD.


Main Products


1. Clif cap.(Cefaclor) Antibiotics - -

2. Atorix Tab.(Atorvastatin Calcium hydrate) Treatment for Hyperlipidemia - -

3. Unazol cap.(Fluconazole) Antifungal agents - -

4. Bronkid syrup.(Hederae Helix Fluid) Expectorants - -

5. Rabiem Tab. (Rabeprazole Sodium) Proton pump inhibitor - -

6. Neocatin tab.(Acetyl Carnitine HCl) Cholinergic drugs - -

7. Neotidine tab.150mg(Ranitidine HCl) H2-blocker - -

8. Anicid cap.(Omeprazol) Proton pump inhibitor - -

9. Talimed Tab.(Talniflumate) NSAID - -

10. Diacerhein Cap.(Diacerhein) Treatment of Osteoarthritis - - RepresentativeYounha Lee

Headquarter Address16F, 218 Narae B/D, Teheran-ro, Gangnam-gu, Seoul, Korea

Foundation Date1996

Research FocusSynthesis of API, Pharmaceutical Product Manufacturing, Selling and Exporting

Total Staff+530


Webwww.hanaph.co.kr

Contact PersonGemma Kim




Fiscal Year 2015 2016 2017

Sales 108,255 125,156 140,155

R&D Expenditure 3,308 4,159 4,164

Capital 35,385 56,923 90,939

Financial Figures

Since founded in 1996, Hana Pharmaceutical Company has been keeping steady product development and pharmaceutical synthesis, and now it is ready to advance to take-off stage.

With our specialized products such as anesthetics (Propofol, sevoflurane, isoflurane) and narcotics (Oxycodone, fentanyl, morphine), we will continue our effort to become as a world-class global pharmaceutical company.

Company Profile

Hana Pharm Co., Ltd


Main Products


1. Propofol Inj. AnestheticsThailand, Yemen,

Vietnam, Dominican republic

2. Sevoflurane Sol. Anesthetics Yemen, Taiwan, Dominican republic

3. Isoflurane Sol. Anesthetics Yemen, Dominican republic

4. Atracurium Besylate Inj. Muscle relaxants Thailand, Philippines

5. Nalbuphine HCl Inj. Analgesics Philippines

6. Bupivacaine HCl + Dextrose Inj. Anesthetics Yemen, Philippines

7. Midazolam Inj. Benzodiazepines Yemen

8. Nitroglycerin Inj. Vasodilators Mongolia

9. Labetalol Inj.Non-cardioselective beta

blockersChile

10. Ramosetron HCl Inj. Antiemetics Taiwan

R&D Pipeline


- HNP-2001 Anesthetics Phase III

- HNP-2006 Contrast media Preclinical

- HNP-7060 Anti-pain Formulation

- HNP-7076 Rheumatoid arthritis Formulation

RepresentativeMr. Sung-Wuk Kim / CEO

Headquarter AddressJamshil I-Space 6F, 11-10 Sincheon-dong, Songpa-gu, Seoul, Korea

Foundation Date1973. 11. 20

Research FocusBio-therapeutics (Biobetter & antibodies), CV Combinations, AMPK activator, Ant-Atopic dermatitis.




Webwww.hanall.co.kr


Fiscal Year 2008 2009 2010

Sales 91,900 98,700 106,900

R&D Expenditure 10,831 10,928 10,651

Capital 18,500 18,500 18,500

Financial Figures

HanAll is a top 20 Korean-based R&D pharmaceutical company established in 1973. Our company initially started R&D with the development of over 30 different combinations of cardiology products through its innovative and proprietary XC Hybrid Combination formulation technology. With the acquisition of Nautilus Biotech and strengthened bio-therapeutics pipeline, we are currently developing engineered protein therapeutics via amino acid replacement engineering and mAb fragment via domain engineering which will provide superior PK/PD profile. We also focus on the treating autoimmune disease with bio-therapeutics.

Not only do we focus on bio-therapeutics, but also strive to develop new chemical entities for the treatment of cancer due to high global needs. It is important to provide effective and safe anti-neoplastic agents with minimized adverse drug events which can significantly increase patient's quality of life. Recently, preclinical and clinical data are emerging for a beneficial effect of Metformin which may affect cancer cell's proliferation and apoptosis. Hence, we are presently developing new chemical entity of biguanide derivatives as an effective and safe anti-neoplastic agent.

Company Profile

HanAll Bio Pharma




Spelear(Fudostein) antitussive agent 2005-01-19

R&D Pipeline


HL009(Adenosylcobalmin) Atopic dermatitisKOR Phase 2 completed

US phase 2 IND approved

HL008(amlodipine, losartan) HypertensionKOR Phase 1 completed

US IND preparation

HL040(losartan, atorvastatin) Hypertension, HyperlipidemiaKOR Phase 3 preparation

US IND preparation

HL156(Biguanide derivative NCE) Anti-cancer Lead optimization

HL032(oral hGH) Growth hormone deficiency KOR Phase 1 ongoing

HL143(sc IFN) Hepatitis C US Phase 1 on-going

HL036(anti TNF-alpha) Rheumatoid arthritis Lead optimization

HL161(FcRn) Autoimmune disease Lead optimization

Main Products


1. Reposporen inj.(Cefazedone) Antibiotics -

2. Tomiporan inj.(Cefbuperazoen Sod.) Antibiotics -

3. Normix tab.(Rifaximin) Antibiotics -

4. Hanall Glimepiride tab.(Glimepiride) Antidiabetes Vietnam

5. Glucodown OR tab.(Metformin HCl) Antidiabetes -

6. Hanall tramadol inj.(tramadol HCl) NSAIDS -

7. Levod tab.(Levosulpiride) Prokinetic agent -

8. Hanall Fluconazole cap.(fluconazole) anti-fungal drug -

9. Lenvard tab.(Rebamipide) antiulcer agent -

10. Hanall finasteride tab. 5mg(Finasteride) 5alpha-reductase inhibitor Vietnam, Philippines

RepresentativeYoung-Jin Kim Chairman & CEO

Headquarter Address132, Teheran Street, Gangnam-Gu, Seoul, 135-755, Korea


Research FocusOncology, Diabetes & Metabolic disorders, CNS, CV, Orphan disease, Eye disorders, Quality of life products



Webhttp://www.handok.co.kr/english/company/company.asp

Contact PersonSo-Hyun Kwon




Fiscal Year 2015 2016 2017

Sales 358,477 396,253 424,903

R&D Expenditure 18,805 18,149 26,855

Capital 316,424 318,324 319,915

Financial Figures

HANDOK, a leading innovation-driven pharmaceutical/health-care company in Korea, develops, manufactures and distributes healthcare solutions to improve the health and quality of human life. Handok has a core business focus in diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health.Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies.

Company Profile

HANDOK Inc.


Main Products


1. Amaryl M (Glimepiride+Metformin/Tablet)

Anti-diabetic drug

14 countries(Taiwan, Indonesia,

Philippines, Hungary, Russia, Dubai, etc)

The first fixed dose combination of glimepiride and metformin HCl in Korea

2. Amaryl Mex (Glimepiride+Metformin/Sustanined–release Tablet)

Anti-diabetic drug

6 countries(Singapore, Hungary, Croissy, Philippines,

Kazakhstan, etc.)

Applied by DRM technology (Dual Release Micro-coating Technology)

3. Tenelia M (Teneligliptin+Metformin/Sustanined–release Tablet)

Anti-diabetic drug -Applied by DRM technology (Dual Release

Micro-coating Technology)

4. Ketotop (Ketoprofen/Plaster)

Osteoarthritis, arthritis,

Humeroscapularis (Stiff shoulder), Muscular pain, Peritendinitis (Tendinitis)

5 countries(Singapore,

Malaysia, Vietnam, Kazakhstan,

Myanmma, etc.)

Korea’s No. 1 pain relief OTC productKetotop relieves pain and reduces

inflammation and Ketotop plaster is designed to penetrate deeply into the site

of pain and works for 12hours

5. Ready-Q ; Drink and Chew(Gummy)

Hangover Remedy 1 country (Taiwan)Delicious hangover remedy contains curcumin, an extract from Tumeric

6. Ulgeum Theracurmin - -

Innovative and best way to consume Theracurmin, Curcumin made as small

particles to be soluble and absorbed well into body

R&D Pipeline


- HL2356 Growth Hormone Deficiency Phase II

- HL5101 Cancer Preclinical development

- HL3501 Glaucoma Discovery

- HL1550 Diabetes + Hyperlipidemia Preclinical development

- DENEX Resistant Hypertension Phase I

Others

We are the best partner to bring your novel drugs to the Korean market.

Innovation and partnership belong to Handok's core values, and we strive every day to bring Innovative new products to patients, wherever they may have been discovered. With a history as a joint venture, Handok knows how to value partnership as a way of growing business for both parties involved. Handok offers its partners core competencies in areas that critical for successful drug development and commercialization.

Excellence in clinical development and management

Our Clinical Research Center is recognized for performing quality clinical trials, pharmacoeconomic studies, data management and biostatistics. The center meets global standards and has been participating in global clinical trials with multinational partners.

Optimized market access through regulatory and pricing expertise

Handok was the first pharmaceutical company in Korea an international pharmacoeconomic team. It has been successful in achieving shorter registration and launch timelines, as well as optimizing pricing fir partners' products in the Korean market.

Maximize returns though strong sales and medical marketing capability

We provide maximum return through scientific and ethical marketing practices and top-tier sales force productivity. Handok also has a high reputation among key opinion leaders in Korea.

World-class manufacturing capabilities

Handok offers high-quality manufacturing and QC capability for multiple dosage forms with the highest standard if production facilities in Korea to meet partners' manufacturing needs in Korea and other export markets.

Rigorous company-wide compliance program

Handok believes that adherence to ethical practices is essential for continuous growth and long-term success or the company and its partners' business. We were the first company to introduce a strict company-wide compliance program in Korea.

Internal research expertise to support your program

Handok has expertise in small molecules, biologics, and drug delivery system and is seeking collaborations on innovative early-stage research programs to build its future pipeline.


RepresentativeHan Sang Wook

Headquarter Address805-15, Joongsan-Ri, Yangchon-myeon, Nonsan, Chungnam Prov., Korea


Research FocusKorean traditional herbal medicine




Webwww.hsp.co.kr


Fiscal Year 2008 2009 2010

Sales - 20,384 21,687

R&D Expenditure - - 646

Capital - - 2,100

Financial Figures

We have a lot of specialized technologies in the natural medicine field, such as Korean traditional medicines. Since our modern Korean traditional medicines, resulting in many accomplishments in the biotechnology sector. Those accomplishments includes development of anticancer substances as well. In 1984, we produced and supplied successfully Korean traditional medicine solutions(i.e., Galgeuntang, Sipjeondaebotang, Sosihotang etc.) to the market. In 1992, we saw another success for development of the anticancer substance having a brand of MESIMA.

Company Profile

Hankooksinyak Pharm. Co., Ltd.Main Products

Product (Ingredient/) Use Exporting Countries

1. Chunsim heart disease, hypotension, etc. -

2. Keopoongshibodan stroke -

3. Woohwangchongshim-won stroke, atherosclerosis, hypertension, etc. Japan

4. Mankyungdan stroke, sciatica, etc -

5. Mesima gastrointestinal cancer Japan

6. Yukmihwan urinary difficulty -

7. Ickbodan fortifying, kidney-essence -

8. Shinbanwan diabetes -

9. Oakbihwan constipation -

10. Chongwidan stomach catarrh, indigestion -



MESIMA Immuno-stimulating drug 1990.2.28

R&D Pipeline


Korean medicine GST anti-atopic dermatitis Evaluation of GST


RepresentativeMr. Jae-Yoon KimMr. Jung-Jin Kim

Headquarter Address42, Seocho-Daero 52-Gil, Seocho-Gu, Seoul, Korea


Research FocusPharmaceutical



Webhttp://www.hanlim.com

Contact PersonMs. Jung-Hwa Yang




Fiscal Year 2015 2016 2017

Sales 130,702 148,629 169,096

R&D Expenditure 11,148 17,255 14,465

Capital 146,882 171,100 196,100

Financial Figures

With the corporate mission of "Protecting the precious human life from various forms of disease", HANLIM has consistently endeavored to manufacture high quality pharmaceutical products. Also, we continue to make a great investment in new medicine development and reorganizing manufacturing facilities.

Company Profile

HANLIM PHARM. CO., LTD.Main Products


1. Dages Cap. (Pepsine, Papain, Diastase, Cellulase, Pancreatin, Pancrelipase, UDCA)

Alimentary Drug China

2. Heparin Inj. (Heparin Sod.) Hemostatics, Anticoagulants

and related agentsVietnam, Singapore

3. Easy-Drops Eye Drops Ophthalmic Drugs USA, Cambodia, Nigeria

4. Numaren Eye Drops (Hydropropylmethyl cellulose, Dextran 70)

Ophthalmic DrugsUSA, Myanmar, Cambodia,Vietnam,

Hongkong

5. Posod Eye Drops (Potassium Iodide, Sodium Iodide)

Ophthalmic Drugs Vietnam, Singapore, Hong Kong, Nigeria

6. Quinovid Ophthalmic Ointment (Ofloxacin) Ophthalmic Drugs Vietnam

7. Quinovid Ear Drops (Ofloxacin) Ophthalmic Drugs Vietnam

8. Desona Nasal Spray (Budesonide)Allergy&ENT Disease

Related agentCambodia, Vietnam, Mongol, Guatemala

9. Peptazole Inj. (Pantoprazole Sod. Sesquihydrate)

Alimentary Drugs Vietnam

10.Protamine Sulfate Inj. (Protamine Sulfate) Hemostatics, Anticoagulants

and related agentsAzerbaijan

R&D Pipeline


- HL-MSC Systemic lupus erythematosus Phase 1

- HL301 Bronchitis Phase 3

- HL217 AMD Phase 1

- HL237 Rheumatoid Arthritis Phase 1

- HL235 Osteoporosis Lead mol

- HL-PIF Mixed hyperlipidemia Phase 3

- HL151 Allergic rhinitis pruritus Phase 3



Research FocusNew Biologics, New Chemical Entities




Webwww.hanmipharm.com

Contact PersonSteven Cho




Fiscal Year 2015 2016 2017

Sales 1,317,535 882,725 916,586

R&D Expenditure 187,159 162,594 170,676

Capital 25,577 26,088 27,909

Financial Figures

Established in 1973, Hanmi Pharmaceutical now is the No.1 R&D focused pharmaceutical company in Korea with highest R&D investment for many years.

Hanmi Pharm. Co., Ltd. is a Korea-based pharmaceutical company, fully integrated with strong focus in R&D which is strategically designed in 3 major fields: 1) Biologics: LAPSCOVERY platform applied long-acting pipelines. Key targeting areas are diabetes, obesity, NASH, and rare diseases / PENTAMBODY platform applied bispecific antibody pipelines. Key targeting areas are targeted immuno-oncology and autoimmune disease; 2) NCE: Mainly oncology and auto-immune disease targeted pipelines; and 3) Fixed-dose combination programs. The company has worked closely with global partners on various co-developments and collaborations. Hanmi continues to further expand through "Open Innovation Strategy" by finding potential partners for innovative solutions.

Focus Area : Innovative R&D - Diabetes, Obesity, NASH, Oncology, Autoimmune diseases, Rare diseases

Company Profile

Hanmi Pharm. Co., LtdMain Products


1. Amosartan (amlodipine+losartan) Hypertension Southest Asia 4counties, Latin America 15countries

2. Rosuzet (Rosuvastatin+ezetimibe) Hyperlipidemia WW 16 countries including Brazil

3. Duted (Dutasteride) BPH Japan

4. Amodipin (Amlopidine camsylate) Hypertension Philippines, Mexico

5. Esomezol (Esomeprazole strontium) GERD, Gastric ulcer U.S.A

6. Pidogul (Clopidogrel napadisilate) Antithrombotic Hongkong



Olita tab(Olmutinib) NSCNC 2017 NOV. /South KOREA

R&D PipelineCompound Name Code Use Stage of Development

LAPSGCSF; Eflapegrastim - Neutropenia Phase 3LAPSGLP-1; Efpeglenatide - Diabetes, obesity Phase 3

LAPShGH; Efpegsomatropin - GHD Phase 2

LAPSInsulin/ LAPSInsulin AnalogHM12460A /

HM12470Diabetes Phase 1

LAPSGLP/GCG HM12525A Diabetes, obesity Phase 1LAPSInsulin/LAPSGLP-1 combination HM14220 Diabetes Pre-Clinical

LAPSTriple Agonist HM15211 Obesity, NASH Pre-ClinicalLAPSGlucagon Analog HM15136 Congenital Hyperinsulinism Pre-Clinical

LAPSASB HM15450 Mycopolysaccharidosis Pre-ClinicalLAPSGLP-2 Analog HM15910 Short Bowel Syndrome Pre-Clinical

Oraxol™; (Paclitaxel+HM30181A) - Breast cancer Phase 3

Olita™ (Olmutinib) - NSCLC Phase 3

Poziotinib - Breast cancer, NSCLC Phase 2

BTK Inhibitor HM71224 Rheumatoid arthritis Phase 2

Oratecan™; (Irinotecan+HM30181A) - Solid tumors Phase 1

RAF inhibitor HM95573 Solid tumor Phase 1

Src kinase/tubulin dual inhibitor KX2-391 Solid tumor Phase 1

FLT3 Inhibitor HM43239 AML Pre-Clinical

GMB Stem Cell Therapy HM21001 Glioblastoma Pre-Clinical

PENTAMBODY - Solid tumor Pre-Clinical

회사 소개용 사진 배치 주력 제품 본사 및 공장 조감도 등 ( ; or )공장 조감도*

주력제품 *

회사 소개용 사진 배치 주력 제품 본사 및 공장 조감도 등 ( ; or )공장 조감도*

주력제품 *


RepresentativeKyoungrak Kim

Headquarter Address76 Hwarang-ro 32-gil, Seongbuk-gu, Seoul, 02789, KOREA

Foundation DateJuly 4, 1976

Research FocusRespiratory diseases etc.



Representative Fax 82-2.959-3621

Webwww.hwpharm.com

Contact PersonJinbo Kim




Fiscal Year 2015 2016 2017

Sales 57,887 65,146 62,719


Capital 3,436 3,436 3,436

Financial Figures

Han Wha Pharma(HWP) is a pharmaceutical company based in Seoul, Korea. HWP is well established in development, manufacture, distribution, marketing/sales and export of pharmaceutical and healthcare products. HWP is recognized to doctors and pharmacists as a specialized company that has ethical products in certain therapeutic areas such as alimentary, cardiovascular, obstetrics/gynecology, neuro-muscular, and respiratory system. Aiming to become a global enterprise, HWP has introduced global marketing techniques through an organic partnership with several overseas companies. As a result, HWP has continued making record growth in sales by successfully launching new products in the domestic market to meet customer needs based on market research. In sales activities, HWP has grown into a most trusted company among customers by successfully supplying high-quality and superior medicines to hospitals and clinics. HWP has expanded its business area to dietary supplements. HWP family consists of NaturaLife focused on nutrition supplements for domestic market and NaturaLife Asia for exporting business to Asian territory.

Focus Area : Gastro-intestinal system, Respiratory system, Obstetrics/Gynecology etc.

Company Profile

Han Wha Pharma Co., Ltd.Main Products


1. Antibio Probiotics Vietnam -

2. Ramnos Probiotics Malaysia -

3. Muteran Mucolytics - -

4. Wingli-M Anti-diabetics Indonesia Under registration

5. Winexge Anti-hypertension Indonesia Under registration

6. Telmiam Anti-hypertension - -


- YJP-14 Cardiovascular agent Phase 2

- YJP-40 Respiratory agent Phase 3

- YJC-50018 Anti-rheumatoid arthritis Preclinical


RepresentativeKooh, Dae-ho

Headquarter Address#135-080, 2~4F Time bldg, 312 Nonhyun-ro, Kangnam-gu, Seoul, Korea

Foundation Date4th May 1981

Research FocusNatural Medicine




Webhttp://www.hawonpharm.co.kr

Contact PersonR&D Department

Contact Phone82-70-8260-6030(#3)



Fiscal Year 2012 2013 2014

Sales 6,190,651 5,865,021 5,320,896

R&D Expenditure 78,894 35,727 49,028

Capital 5,777,685 5,254,988 5,915,659

Financial Figures

Hawon believes that "To contribute to the health and happiness of people through developing good medicines". We will keep the level of global standards of competition and place high priority on R&D for devised out new products and raw materials of new brand.

Focus Area : Antibiotic Drug etc

Company Profile

Hawon Pharmaceutical CorporationMain Products


1. Fazidone Inj. 1g,2g (Cefazedone sodium 1g,2g)

- urinary tract infection, cholangitis, intrauterine infection, adnexitis

-

2. Hawon Ceftriaxone Inj. 1g,2g (Ceftriaxone Na 1g,2g)

- pneumonia, bronchitis and breathing device nfection- ear, nose and throat nfection- nephritis and urinary tract infection- sepsis- bone and joint infection- skin, laceration and soft tissue infection- peritonitis, cholecystitis, cholangitis- meningitis

Mongolia

3. Ciploxacin Inj. 200mg (Ciprofloxacin 2mg)- Respiratory Infections- ENT infections, Oral, Teeth, jaw infections - kidneys, urinary tract infection

-

4. Myal Inj. (Sodium hyaluronate/10mg) - Osteoarthritis of the knee, shoulder treatment -

5. Coxicam Cap. (Meloxicam 7.5mg)- perceived exercise barrier- Symptomatic treatment of rheumatoid arthritis- Symptomatic treatment of poker back

Vietnam

6. Furoxetil Tab.(Cefuroxime axetil 300.72mg (cefuroxime axetil(as cefuroxime) 250mg))

- upper airway infection : otitis media, tonsillitis, pharyngitis

- lower respiratory tract : acute bronchitis and chronic bronchitis, pneumonia

- urogenital system infection : nephropyelitis, cystitis, urethritis

-

7. Remist Tab. (Rebamipide 100mg)

- Ulcer- Gastric mucosal lesions in the following diseases

(erosion, bleeding , redness, swelling) improvement of acute gastritis, acute exacerbation of chronic gastritis group

-

8. Fronan Cap. (Fluconazole 50mg)

- Acute or recurrent vaginal candidiasis- Hand, nail fungus, athlete's foot (foot ringworm),

tinea corpus, wanseon (groin ringworm), Skin and skin fungal infections, including candida eorureogi

-

9. Lipitrol Tab. (Atorvastatin calcium 10.35mg)

- Reduced risk of myocardial infarction- Reduced risk of stroke- Vascular regeneration and reduce the risk of chronic

stable angina

-

10. Mosadin Tab. (Mosapride citrate 5.29mg)- Functional due to poor digestion digestive symptoms

(heartburn, nausea, vomiting)-


RepresentativeChung, Bong-Yeol

Headquarter AddressUnit 603 Mega Valley, 268, Hagui-ro, Dongan-gu, Anyang-si, Gyeonggi-do, Korea

Foundation Date2003

Research FocusBiomaterials & Applications




Webwww.humedix.com

Contact PersonLee, Jong-Oh




Fiscal Year 2012 2013 2014

Sales 11,704 23,544 29,200

R&D Expenditure 1,916 1,832 2,602

Capital 2,042 2,304 3,158

Financial Figures

We, humedix, have platform technology for application of biocompatible polymers just like hyaluronic acid and PEG.

And then, we are trying to research and develop the improvement of drugs with biocompatible polymers.

We've rapidly grown up recently due to our products developed with hyaluronic acid and have been listed in korean stock market(KOSDAQ),

Focus Area : application of biocompatible polymer as hyaluronic acid and PEG etc.

Company Profile

Humedix Co., LtdMain Products


1. Sodium Hyaluronate (Sodium Hyaluronate/Powder)

Remedies for Arthritis Worldwide

2. High Hyal Plus Inj. (Sodium Hyaluronate/Injection)


3. High Hyal Inj. (Sodium Hyaluronate/Injection)


4. High Eye Inj. (Sodium Hyaluronate/Injection) Ophthalmological surgical aids Worldwide

R&D Pipeline

Compound Name Use Stage of Development

cross-linked hyaluronic acid improvement of osteoarthritis pre-clinical

conjugated Vit. D derivative whitenning pre-clinical

scFv macular degeneration pre-clinical


RepresentativeKEY AN, UM

Headquarter Address902-c, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea


Research FocusNCEs, Biologics and Generics



Webwww.huons.com

Contact PersonHan Seok, Ko



Huons has existed for more than 50 years, and grown to a competent global company, producing original and effective essential medicine and medical products, through continual challenges and innovations over 50 years.

Huons is putting a ceaseless effort for human healthy life based on the advanced manufacturing technologies and production facilities. Our goal is to achieve 1 billion USD in 2020 and aiming to be the TOP TEN global company in the industry. Huons is trying to develop 4 cores businesses in order to be the successful model of cooperation case. Our 4 main values are research and development, management of distribution, manufacturing production and developing a global business.

Company Profile

HUONS CO., LTD.


Fiscal Year 2015 2016 2017

Sales - 167,572 -

R&D Expenditure - 14,003 -

Capital - 95,051 -

Financial Figures

Main Products


1. Hutox Inj. 100units (Botulinum Toxin Type A)Temporary improvement of

moderate to severe glabellar wrinkles

Worldwide -

2. Elraive premier (Sodium hyaluronate + Lidocaine) HA Dermal Filler Worldwide -

3. High Hyal Plus Inj. (Sodium Hyaluronate) Osteoarthritis treatment Worldwide -

4. Lidocaine / Articaine with Epinephrine Inj. Dental Anesthetics Worldwide -

5. Dermashine Balance Skin hydro-lifting Worldwide -

6. Derma Akne Acne treatment Worldwide -

7. Vitamin D Inj. (Chloecalciferol 200,000IU)Treatment and Prevention of

Vitamin D deficiencyWorldwide -

8. Sodium chloride inj. Diluent WorldwideANDA

Approval in US FDA

9. Honey bush Inner beauty Worldwide -


- HU007 Dry eye syndrome Phase II

- HU002 Fatty liver Phase II

- HU014 Glabellar wrinkle Phase I/II

- HU024 Dry eye syndrome Pre-Clinical

- HU036 Auto-immune disease Discovery

- HU035 Atopy Discovery

- HU017 Inflammatory bowel disease Discovery



Clacier Eye drop (Cyclosprine 0.05%) Dry eye SyndromesMarch, 2015/ Korea(Modified generic)

Others

We, Huons are a new company separated from the former Huons established in 1965. The former Huons split into Huons Global (a holding company) and the new Huons (operations). In assuming that Huons has not split, the sales was 21.5b(KRW) in 2015 & 24.5b(KRW) in 2016 based in separated income statement.


RepresentativeLee, Han Koo

Headquarter AddressHyundaipharm Bldg, Bongeunsa St 135, Gangnam-Gu, Seoul, Korea

Foundation Date1965

Research FocusPharmaceutical products, Health food drinks, Medical equipment & device

Total Staffover 400



Webwww.hyundaipharm.co.kr/english

Contact PersonYuna Chae



We, Hyundai Pharm. with corporate philosophy in "Contribute to public health promotion" which embodies humanistic philosophy in improving public health and quality of life and CEO's philosophy focused in transparent enterprise spirit, implements organization's vision and value and actively handle fast changing business are in order to have a new leap forward in 21st century.

Focus Area : Caridovascular, CNS, Oncology support, Women's Health Care, Respiratory

Company Profile

Hyundai Pharm


Fiscal Year 2012 2013 2014

Sales 101,116 106,627 107,837

R&D Expenditure 8,083 8,368 8,243

Capital 14,000 14,000 14,000

Financial Figures

Main Products


1. Surfolase Capsule (Acebrophylline 100mg)

Acute, chronic respiratory disease, acute, chronic bronchitis, bronchial asthma, paranasal sinustis, dried

rhinitis

China IND submission

2. Minoxyl solution 5% (Minoxidil 5g/100mL)

Main pattern baldnessHong Kong, Vietnam, Cambodia, Myanmar

Preparation Approval

SubmissionApproval

3. Hyundai Moolpas-F Solution (Methyl salicylate, dl-camphor, etc)

Antiinflammatory analgesic, pernioHong Kong, USA,

Mongolia

ApprovalRegistration

Approval

4. Bumooly-S Solution (Diphenhydramine HCl, Dibucaine HCl, etc)

Eczema, dermatitis, erosion, miliaria, rhus dermatitis, pruritus, pernio,

insect bite, hivesUSA Approval

5. Varosc Tablet (Amlodipine besylate 5mg)

Hypertension, coronary artery disease Vietnam, CambodiaApprovalApproval

6. Olanpin Tablet (Olanzapine 5mg, 10mg)

Treatment of schizophrenia, bipolar disorder

Hong Kong, MacaoApproval

Preparation

7. Mirtapin Tablet (Mirtazapine 15mg)Treatment of episodes of major

depressionHong Kong, Macao

ApprovalPreparation

8. Mirap SR tablet (Pramipexole HCl) Idiopathic parkinson's disease Thailand Submission


RepresentativeYoung Kweon Choi

Headquarter Address7, Saimdang-ro 1-gil, Seocho-gu, Seoul 137-87, Korea

Foundation DateMay 29, 2000

Research FocusTDDS(Transdermal Drug Delivery System)




Webwww.icure.co.kr

Contact PersonTom Chung


Contact [email protected]@icure.co.kr

Icure Pharmaceutical Inc. is a privately held specialty drugs company with its HQ located in Seoul, R&D Center in Pyeongtack-si and KGMP approved manufacturing facility in Anseong-si in Korea. Icure's business strategy is to develop innovative transdermal drug delivery systems for local, systemic and device aided delivery of drugs. Icure is developing the transdermal formulations that enhance therapeutic value of the drugs by reducing side effects, enhancing efficacy and promoting patient compliance.

The company has successfully developed and commercialized several pharmaceutical plasters and patches for the treatment dementia associated with Alzheimer Disease, rheumatic arthritis pain, nicotine replacement therapy.

These products have been licensed to several leading Korean Pharmaceutical firms for sales in Korea.

Focus Area : Central nervous system, Respiratory, Nicotine Replacement Therapy, Pain management, Skin care

Company Profile

ICURE Pharmaceutical Inc


Fiscal Year 2012 2013 2014

Sales 9,122 9,347 14,930

R&D Expenditure 309(3%) 372(4%) 305(2%)

Capital 10,111 12,930 14,997

Financial Figures

Main Products


1. Rivaderm Patch (Rivastigmine)

Treatment of mild to moderate dementia of the Alzheimer and Parkinson`

disease

- -

2. Exoderm Patch (Nicotine) Nicotine replacement therapy - -

3. NSAIDs Plaster (Ketoprofen/ Diclofenac Sodium, diethylammonium/ Flurbiprofen/ Indomethacin /Felbinac/ Loxoprofen)

Relief for Rheumatic arthritis pain

Russia, Hong Kong, Bolivia, India

-

4. Lidogesic Cataplasma (Lidocaine) Local anesthetics - -

5. Tulobuterol Patch (Tulobuterol)

Treatment of bronchial asthma and chronic

obstructive pulmonary disease (COPD)

- -

6. Teeth whitening strips (Hydrogen perxide)

Teeth whitening treatment Taiwan, Finland -

7. Cosmetics Patch and Facial mask Anti wrinkles, Whitening,

Moisturizing Several countries

-

8. Skin care Product Anti wrinkles, Whitening,

Moisturizing -


Donepezil Patch - Treatment of mild to moderate dementia associated with Alzheimer`s disease and

Parkinson`s disease

Clinical study phase 1

Ropinirole Patch - Formulation phase

Fentanyl Patch - Relief for Severe cancer pain BE Study phase

Granisetron Patch -Prevention for nausea and vomiting caused by cancer

chemotherapy-


RepresentativeYong-Jin Chung

Headquarter Address2~4F, Iksu Building., 315, Gucheonmyeon-ro, Gangdong-gu, Seoul, 134-050, Korea

Foundation Date1970

Research FocusHerbal medicine


Representative Phone82-2-416-1116~7

Webwww.iksu.co.kr

Contact PersonYong Kim



With 50-year history Iksu Pharm. Co., Ltd. has made continuous growth on herb medicine in a half century history. Iksu Pharm. which has developed ‘Gohowhan’, a neuralgia, arthritis treatment medicine, Korean wonder drug ‘Woowhangchungshimwon.’, and ‘Gongjindan’ known as the best royal tonic medicine with its distinguished Korean herbal medication technology, is raising its public trust such as receiving license of Gongjindan, Banhasashimtang and Cheers liquid released by its technology knowhow.

By releasing various products through dosage form change with securing of GMP and quality management system for excellent medical suplies manufacturing we continue development of high quality liquid herb medication medicine. Iksu Pharm. also completed license registration of Gongsjindan liquid, fresh blood peritomy liquid, Banhasashimthag liquid, Engyosan liquid and Daesenggi liquid first in domestic.

Company Profile

IKSU PHARMACEUTICAL CO., LTD.


Fiscal Year 2015 2016 2017

Sales 14,300 17,800 21,100


Capital - - -

Financial Figures

Main Products


1. Iksu gongjindan pill/liquidvaletudinarianism, asthenia, reduced stamina,

dizziness by aggravated liver functions, headache, chronic fatigue, emmeniopathy

-Achieved the first

liquid production in the world

2. Yongpyo wonbang woohwang chungsimwon pill/liquid

Cerebral apoplexy (total paralysis, hemiplegia, speech defect, coma, lethargy condition,

facial paralysis), hypertension, palpitation, anxiety neurosis, acute & chronic convulsion,

autonomic imbalance, insensibility

- -

3. Yongpyo woohwangchungsim won pill/liquid

Cerebral apoplexy (total paralysis, hemiplegia, speech defect, coma, lethargy condition,

facial paralysis), hypertension, palpitation, anxiety neurosis, acute & chronic convulsion,

autonomic imbalance, insensibility

Vietnam -

4. Iksu banhasasimtang liquid

Following symptom of the person with stuffiness of epigastrium, nausea, anorexia,

soft stools or diarrhea : acute&chronic gastric catarrh, fermental diarrhea, dyspepsia, gastric ptosis, gastraneuria, weak stomach, hangover,

heartburn, stomatitis, nervousness

-Achieved the first

liquid production in the world

5. Cheers liquidMaldigestion, vomiturition, thirst, headache

caused by heavy drinking- -

6. Iksu galgeuntang liquidCommon cold, coryza, headache, pain of

shoulder and hands- -

7. Yongpyo ansin pill/liquidInsomnia, unrest, anxiety, thirst, palpitation, neurasthenia, shortness of breath, amnesia

- -

8. Iksu gohohwan pill Neuralgia, arthralgia, myalgia - -

9. Iksu samsoeum liquid Headache, fever, cough caused by cold - -

10. Hwangjinhwan gold pillvaletudinarianism, asthenia, reduced stamina,


- -

11. Hwangjejinsangbo liquidvaletudinarianism, asthenia, reduced stamina,


- -

12. Wisokchung Q loss of appetite, stomach swelling,

indigestion, overeating, dyspepsia, nausea, vomiting

- -



Antlers and 5 other ingredients IK-101 Improve Liver Function Under registration

Corni and 5 other ingredients IK-102 Improve Liver Function Under registration

Rehmannia glutinosa and 5 other ingredients

IK-103 Improve Liver Function Under registration

Angelica root and 5 other ingredients IK-104 Improve Liver Function Under registration

Ginseng and 5 other ingredients IK-105 Improve Liver Function Preclinical

Peony and 1 other ingredients IK-106 Pain relief Formulation

Asparagus tuber and 15 other ingredients

IK-301 Atopic Dermatitis Phase II

Antlers and 2 other ingredients IK-401 Immunity Improvement Formulation

Foundation DateMar. 14th, 1941

Research Focusprescribed drugs, OTC, probiotics, nutrient food



Webhttps://www.ildong.com

Contact PersonNathan Ahn(Sales) / Sungsang Seo(IR)

Contact Phone82-2-526-3500(Sales)82-2-526-3500(IR)

Contact [email protected](Sales) [email protected](IR)

ILDONG Pharmaceutical, as one of the leading pharmaceutical companies in Korea, strives to create a healthier and happier future for mankind with developing, manufacturing and distributing the finest pharmaceutical products.

With latest research facilities and passionate professionals, we have concentrated on new drug development project targeted at resistant bacteria, malignant tumor, and Alzheimer’s disease, and pushed forward our production of outstanding quality APIs, generic drugs, IMDs, OTC(Over-The-Counter) products as well as nutraceuticals. ILDONG Pharmaceutical has been successful for a few decades in OTC Market with several power brands. Representatively, ILDONG’s Multi-vitamin brand ARONAMIN ranked no.1 sales OTC brand in Korean OTC market in 2016.

ILDONG succeeded in developing a chronic hepatitis B treatment BESIVO in 2017 and it has been approved as a new drug from MFDS(KFDA). ILDONG also has strengthen the competitiveness in Ethical market with many original brand-name drugs through technical and marketing partnership with global pharmaceutical companies and outstanding quality generic drugs by own synthetic technology.

Company Profile

ILDONG Pharmaceutical


Fiscal Year 2015 2016 2017

Sales 458,600 479,900 461,200

R&D Expenditure 50,900 53,800 50,000

Capital 25,068 17,845 19,629

Financial Figures


Main Products


1. Biovita ProbioticsAsia / Central

AmericaFDF

2. Aronamin series Vitamin complex Asia FDF

3. Capecitabine Anti-cancer Asia / Pakistan FDF

4. Pemetrexede Anti-cancer Asia / CIS FDF

5. Fursultiamine Active vitamin Japan / Asia API

6. Levofloxacin AntibioticsAsia / CIS / Central

AmericaFDF

7. Ceftriaxone Antibiotics Asia / CIS FDF

8. Besifovir Hepatitis B Asia FDF

9. Telmisartan/Rosuvastatin Cardiovascular Asia FDC

10. Rosuvastatin/Ezetimibe Cardiovascular Asia FDC


Toosendanin (botanical drug) ID 1201 Alzheimer's disease Phase 2

PARP inhibitor (compound name has not been disclosed)

IDX 1197anticancer (target indication will be determined after P1)

Phase 1 (Single Ascending dose)

HIF modulator(compound name has not been disclosed)

IDF-11774anticancer (target indication will be determined after P1)

Preclinical

Lucentis bio-betters IDB0062 Macular Degeneration Preclinical

Avastin bio-betters IDB0072 anticancer Preclinical



Besivo (Besifovir) Hepatitis B virus Nov. 1, 17 / S.Korea

RepresentativeSuk Keun Yoon

Foundation DateFEB 15th 1061

Research FocusAntibiotics, Anesthesia, Contrast Media




Webwww.ilsung-ph.co.kr

Contact PersonJi Young Lee



ILSUNG Pharmaceuticals is one of the well-known pharmaceutical companies in Korea. ILSUNG has been focused on antibiotics, anesthetics and contrast media and is expanding to GI, CV, CNS and other areas. ILSUNG is famous for its in-licensing activities with global partners such as GSK (UK), Bracco (Italy), Abbott / Baxter (USA), Ono / Teijin (Japan). ILSUNG is selling various kinds of the branded products such as Augmentin, Suprane, and Rytmonorm. In addition to this, ILSUNG is interested in exporting business for contrast media and CMO business for antibiotics based on well organized KGMP manufacturing facilities approved by PMDA for contrast media and antibiotics.

Focus Area : Antibiotics, Anesthesia, Contrast Media, GI, CV, CNS

Company Profile

Ilsung Pharmaceuticals


Fiscal Year 2012 2013 2014

Sales 77,161 62,807 62,829

R&D Expenditure 1,903 1,402 1,213

Capital 318,059 322,744 328,683

Financial Figures


Main Products


1. Raypam Injection(Iopamidol) CT Contrast Media - -

2. Sevoprane Inhalation (Sevoflurane) Anesthesia - -

3. Augmentin (Amoxicillin + Clavulnate)

Antibiotics - -


Iohexol - CT Contrast Media -

Iopromide - CT Contrast Media -

Ioversol - CT Contrast Media -

Iomeprol - CT Contrast Media -

Meglumine Gadoterate - MRI Contrast Media -

Gadobutrol - MRI Contrast Media -

RepresentativeDong Yeon KIM, Ph.D

Headquarter Address110, Hagal-ro, Giheung-gu, Yongin-si, Gyeonggi-do, 17096, Republic of Korea

Foundation DateJuly 1st , 1946

Research FocusGastroenterology, Oncology, Virology, Vaccine


Representative Phone82-31-281-7851 (Headquarter)82-2-570-3700~7 (Seoul)

Webwww.ilyang.co.kr

Contact PersonYoung Hwi KO



With the company`s slogan, 'Respect humanity', 'Promote human's health' and 'Improve welfare', IL-YANG PHARM. CO., LTD., has tried its utmost to manufacture superior medicines for the last half a century. In addition, IL-YANG has put forth its strength for the construction of the country with healthy people under the banner of "Challenging the limitations of the medical practice and pharmaceutical dispensing for one hundred years". On the basis of the most advanced medical practice and pharmaceutical dispending and a solid business footing in the Korean market, IL-YANG has exported a variety of pharmaceuticals to approximately 30 countries in the world including the USA and Europe. And also IL-YANG has opened an era of local production, by establishing 2 Joint Ventures in China; YangZhou-IlYang and TongHua-IlYang.

Company Profile

IL-YANG PHARM. CO., LTD.


Fiscal Year 2015 2016 2017

Sales 186,285 261,614 290,000

R&D Expenditure 15,007 14,646 16,000

Capital 48,727 48,727 48,727

Financial Figures


Main Products


1. Supect Cap / Radotinib 1st and 2nd line of CML-CP -New Drug

2. Noltec Tab / IlaprazoleGastric Ulcer, Duodenal Ulcer, Erosive Esophagitis, H.pylori

EradicationEcuador, Cambodia

New Drug

3. Il Yang Flu Vaccine Pre-filled Syringe inj / Trivalent purified inactivated influenza virus antigen

Influenza Vaccine - Generic

4. Teratect Pre-filled Syringe inj / Quadrivalent purified inactivated influenza virus antigen

Influenza Vaccine - Generic

5. Rosatan Tab / Losartan potassium Hypertetion - Generic

6. Nizaractine Cap / Nizatidine H2-blockers - Generic

7. Neusilin A Tab / Magnesium Aluminum Silcate

Antacid, Absorbent - Generic

8. Andilac-S Cap / Lactobcillus Acidophillus

Digestive - Generic

9. Mutacil Powder / Psyllium huskHabitual constipation,

irritable bowel syndrome - Generic

10. Motive Tab / Mosapride Cirtate Anticonvulsive - Generic

11. Etive Tab / Itopride HCI Anticonvulsive - Generic

12. Montidin Tab / Levosulpiride Anticonvulsive - Generic

12. Telmisartan Tab / Telmisartan ARB - Generic

13. Betaprol Tab / Bisoprolol -blockers - Generic

14. AmBP Tab / Amlodipine Mesylate Monohydrate

CCB - Generic

15. Furix Tab / Furosemide Diuretics - Generic

16. Indapam Tab / Indapamide Diuretics - Generic

17. Atrovastatin Tab / Atorvastatin Hyperlipidaemic - Generic

18. Pista Tab / Pitavastatin Hyperlipidaemic - Generic

19. Actigli Tab / Piolitazone HCI Hypoglycemic agent - Generic

20. Hinechol Tab / Bethanechol Chloride

Autonomic nervous system - Generic

21. Poverin Tab / Propiverine HCIgenitourinary, Urinary

frequency, urinary incontinence

- Generic

22. Sildenafil Tab / Sildenafil citrate Erectile dysfunction - Generic

23. Arthalgyl Inj / Aspirin lysine Fever reducer, Pain reliever - Generic

24. Nutrix Tab / Acetly-L-CarnitineImprovement of brain

metabolism - Generic

25. Bonaring A Tab / DimenhydrinateMotion sickness, Vomiting, Nausea, Meniere’s disease

- Generic


26. Alvorin Tab / Levocetirizine Antihistamine - Generic

27. Epinastine Tab / Epinastine HCI Antihistamine, Antiallergy - Generic

28. Kukuratum Syrup / Pelagonium sidoides

Acute laryngitis - Generic

29. Ambosol Inj / Amino acid Amino acid - Generic

30. Ibandronsan Tab / Ibandronic Acid Osteoporosis - Generic

31. Clopidogrel Tab / ClopidogrelCVA, Cardiac infarction, Peripheral artery disease

- Generic

32. Glimed Tab / GlimepirideNon-insulin dependent

diabetes, mellitus - Generic

33. Finasterid Tab / FinasterideNeurogenic bladde,r Nervous

pollakiuria - Generic

34. Cefadroxil Cap / Cefadroxil Pyelonephritis, Cystitis,

Urethritis- Generic

35. Nofaxin Tab / Levofloxacin Antibiotic - Generic

36. Aldrin Tab, Susp / Almagate Antacid action Vietnam, Cambodia, Mongolia, Etc Generic

37. Noigel Susp / Aluminium magnesium silicate

Antacid action Vietnam, Cambodia, Mongolia, Etc Generic

38. Norumo Susp / Boehmite Antacid action Cambodia, Etc Generic

39. Shumecton Susp / Dioctahedral smectite

Antidiarrhotica Cambodia, Etc Generic

40. Alluphose Plus Susp / Colloidal Aluminum phosphate

Antacid action Cambodia, Etc Generic

41. Azintal Forte Tab / AzintamideSymptoms due to insufficient

bile secretionVietnam Generic

42. Ginkgo Biloba Leaf Ex Cap / Ginkgo biloba leaf extract

Circulatory Improvement Vietnam Generic

43. Alled Tab / Cetirizine HCI Allergin rhinitis Mongolia Generic

44. Alcom Tab / Flubendazole Anthelmintics Mongolia Generic

45. Epiderm Cream / Triamcinolone Acetonide

Dermatologicals Cambodia, Singapore Generic

46. Aminopi Tab / Thiamine Vitamin, Mineral & Nutrition - Generic

47. Jointap Plus Cap / Sodium chondrotin sulfate

Vitamin, Mineral & Nutrition - Generic

48. Poweramin Softcap / L-leucine Vitamin, Mineral & Nutrition - Generic

49. Wonbi-D / White Ginseng Extract Health Drink Malaysia, Mauritius -

50. Sol+(Ginseng energy) / Guarana powder

Energy DrinkAfghanistan, Mongolia, USA,

Pakistan, Etc-

51. D.A.H.G (API) / Dried Aluminum Hydroxide Gel

Antacid Raw Material

Guatemala, Singapore, South Africa, Taiwan, Malaysia, USA, Bangladesh,

Vietnam, Spain, Syria, Iran, Egypt, India Ney Oh, China, Cambodia, Costa Rica, Colombia, Thailand,

Tunisia, Pakistan, the Philippines, Australia, Hong Kong

-



Ilaprazole - N.E.R.D Phase III

Radotinib - Chronic Myeloid Leukemia Phase III

- IY-7640 Anti-viral Phase I

Flu Vaccine - Pediatric Quadrivalent Flu Vaccine Phase III



Noltec (Ilaprazole) Anti-Ulcer AgentDec. 2007 / China, Oct. 2008 / Korea,

Oct. 2016 / Ecuador, Jan. 2017 / Cambodia

Supect (Radotinib) Anti-CML Agent Jan. 2012 / Korea


52. Magnesium Hydroxide Gel (API) Antacid Raw Material

Taiwan, Malaysia, the US, Spain, Singapore, Indonesia, Thailand, Pakistan, Australia, Hong Kong, Bangladesh, Guatemala, New

Zealand, Syria, Egypt,

-

53. Almagate (API) / Aluminum Magnesium Hydroxide Carbonate

Antacid Raw Material China -

54. Magnesium Aluminum Metasilicate (API)

Antacid Raw Material

Taiwan, Malaysia, the US, Spain, Singapore, Indonesia, Thailand, Pakistan, Australia, Hong Kong, Bangladesh, Guatemala, New

Zealand, Syria, Egypt,

-

55. Magaldrate (API) Antacid Raw MaterialBangladesh, Bolivia, Switzerland,

Taiwan, Spain, Ecuador, Egypt, India, Chile, Pakistan

-

56. Dried Aluminium Phosphate (API) Antacid Raw MaterialVietnam, Taiwan, United States,

Singapore, China-

57. Hydrotalite (API) / Aluminum Magnesium Hydroxycarbonate

Antacid Raw Material Germany, Indonesia -

Others

OUT-LICENSING BUSINESSIL-YANG PHARM CO., LTD. is seeking for a partner in every continent to License out new chemical entity developed by IL-YANG's very own technology and R&D. IL-YANG is fully focusd on promoting "ILAPRAZOLE (Proton Pump Inhibitor)" and "RADOTINIB (Tyrosine Kinase Inhibitor)" as well as "INFLUENZA VACCINE (Trivalent/Quadvalent)" with other biological products globally with mutual business relationships.

IN-LICENSING BUSINESSIL-YANG PHARM CO., LTD. is dedicated to realize the true value of the products which compliance to IL-YANG's own vision and strategy. IL-YANG is actively engaged in the In-Licensing business to introduce innovative products from all nations to Korea. ILYANG and Licensor will synergistically maximize the effect of registration, marketing, distribution and sales regarding the product.

RepresentativeMr. Seok Joo Lee

Headquarter AddressGlobal R&D Center C-5F, 22 Daewangpangyo-ro, 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Korea

Foundation DateMarch 28, 2001

Research FocusOncology, Metabolic disorder



Webhttp://www.abxis.com

Contact PersonMira PARK



Since 2001, ISU Abxis has established its own platform technologies and product pipelines with a desire of being an axis of all therapeutic antibody industry as its name stands (ABXIS=AntiBody + aXIS). Beginning with the successful development and market-launch of Korean first therapeutic antibody in 2006. Consequently in 2013 and 2014, ISU Abxis launched two biotherapeutics for orphan diseases of Gaucher and Fabry disease. ISU’s three products, supplied to over 30 countries including Turkey, Iran, Mexico and Algeria, are available as the only alternative against the reference drugs worldwide. Moreover, ISU ABXIS GMP which is for drug substance has been inspected under PIC/S guideline and successfully registered, and application of variation for DS manufacturing site addition were approved by MFDS (Ministry of Food and Drug Safety). ISU Abxis will grow its advanced technology based business for difficult-to-treat and orphandisease market both domestically and worldwide.

Company Profile

ISU Abxis Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 11,471 19,055 30,051

R&D Expenditure 5,339 5,344 4,831

Capital 9,791 9,875 9,875

Financial Figures


Main Products


1. Clotinab®(Abciximab)Adjunct to Percutaneous

Coronary Intervention (PCI)

12 countries including Algery, Turkey, Columbia,

Venezuela and etc.

The first therapeutic antibody developed in Korea and the world’s

second Abciximab

2. Abcertin®(Imiglucerase)Enzyme Replacement Therapy

(ERT) for Gaucher disease (GD)

20 countries including Mexico, Sri Lanka, Iran, Russia

and etc.

The first drug for GD developed in Korea

and the world’s second Imiglucerase

3. Fabagal®(Agalsidase beta)Enzyme Replacement Therapy (ERT) for Fabry disease (FD)

Launched only in Korea in 2014

The first drug for FD developed in Korea

and the world’s second Agalsidase beta


Recombinant Factor IX ISU304 Hemophilia B Phase I

Novel drug (mAb) ISU104 Solid tumor Phase I

Eculizumab ISU305Paroxysmal nocturnal hemoglobinuria (PNH)

Phase I (2018)

Nivolumab ISU106Non Small Cell Lung Cancer,

MelanomaNon-clinical study (ready)

Trastuzumab ISU103 Breast cancer Non-clinical study (ready)

RepresentativeSuk Je Sung

Headquarter Address343, Sapyeong-daero, Seocho-gu, Seoul, 06543, Korea

Foundation Date1959

Research FocusCardiovascular, Gastrointestinal, but no limitation


Representative Phone82-8-529-7451~65 (546)

Webwww.jeilpharm.co.kr

Contact PersonPil Joong Kim

Contact Phone82-2-529-7451~65 (520)


We, Jeil pharma have started global business by supplying Penicillin APIs to a Japanese renowned company and also wide range of plaster products to South East Asian countries in the late 1990s.

Our factory has passed the strict standard of PMDA, Japan and also has PICS GMP as Korea has enrolled a member of PICS. As for API facilities, we have 5 dedicated factories such as Cephalosporin injection, Cephalosporin Oral, Caba-penem, Cytotoxic anti-cancer and General APIs.

In finished dosage as well, we have installed dedicated production lines such as Caba-penem injection and Cytotoxic Anti-cancer products. Besides these, we produce many kinds of generics to meet the need of our customers around the world. In 2016, our overseas sales turnover exceeds 60 million US dollarsand more than 50 countries, we are supplying our products.

We, Jeil pharma will keep expanding our market with best quality of products and contribute to the enhancement of global citizens' health.

Company Profile

JEIL Pharmaceutical Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 594,716 617,280 640,000

R&D Expenditure 20,299 22,313 23,000

Capital 7,425 7,425 7,425

Financial Figures


Main Products


1. Cefditoren (Ingredient) Antibitotics Japan -

2. Cefcapene (Ingredient) Antibitotics Japan -

3. Epinastine (Ingredient) Allergy Japan -

4. Meropenem (Ingredient) Antibitotics Japan -

5. Meropenem (Formulation) AntibitoticsVitenam,Thailand,

Azerbaijan-

6. Imipenem (Formulation) Antibitotics Vietnam, Thailand -

7. Entecavir (Formulation) Anti Viral Japan, Hong Kong -


JPI-289 JPI-289 Stroke Phase 2A

JPI-547 JPI-547 Cancer Phase 1

JP-1366 JP-1366 GERD Phase 1

JP-2266 JP-2266 Type 1 Diabetes Mellitus Pre-clinical

JCT1-PD JCT1-PD Parkinson’s disease, AMD Pre-clinical

Tamsulosin/Solifenacin JLP-1207Fixed dose combination drug

for BPHPhase 3

Metformin/Rosuvastatin JLP-1310Fixed dose combination drug for diabetes / dyslipidemia

Phase 3

Telmisartan/Amlodipine/Rosuvastatin JLP-1401Fixed dose combination drug for hypertension /

dyslipidemiaNDA

Varenicline JLP-1603New salt form drug for smoking cessation aid

NDA

UNI-DEB (Medical Device) JLM-1401 Liver Cancer (TACE)Clinical trial study

(Pivotal study)

Others

Jeil is partnered with many multinational companies like Pfizer, Takeda, Daiichi Sankyo and etc.

We are currently promoting Pfizer's Lipitor, Takeda‘s Nesian, and Daiichi Sankyo's Cravit in Korea, so we have a very good understanding of various market and plenty of sales marketing experience.

We seek new opportunities through in licensing as well as co-promotion. If you are interested in entering the Korean market, partnering with us will be a great opportunity to both of us.

RepresentativeJae-Joon, Choi

Headquarter Address231, Hyoryeong-ro, Seocho-gu, Seoul, Korea


Research FocusCapsule, Tablet, Dry Syrup

Total Staff217 Employee


Webhttp://www.jinyangpharm.com/

Contact PersonChang Hwan, Lim



Since Jin Yang Pharm. Co., Ltd. was established in 1971, we have been trying to stay ahead of the pharmaceutical industry in Korea with our full automatic production system in the most modern and up-to-date manufacturing facility.

In 2017, new manufacturing facility which is designed to export our products to advanced countries including U.S. & Europe (cGMP/EU-GMP standard) was completed and PIC/s GMP was approved. It is capable of manufacturing oral formulations over 500 million Tablets(Capsules) per year by using state-of-the-art technologies & equipments.

We have also been leading the development of the pharmaceutical industry in Korea through cooperation with the global pharmaceutical companies.

For more than forty years, based on the principle of honesty and sincerity, all the staffs and employees of our company have been putting all their efforts into building a better world with the aim of developing good quality drugs for health and happy life of the people and with the faith of managing the company in a profound respect for humanity. We promise to be a company that keeps on doing research and development for the improvement of life quality of the people and clients can give their confidence to our company. We will contribute to healthy life of the people by bending over backwards to help you not to lose your healthy body and happy life.

Company Profile

JINYANG PHARM. Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 40,100 36,100 46,000

R&D Expenditure 2,172 1,390 1,600

Capital 6,000 6,000 6,000

Financial Figures


Main Products


1. CLIVIX (Clopidogrel bisulfate/Tab.) Anti-coagulants - -

2. ESZOL (Esomeprazole/Cap.) GERD - -

3. ATORAN (Atorvastatin/Tab.) Hyperlipidemia - -

4. Acechol (Choline Alfoscerate/Soft Cap.) Neuropsychiatric system - -

5. ELBUNAL (Erdosteine/Cap.) Respiratory system - -

6. BESDIPINE (Amlodipine besylate/Tab.) Anti-hypertensives - -

7. HYALLON (Hyaluronate sodium/Inj.) Osteoarthritis - -

8. ALBIJIN (Pot.bismuth citrate, Ranitidine hydrochloride,Sucralfate hydrate/Tab.)

Digestive system - -

9. MOGATON (Itopride HCl/Tab.) GI-regulator - -

10. RAMISTA (Rebamipide 100mg/Tab.) Digestive system - -

11. ROSUVATIN 10mg (Rosuvastatin Ca./Tab.) Anti-hyperlipidemics - -

12. JINFLAG (Sarpogrelate HCl/Tab.) Anti-coagulants - -

13. OCTIRAN 40mg (Octylonium bromide/Tab.) Digestive system - -

14. DAPID (Indapamide/Tab.) Anti-hypertensives - -

15. KAZATAN (Losartan potassium/Tab.) Anti-hypertensives - -

16. MIARYL (Glimepiride/Tab.) Anti-diabetics - -

17. BANDRON (Ibandronate sodium monohydrate/Inj.)

Osteoporosis treatment - -

18. ACTOGREEN (Pioglitazone HCl/Tab.) Anti-diabetics - -

19. SIMECOPAN (Simethicone, Alverine citrate/Soft Cap.)

Digestive system - -

20. TRIMA (Trimebutine maleate 200mg/Tab.) Digestive system - -


Atrovastatin Calcium - Antilipidemic Agents BE study

Choline Alfoscerate - Nootropics % Neurotonics Formulation Study

Clopidogrel bisulfate / Aspirin -Antithrombotics & Antiplatelet

AgentsFormulation Study

Linagliptin - DPP-4 Inhibitors Formulation Study

Sitagliptin - DPP-4 Inhibitors Formulation Study

Empagliflozin - SGLT Formulation Study

RepresentativeMr. Kyung Ha Lee / CEO

Headquarter Address698, Shindaebang-dong, Dongjak-gu, Seoul, 156-757


Research FocusAnti cancer, Formulation research




Webhttp://www.jw-pharma.co.kr/

Since its foundation, JW Group has led the hospital market based on respect for life and the pioneering spirit, and is now being reborn as a global healthcare company to lead the industry into the 21st century.

Based on leading competitiveness in the ethical drug market, JW Pharmaceutical has built up strong sales network across the country and superior pipelines in I.V solutions, antibiotic, cardiovascular, gastrointestinal, nephrology, anticancer and neuropsychiatry. And now, it is pioneering the rapidly growing new field such as diabetes and so on. It has been striving to produce and provide innovative new technologies and services heading for healthy lives of human beings on the basis of its founding spirit of "Respect for life".

Company Profile

JW Pharmaceutical Corporation


Fiscal Year 2008 2009 2010

Sales 437,648 455,147 443,276

R&D Expenditure 19,942 22,173 24,231

Capital 23,033 23,774 24,487

Financial Figures


Main Products


1. Carbenem Antibiotics (Imipenem/Cilastin)

Infection by Gram - positive bacteria

Japan, China EU (Spain, Germany)

South-East Asia (Hongkong, Indonesia, Malaysia, Mongol, Parkistan, Philippines, Syria, Thailand,

Vietnam, Yemen, Nigeria, India, Bangladesh etc.)CIS (Russia, Kazahstahn, Belarus, etc.)

Latin America (Brazil, Mexico, Argentina etc.)

2. I.V SolutionsSupply electrolytes and trace

elementsSouth-East Asia (Vietnam, Cambodia, etc.)

3. Antifungal Agents (Itraconazole,ketoconazole)

Infection by fungiJapan

South-East Asia (Indonesia, Parkistan etc.)

4. Other antibiotics (Cefmetazole, amikacin)

Various infectionJapan

South-East Asia (Vietnam etc.)

5. Anticancer drugs (Cytarabine,Alkyloxan,5-FU)

Care for various cancer including hematological

cancer

South-East Asia(Turkey, Malaysia, Bangladesh etc.)


WnT - Hematological Malignancy Phase I clinical trial approved by FDA in April,

2011

Lucentis bio-betters - Metastatic Colorectal Cancer Pre-clinical study for IND application

Montelukast - Anti-AsthmaBUSH-Tab® Tech (Formulation research)

To be launched in January, 2012



Q-ROXIN (Balofloxacin) Antibiotics100mg: 6th, May, 1993200mg: 7th, Jul., 1995

Zepeed (Avanafil) Erectile Dysfunction 17th, Aug., 2011

Foundation DateJuly 1997

Research FocusFinished medicines



Webwww.kmspharm.com

Contact PersonJong Ho, Kim

Contact Phone82-31-215-5456(ext. 403)


Future oriented pharmaceutical manufacturer producing and distributing finished medicines such as tablets and capsules to the domestic and overseas hospitals, pharmacies, etc. under KGMP based on PIC/S GMP guidelines.

Company Profile

KMS Pharm Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 9,500 11,000 12,900


Capital 1,200 1,200 1,200

Financial Figures


Main Products


1. Levocetirizine dihydrated 5mg Tab Anti-histaminesCambodia, Myanmar Hongkong, Mongolia

-

2. Tramadol hci 37.5mg / Acetaminophen 325mg Tab

Anti-inflammatoryVietnam, Cambodia

Hongkong-

3. Levosulpiride 25mg Tab IndigestionVietnam, Cambodia

Hongkong-

4. Losartan potassium 50mg Tab Hypertension Vietnam -

5. Rebamipide 100mg Tab Gastric ulcer Vietnam -

6. Felodipine 5mg Tab Hypertension Cambodia -

7. Levodropropizine 60mg Tab Antitussives & Expectorants Hongkong -

8. Streptokinase / Streptodornase 10mg Tab

Enzymes Ecuador -RepresentativeCho Hong Koo

Headquarter Address245 Sandan-gil, Jeonui-myeon, Sejong city, Korea


Research Focus42 (Pharmaceutical division)




Webhttp://www.kolmarpharm.co.kr

Contact PersonMr.M.S.Pyo



Since founded in 1990 as a joint venture company with Nihon(Japan) Kolmar, Kolmar has grown to the biggest Korean Pharmaceutical contract manufacturer.

Kolmar Korea has extended our business to pharmaceutical business from 2002. And provide specialized production system with total outsourcing service on development and production of pharmaceutical and quasi-drug.

Kolmar Korea has provided customized contract manufacturing service with customers who want to outsource their pharmaceutical products, cosmetics and healthcare foods to be more competitive and to develop new formulations feasible in the market.

Focus Area : CMO (Contract Manufacturing Organization), Generic drug.

Company Profile

Kolmar Korea Co.,Ltd.


Fiscal Year 2012 2013 2014

Sales 177,779 267,881 439,080

R&D Expenditure 7,418 11,997 17,200

Capital 9,742 9,742 10,550

Financial Figures


Main Products


1. Painless Tablet Anti inflammatory Philippines EU-GMP 추진품목

2. Hiforge Tablet Hypertensive Ajerbaijan -

3. Cerephone Dry Syrup Anti-biotic Vietnam -

4. Azithrobiotic Dry Syrup Anti-biotic Vietnam -

5. Romaryl Cream Anti-fungi HongKong -

6. Levocetirizine HCl Tab. Anti-histamine The Philippines -

7. Minoxidil solution Male pattern alopecia Japan -


Tadalafil - Eretile dysfunction BE

Amlodipine + Olmesartan - Hypertension BE

Celecoxib - Antiinflammatory BE

Atorvastatin Calcium - Hyperlipidemia BE

Entecavir - Treatment of HBV BE

RepresentativeWoosok Lee

Headquarter Address13 Kolon-ro, Gwacheon, Gyeonggi, Korea

Foundation DateSeptember, 1958

Research FocusRespiratory, Dermatology



Webhttp://www.kolonpharma.co.kr

Contact PersonNarae Song



KOLON Pharma is focusing on developing and distributing high-quality over the counter pharmaceuticals, prescription medications (mainly respiratory and dermatology) and sports nutrition products in Korean market with a vision of expanding globally.

KOLON PHARMA is now working on expanding our business through the open R&D process in Oncology, CNS and Hepatology areas as well as focusing on developing of new drugs by using Incrementally Modified Drug(IMD) technique.

Company Profile

Kolon Pharma


Fiscal Year 2015 2016 2017

Sales 73,500 81,600 100,200

R&D Expenditure 1,478 1,494 1,600

Capital 6,000 6,000 6,000

Financial Figures


Main Products


1. Foster HFA (Beclomethasone Dipropionate, Formoterol Fumarate / inhalation)

Asthma, COPD - No.1 in MDI Market

2. Topisol Milk Lotion (Methyl Prednisolone aceponate/ Topical Lotion)

Topical Corticosteroids - No.1 in Topical Steroid Market

3. Curosurf (Poractant Alfa/Oral Solution)

Neonatal Distress Respiratory syndrome

-

World’s No.1 SurfactantOne of the leading product s in

hospital -Accounting for 63% of the Korean market

4. COMY Syrup (Pseudoephedrine, Chlorphenylephrine/Oral Solution)

Nasal & Sinus Congestion

--Ranked No.1 in pediatric

decongestion and rhinitis market

5. INVOSSA-K Inj. (1: hChon J, 2: hChonJb#7)

Osteoarthritis -The World's first cell-mediated

gene therapy

5. APNIBEN Q Soln (Diclofenac/Gargle Solution)

Cold sores/ Stomatitis -Disposable sachet

The only mouthwash type Ranked No 1. in Somatitis Tx Market

6. BICOGREEN S Tab (Bisacodyl, Sennoside, Sod.Docusate)

Constipation -Ranked No 1. in Constipation

Market


beclomethasone dipropionate + formoterol + CHF-5992

KPC-7001 Asthma COPD Pre-registration

beclomethasone dipropionate + formoterol high dose

KPC-7002 Asthma COPD Pre-registration

Oseltamivir Capsule/Dry Powder for suspension

KPC-1023 Influenza Launched

Bepotastine Dry Syrup/SR tablet KPC-2003/2004 Rhinitis Phase 1

Bepotastine + Montelukase KPC-2007 Rhinitis Phase 1

Undisclosed KPC-9007 Psoriasis registration

Sinecatechins KPC-7104 Warts Pre-registration



Morniflu Tab(Monriflumate) NSAIDs 2004.06.09. / Italy

Remicut Cap(Emedastine Difumarate) Anti histamine, For allergic Rhinitis 1994.04.31. / Japan

Brexin Tab (Piroxicam beta cyclodextrine) NSAIDs 1992.01.22. / Italy

RepresentativeHang Gu Lee

Headquarter AddressKorea Arlico B/D, 7-21,Baumoe-ro27-gil, Seocho-gu, Seoul, 06752, Republic of Korea

Foundation DateOCT. 01, 1992

Research FocusTablets, Ointments, Creams, Gels



Webwww.arlico.co.kr

Contact PersonSEUNG CHAN HAN



About 20 years, we Korea Arlico Pharm have been poured our energy into helping people to live healthier and happier based on the belief that life is precious and nature is the source of all life.

We value our quality through KGMP validation for better circumstance.

In the year 2010, we had 30% increase from 2009 and keep growing its sale record in 2011 and exports to 4 Countries as for April. 2011.

We Awarded a million dollars "Export top" by Korea International Trade Association in 2013.

And we went public on February 12, 2018.

In the near Future, we hope to find more countries to have a strong partnership.

Company Profile

Korea Arlico Pharm Co.,Ltd.


Fiscal Year 2015 2016 2017

Sales 32,985 48,214 71,346

R&D Expenditure 1,770 1,358 1,925

Capital 1,112 1,216 3,211

Financial Figures


Main Products


1. Thioct HR Tab. (Thioctic Acid 600mg / Solid oral)

Relief and treatment of diabetic multiple neuritis

Vietnam, Mongol -

2. Acrasone Cream 10g (Betamethasone Dipropionate 0.64mg, Clotrimazole 10mg, Gentamicin Sulfate 1mg)

Anti-inflammatory action and good antifungal action

Vietnam, Tanzania, Hongkong

-

3. Cozasartan Tab. (losartan potassium 50mg)

Hypertension Renal disease in diabetic patient with

hypertension - -

4. Curazol Cap. (Omeprazole 20mg)Duodenal ulcer, gastric ulcer,

reflux esophagitis etc.,Ecuador -

Others

Our ultimate goal is to become a global pharmaceutical company competing against current multi-national companies. We will vigorously continue to improve our products.

RepresentativeMoon Sungho

Headquarter Address226 Yeoksam-ro, Gangnam-gu, Seoul, Korea

Foundation DateJuly 9,1982




Webhttp://www.otsuka.co.kr

Contact PersonKim Taejin



Established in 1982, Korea Otsuka Pharmaceutical Co.,Ltd. is a joint-stock company that provides excellent and innovative medicines as part of its mission of contributing to the Korea healthcare industry. We have large-scales production facilities in Korea for the consistent production of finished goods from synthesis of life. Moreover our products have help treat patients in Korea and improve quality of life. Moreover our products been exported Europe, Asia and the Middle East contributing to the taken an active part in international clinical studies, and strived to expand our business starting with the healthcare business in 2012.

Focus Area : CNS, Neurology, Cardiology, Gastroenterology

Company Profile

Korea Otsuka Pharmaceutical Co.,Ltd.


Fiscal Year 2012 2013 2014

Sales 11,517,041 12,124,578 12,100,153

R&D Expenditure 402,665 213,818 177,080

Capital 17,356,368 17,457,246 18,287,237

Financial Figures


Main Products


1. ABILIFY Tab. Anti-psychotic agentHong-Kong, Philippines,

Thailand, Indonesia-

2. ABILIFY ODT Anti-psychotic agent OPEL(Europe) -

3. PLETAAL Tab. Anti-platelet agentHong-Kong, Philippines,

Thailand, Vietnam, Malaysia-

4. PLETAAL SR Cap Anti-platelet agent - -

5. MUCOSTA Tab. Anti-ulcer agentPhilippines, Thailand,

vietnam, Cambodia, Malaysia-

6. SAMSCA Tab. Aquaretic agent Philippines, Thailand -

7. Meptin Tab. Anti-asthmatic agent - -

8. Meptin swinghaler Anti-asthmatic agent Philippines, Indonesia -

9. OBUCORT swinghalerAnti-asthmatic agent

(Inhalation)Philippines, Thailand,

Indonesia-

10. Mikelan Tab. Anti-arrhythmic agents - -

11. Busulfex IVHSCT (hematopoietic stem cell transplantation)Conditioning

agent- -

12. Lorelco Tab. Anti-hyperlipidemic agent - -

RepresentativeJae Don Park

Headquarter Address87, Jeyakgongdan 3-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea

Foundation DateSep. 03, 1974

Research FocusDeveloping innovative new medicines



Representative Fax 82-2-558 1678

Webwww.koreapharma.co.kr

Contact PersonJin Wook Lee


Contact [email protected]@koreapharma.co.kr

Korea Pharma Co., Ltd.(KP) established in 1974, have acquired KGMP as we have safe and stabilized production systems. KP maintain the production process to assure the efficacy, safety and stability of all our products such as oral solid forms, oral liquid forms, topical liquid forms, ointment etc. We have built up perfect Q.C. systems, and we are supplying our products to the domestic markets, and exporting to over 16 countries to be widely recognized the manufacturing and technological achievements in the world.

Focus Area : CNS Drug, Colon Cleansing Agent, Alimentary Preparation etc.

Company Profile

KOREA PHARMA CO., LTD.


Fiscal Year 2012 2013 2014

Sales 44,744 50,046 54,829

R&D Expenditure 1,010 1,350 1,453

Capital 3,300 4,200 4,200

Financial Figures


Main Products


1. VASTIA Tab. 5mg/10mg (Donepezil HCl 5mg, 10mg)

Central nervous system agent Hong Kong -

2. ALBIX Tab. 10mg (Memantine HCl 10mg)

Central nervous system agent Hong Kong -

3. KOTASE Tab. (Bromelaine 40mg & Crystalline Trypsin 1mg)

Anti-tumefacient enzyme preparation

Myanmar, Vietnam -

4. BAB Chewable Tab. (Hydrous dibasic calcium phosphate 100mg, Calcium lactate 25mg, Vitamins, etc.)

Alimentary preparation Myanmar -

5. AMOROLFINE Nail Lacquer (Amorolfine HCl 5g)

Topical antifungal agent for onychomycosis

- -

6. CRICOLON Tab. (Dibasic Sodium phosphate anhydrous 398mg, Monobasic Sodium phosphate monohydrate1,102mg)

Tablet type colon cleansing agent

- -

7. RISDON Tab. 1mg/2mg (Risperidone 1mg, 2mg)

Central nervous system agent - -

8. PAROXETINE Tab. 20mg (Paroxetine HCl 22.8mg)

Central nervous system agent - -

RepresentativeKim Dae Ik

Headquarter Address8F, Daein B/D, 158-3, Daein-dong, Dong-gu, Gwangju, Korea


Research FocusMedicine




Webhttp://www.koreaprime.co.kr/english/main.htm

KOREA PRIME PHARM. CO., LTD. is specializes in manufactures and sales of pharmaceutical drugs(ETC) and Hospital doctors prescribe medications, and going to achieve higher growth rate of 30% per year rather than the average growth rate of the pharmaceutical industry.

Furthermore, domestic pharmaceutical companies are noticed to a big change by Korea-US FTA agreement recently. Therefore, Our c35,145ompany cope with the policy changes of the domestic pharmaceutical industry and the opening of the global pharmaceutical market, and we think to develop new products as a top priority in order to grow as a global company, and are focusing on doing business making new drugs(improved new drugs, Biomedicine, drug formulation development, and so on) by R&D cooperation.

In particular, our company awarded "2009, Korea Health Industry Award", and "Grand Prize"in the part of independent medium venture company. With this opportunity, we will increasingly continue to work hard with the responsibility of the development of domestic pharmaceutical health industry.

Company Profile

Korea Prime Pharm. Co., Ltd.


Fiscal Year 2008 2009 2010

Sales 35,145 43,544 60,233


Capital 1,950 2,150 2,150

Financial Figures


Main Products


1. Denical Tab. (Calcium lactate pentahydrate 271.8mg, Calcium Glluconate 240mg, Precipitated Calcium Carbonate 240mg, Dried Crgocalciferol 0.118mg)

In case of calcium shortage/supply Vietnam, Cambodia -

2. Throgin Tab. (Roxithromycin 150mg)

Pharyngolaryngitis, acute bronchitis, tonsillitis, bacterial pneumonia, otitis media, sinusitis,

periodontitis, etc.Vietnam, Cambodia -

3. Rocin Tab. (Ciprofloxacin 250mg)

Respiratory tract infection, infections in ear, nose, throat, mouth and tooth, renal and urinary tract

infection, etc.Vietnam, Cambodia -

4. Anflaim Tab. (Ofloxacin 100mg)

respiratory tract infections, urinary tract infections, dermatological infections, gynecological infections

Vietnam, Cambodia -

5. Simbidan Tab. (Simvastatin 20mg)

hyperlipidemia, prophylactic use in hypercholesterolaemic patients with ischaemic

heart diseaseVietnam -

6. Loxorofen Tab. (Loxoprofen sodium 68.1mg) (60mg as anhydrous)

1. Anti-inflammation and analgesia in the following diseases and symptoms : Chronic

rheumatoid arthritis, osteoarthritis, low back pain, scapulohumeral periarthritis and neck-shoulder-arm

syndrome.2. Anti-inflammation and analgesia after operation,

trauma or tooth extraction.3. Anti-pyresis and analgesia in the following

diseases : Acute upper respiratory tract inflammation(including acute upper respiratory tract

inflammation accompanied by acute bronchitis)

Vietnam, Cambodia -

7. Talpain Tab. (Talniflumate 370mg)

Rheumatoid arthritis, osteoarthritis, (degenerative arthritic disease), sciatic neuralgia, amenorrhoeic

pain, pain caused by trauma, inflammation and pain after surgery, tendosynovitis, sprain, adnexitis,

pharyngitis, tonsillitis, otitis, sinusitis

Vietnam, Cambodia -

8. Exad Cap. (Nizatidine 150mg)Duodenal ulcer, gastric ulcer, Gastric oesophageal

reflux diseaseVietnam, Cambodia -

9. Borad Tab. (levosulpiride 25mg)

Alleviation of the following symptoms due to functional dyspepsia: abdominal fullness, epigastric

discomfort, and stomach soreness, belching, nausea and vomiting

Vietnam, Cambodia -

10. Apepsia-m Tab. (Domperidone maleate 12.72mg) (10mg as Domperidone)

Following diseases and dyspepsia in case of drug administration nausea, vomiting, anorexia,

abdminal Distension, abdominal pains, flatulence, etc.

Vietnam, Cambodia -

R&D PipelineIngredient Use Stage of Development

Sildenafil citrate Treatment for erectile dysfunction. Bioquivalence Test completion

RepresentativeDuk-young Kang

Headquarter Address25-23, Nojanggongdan-Gil, Jeondong-Myeon, Sejong, Korea

Foundation DateDec. 03, 1987

Research FocusDrug delivery system - Novel Controlled Release Formulation - Novel Fixed Dose Combination



Webhttp://www.kup.co.kr

Contact PersonJihyun Ahn



· Establishment Date : Dec. 3, 1987

· Business Activities : Manufacture, Marketing & Sales of Pharmaceuticals and Other Healthcare Products

· Number of registered products : about 307 items

· Number of employees : 810 (Feb. 28, 2017)

· Investment in R&D : 12.8% of net sales (2016)

· Sales : $160M (2016)

· Growth Rate from 2015 to 2016 : 9.2%

· Incrementally Modified Drug : Clanza®CR, Clavixin®Duo Cap, Cilostan®CR, Kalomin®Tab, Losasc®Tab5/50, Losasc®Tab5/100, Gastiin®CR, Levotics®CR

KUP is an export-oriented company. KUP is aiming to be not only a local leader but also global leading company by offering wide range of generics as well as differentiated products, incrementally modified drugs.

KUP has broad and well balanced portfolio of 307 products and exports 416 different items to 32 countries through global marketing, and overseas manufacturing facilities in USA, Vietnam, and has business alliances with oversea companies. Especially, KUP established manufacturing facility in Alabama, US for manufacturing and distrubuting drugs and health functional foods in 2003. This facility have allowed KUP to expand markets in US, Japan, and Europe with know-hows of FDA regulatory processes.

Company Profile

KOREA UNITED PHARM.INC.


Fiscal Year 2015 2016 2017

Sales 162,039 176,905 -


Capital 227,804 234,220 -

Financial Figures


Main Products


1. Clanza®CR Tab. (Aceclofenac 200mg / Controlled Release Formulation)

Pain caused by rheumatism(Antiinflammatory Analgesic

drug)

Ukraine, Vietnam, Philippines

· Improved dosing regimen from b.i.d. to q.d.

· Less side effects of gastrointestinal

2. Cilostan®CR Tab. (Cilostazol 200mg / Controlled Release Formulation)

Ischemic symptoms, Thrombosis (Antithrombotic

drugs)-

· Improved dosing regimen from b.i.d to q.d.

· Reduced side effects of headache & tachycardia

3. Clavixin®Duo Cap. (Clopidogrel 75mg and Aspirin 100mg / Fixed Dose Combination)

Acute coronary syndrome(Antithrombotic drugs)

-· Improved patient

compliance

4. Kalomin® Tab. (Pelargonium Sidoides(as dry extract) 20mg / New Dosage Formulation)

Upper respiratory tract infections (Antitussive)

-· Improved patient

compliance for adults

5. Losasc® Tab5/50, 5/100 (Amlodipine 5mg and Losartan 50mg / Amlodipine 5mg and Losartan 100mg, Dual Layer Anti-Oxidant)

Hypertension(Anti-hypertensive drugs)

-· CCB+ARB in ONE tablet· Patent protected unique

formulation

6. Gastiin®CR Tab (Mosapride 15mg / Controlled Release Formulation)

Gastrointestinal symptoms associated with functional dyspepsia(brash, nausea,

vomiting)

-· Improved dosing

regimen from t.i.d. to q.d.

7. Levotics®CR Tab. (Levodropropizine 90mg)

Antitussive -

· Just one tablet, twice a daily

· Performed clinical trial lll phase of 8 university hospitals

KUP invested in Research&Development. KUP invested about 12% of net sales and 10% of total employees in R&D continuously. KUP is successful developing innovative drugs and commercializing them. As a result, KUP has launched several IMDs including Clanza®CR Tab., Calvixin®Duo Cap., Cilostan®CR Tab., Kalomin®Tab., Losasc®Tab5/50, Losasc®Tab5/100, Gastiin®CR Tab., Levotics®CR Tab.. In addition, KUP has well balanced R&D portfolio including differentiated products of anti-neoplastic, Anti-hypertensive, and Antithrombotic Drugs.

KUP has been acknowledged at home and abroad. KUP was nominated as Forbes’ ‘Asia’s 200 Best Under A Billion’ over two consecutive years. KUP is one and only pharmaceutical company in Korea nominated by the Forbes magazine as one of the ‘Asia’s 200 Best Under A Billion’ over two consecutive years (2009~2010). KUP was awarded the Best Drug Research Award in Korea for Cilostan®CR Tab in 2015.

RepresentativeDeok-Ho Choi

Headquarter Address128, Mongnae-ro, Danwon-gu, Ansan-si, Gyeonggi-do, South Korea

Foundation Date1956.01

Research FocusVaccines


Representative Phone82-31-495-6397~882-2-443-1961~5


Webwww.koreavaccine.com

Contact PersonSungbae Ha



Specializing in production of infectious disease preventive medicine(Vaccine) and disposable medical devices, Korea Vaccine has contributed to people's health since 1954.

Focus Area : Pediatric vaccine and disposable medical supply.

Company Profile

Korea Vaccine


Fiscal Year 2012 2013 2014

Sales 115,774 100,700 133,200


Capital 46,790 55,646 63,256

Financial Figures


Main Products


1. Freeze-dried BCG vaccine(percutaneous)

Prevention of Tuberculosis - Global distributorship

2. Kovax Polio PF. Prevention of Poliomyelitis - -

3. Typhoid Kovax Inj.Prevention of Thphoid

bacillus- -

4. Kovax Influ PF (Influenza Vaccine) Prevention of Influenza - -

5. IL-YANG Flu Vaccine (Influenza Vaccine)

Prevention of Influenza - Global distributorship

6. Vari-L Vaccine Inj. Prevention of Varicella - Global distributorship

7. CD.JEVAX Inj.Prevention of

JapaneseEncephalitis Virus

- Global distributorship

RepresentativeSang Hun, Park

Headquarter Address34, 28 Gil, Nonheyon-ro, Gangnam-gu, Seoul, Korea

Foundation DateJanuary, 1980.

Research FocusCentral Nervous System drugs



Webwww.nicepharma.com

Contact PersonEun Young, Park

Contact Phone82-2-529-6100 (Ext. 313)


We manufacture, distribute, export and import more than 180 medicines, health functional foods and cosmetics. Also, do contract manufacturer of specific dosage forms, supplies medicines and diverse products.

We have always been eager to be the most reliable and trustworthy pharmaceutical company that can bring the highest value to the society, clients and employees since our establishment in 1980.

We started the progressive sales of our OTC products and we become a famous local brand in Korea with the launch of our brand Haben®, a common cold remedies. Also, another brand called Santamon®, an anti-anemic, had a very good reception in the market. These achievements made us an important place in the OTC market and we earned the affection and respect of the Korean society.

Later on, after continuously developing and researching new drugs day and night and start the incrementation of our sales in the ETC market with notorious and innovative products.

Nowadays, we are developing and doing research in Lifestyle modification products, such as Vitamins, Omega 3 and nutrients, essentials for patients and human’s healthy lifestyles.

Company Profile

KOREAN DRUG CO., LTD.


Fiscal Year 2015 2016 2017

Sales 47,390 55,308 59,000

R&D Expenditure 2,405 3,278 3,600

Capital 5,500 5,500 5,500

Financial Figures


Main Products


1. Neuromed (Oxiracetam/Tablet, Syrup, Injection)

Alzheimer's dementia China -

2. Gabatin (Gabapentin/Tablet, Capsule)

Epilepsy, Neuropathic painVietnam, Myanmar,

Cambodia-

3. Neurocept (Donepezil/Tablet) Alzheimer's dementia Vietnam -

4. Lukema (Montelukast/Tablet, Chewable tablet)

Asthma, Allergic rhinitis Vietnam -

5. Zypeace OD (Olanzapin/OD Tablet)Schizophrenia, Bipolar

disorderVietnam -

6. Allertec (Cetrizine/Tablet) Allergic rhinitis, Skin itchingSingapore, Vietnam,

Cambodia-

7. Isotren (Isotretinoin/Soft capsule) Severe acne Vietnam, Cambodia -

8. Plamed (Clopigorel/Tablet) Atherosclerotic symptoms Vietnam -


Crude extract KDC14-1 Osteoporosis Phase I

Crude extract KDC14-2 Anti-thrombosis Research

Crude extract KDC14-3 Brain disease Research

Crude extract KDC14-4 Inflammatory bowel disease Pre-clinical

Crude extract KDC14-6 Atopy treatment Pre-clinical


Other


Neuromed Tablets (Oxiracetam) Alzheimer's dementia 1992-03-11/Korea

Ribecca Cream (Difluprednate) Eczema, dermatitis 1995-01-05/Korea

RepresentativeHO-YOUNG AHN

Headquarter Address49, SANDAN-RO, HEUNG DEOK-GU, CHEONGJU-SI, SOUTH OF KOREA


Research FocusMANUFACTURING


Representative Phone010-6844-1527

WebWWW.KUKBOSCIENC.CO.KR

Contact PersonSOPHIA KIM

Contact Phone010-3845-0842


We, KUKBO SCIENCE LTD., have produced public health insecticides and rodenticides and made effort to make eco-friendly products over 47 years under 'Human Living, Human Environment' as company philosopy.

KUKBO SCIENCE. LTD is the biggest pest control company in South of Korea. We have exported our products about 20 countries around the world.

Company Profile

KUKBO SCIENCE


Fiscal Year 2015 2016 2017

Sales 9,517 9,713 9,192


Capital 2,300 2,300 2,300

Financial Figures


Main Products


1. Cleanbait power 35g (Hydramethylnon 2%)

Pest controlThailand, Oman,

Qatar, Russia, Hong kong etc

-

2. Coumafen (Flocoumafen 0.005%)

Pest controlJordan, Philippine

etc-

3. Delta zone MC (Deltamethrin 2.5%)

Pest controlVietnam, Chile,

Spain, South Africa, UAE etc

-

RepresentativeMr. Nam Tae-Hoon

Headquarter Address96-8, Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

Foundation DateJul. 27, 1959



Webwww.kukjepharm.co.kr

Contact PersonMr. H. J. Lee



Kukje took its first step as a prescription drug manufacturer 57 years ago. It is now Korea’s representative pharmaceutical company and continues further growth in becoming a global leader that will help render people around the world healthier. Kukje is committed to its vision of developing prescription drugs to prevent diseases as well as render your lives more meaningful and beautiful.

Company Profile

Kukje Pharma Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 111,651 114,992 122,291

R&D Expenditure 3,438 4,424 6,511

Capital 16,607 16,607 17,397

Financial Figures


Main Products


1. Cefminox Sod. Inj. 1g/0.5g Antibiotics China -

2. Ceftazidime Inj. 1g Antibiotics Vietnam -

3. Lincomycin Hcl. Inj.600mg Antibiotics Vietnam -

4. Spectinomycin Hcl Inj. 2g Antibiotics Iran -

5. Amlodipine Tab.5mg Hypertension Cambodia -

6. Cefotetan Inj. Antibiotics UAE -


Nizatidine&Irsogladine Cap. - Gastritis Phase 3 is completed

Cyclosporin eye-drop - Dry Eye syndrome Phase 3 is ongoing

Rebamipide eye-drop - Dry Eye syndrome nonclinical trial is ongoing

Other

Our product line with certified PIC/s GMP is fully equipped with high performance modern technology such as high-quality lyophilizer for producing Cephalosporin Injections. Approximately 150 kinds of medicines including ophthalmic products, antibiotics, GI products, CV products, NSAIDs and etc. are produced and sold as of now and, at the same time, we are constantly expanding the CMO business.

RepresentativeSoo Boo Choi

Headquarter Address1577-4, Seocho-dong, Seocho-gu, Seoul, Korea

Foundation DateOctober. 16, 2012

Research FocusPharmaceutical




Webwww.ekdp.com

Kwang Dong Pharmaceutical Co., Ltd. has tried its utmost to manufacture superior medicines for the last half a century since it took the first step to supply medicines in Korea,abarrenlandforthemedicalindustryin1960’s. Kwang Dong has been advancing in to a top-ranking pharmaceutical company in the world through thee establishment of the most advanced factories in Pyungtaek City. We have been enjoying an excellent reputation in technology over forty years because of the goods quality and dependability of our goods. We are one of leading pharmaceutical manufacturer in Korea having GMP factory for ETC, OTC, drink and nutrition supplement. So, we have been exporting to our pharmaceutical products (Finished products) to sell all over the world.

Company Profile

Kwang Dong Pharmaceutical Co.,Ltd.


Fiscal Year 2008 2009 2010

Sales 276,173 276,585 289,435

R&D Expenditure 6,500 6,630 6,150

Capital 52,400 52,400 52,400

Financial Figures

Primary Logo Secondary Logo

Primary Signature Secondary Signature


Main Products


1. Bicalude Tablet (Bicalutamide 50mg)Advanced prostate cancer in combination with LHRH

analogue therapy or surgical castrationVietnam, Nigeria

2. Lenara Tablet (Letrozole 2.5mg) Breast cancer -

3. Kwangdong Woohwang Chungsimwon

Stroke, Hypertension, Palpitation, Mental anxiety, Acute. Vietnam

4. Sedera ODF (Sildenafil citrate 50mg) Treatment of erectile dysfunction -

5. Cool strip ODF (Cetylpyridinium chloride 1.5mg)

Preventive treatment of pharyngitis, amygdalitis, stomatitis

-

6. KD-Fen Plaster(Diclofenac Diethylammonium 120.0mg)

Analgesia, anti-inflammatory : arthrosis deformans, tenontothecitis, tennis elbow, myalgia, post traumatic

painHong Kong

7. Clisia Solution(Clindamycin phosphate 1.188g/100mL ( 1g as Clindamycin)

acne vulgaris Hong Kong, Cambodia

8. Beaurasen Injection(placenta 100mg, Benzyl Alcohol 0.03mg)

menopausal disorder Malaysia, Hong Kong

9. Kwangdong Ceftriaxone Sodium Inj.(Ceftriaxone Sodium1g)

Treatment of community-acquired or mild to moderate health care-associated pneumonia

Afghanistan, Vietnam

10. Iritesin Injection(Irinotecan 20mg)

1. after 5-FU therapy recurrent, progressive metastatic rectal cancer, colon carcinoma

2. combined treatment with 5-FU or Leucovorin, progressive metastatic rectal cancer, colon carcinoma without other therapy

3. gastric cancer (incapable surgery or requrrent) 4. small cell lung cancer5. progressive small cell lung cancer

Georgia

R&D PipelineCategory Product Name Development Phases Indicant dosage form Development Type

Central Nervous System

KD501 Clinical test Phase II dementia oralLicense in from

Elcomscience (Kor) Self developed

KD103 Developingdementia,

Alzheimer's disease

considering Self developed

Metabolic disease

KD101 Pre clinical obesity oral Self developed

Endocrine System

KD802 Pre clinical short stature InjectionLicense in from Genexine (Kor) /

joint research

Digestive trouble

Ramosetron ODF INDantinauseant

medicineoral / film Self developed

RepresentativeTaewon Kang

Headquarter Address174, SIROK-RO, ASAN-SI, CHUNGCHEONGNAM-DO, 336-020, KOREA

Foundation DateMar., 31, 1987

Research FocusGENERIC




Webwww.kbpharma.co.kr

Contact PersonRichard Kim



Kyongbo Pharm. has committed Contract Manufacturing Organization(CMO) business with sufficient technical and marketing resources. As one of major manufacturers of APIs and finished dosages in Korea, we will put utmost efforts along with the best staff of R&D and quality assurance to be a global pharmaceutical manufacturer. Our modern facilities and infrastructure guarantee that our products meet superior quality in accordance with cGMP standards.

Focus Area : General API, Anti-Cancer API, Cephalosporins API, Carbapenem API

Company Profile

Kyongbo Pharmaceutical Co., Ltd.


Fiscal Year 2012 2013 2014

Sales 152,822 162,238 170,278

R&D Expenditure 4,408 4,724 5,357

Capital 10,758 10,758 10,758

Financial Figures


Main Products


1. ATORVASTATIN Hypolipidemic Japan -

2. CEFTIZOXIME Anti-BioticChina, Japan, South

east Asia(SEA)-

3. CEFTRIAXONE Anti-BioticEU, Japan, SEA,

Russia etc-

4. CLARITHROMYCIN Anti-Biotic Japan -

5. PRANLUKAST Anti-asthmatic Japan -

6. Loxoprofen Anti-inflammatory Turkey -

7. SULBACTAM -lactamase inhibitor Japan, Russia -

8. Cefroxadine Anti-Biotic Japan -

9. Cefotaxime Anti-Biotic Russia, SEA etc -

10. Clopidogrel Anti-platelet Japan -


Tenofovir Disoproxil - HBV Pilot scale

Duloxetine HCl - Antidepressant Pilot scale

Ezetimibe - Hyperlipidemia Pilot scale

Cinacalcet HCl - Hyperlipidemia Completed Process validation

Dabigatran Etexilate - Anticoagulant Pilot scale

Vildagliptin - Diabetes Pilot scale

Sitagliptin Phosphate - Diabetes Pilot scale

Memantine HCl - Alzheimer'S Disease Completed Process validation

Headquarter Address5th Floor, Samwon Tower, Yeoksam-dong, 124, Teheran-ro, Gangnam-gu, Seoul, Korea

Foundation DateMay 24th, 1991

Research FocusHemato-oncology, Nephrology, Immunology, CNS




Webwww.kyowa-kirin-korea.com

Contact PersonMr. Sang Heon Lee



Korean affiliate of Kyowa Hakko Kirin Co., Ltd., Japan

A global specialty pharmaceutical company mainly focused on Hemato-oncology, Nephrology, Immunology and CNS area with world leading high technology on antibody.

Focus Area : Hemato-oncology, Nephrology, Immunology and CNS area

Company Profile

Kyowa Hakko Kirin Korea Co., Ltd.


Fiscal Year 2012 2013 2014

Sales 41,919 47,768 50,528

R&D Expenditure 1,097 1,925 3,623

Capital 2,000 2,000 2,000

Financial Figures


Main Products


1. Neulasta (Peg filgrastim) Neutropenia - -

2. Grasin (Filgrastim) Neutropenia - -

3. Nesp (Darbepoetin alfa) Anemia - -

4. Regpara (Cinacalcet HCl) Secondary Hyperparathyroidism - -

5. Renagel (Sevelamer HCl) Hyperphosphatamia - -

6. Nplate (Romiplostim) Idiopathic Thrombocytopenic Purpura - -

7. Mitomycin-C (Mitomycin) Cancer - -

8. Leunase (L-asparaginase) Cancer - -


Romiplostim AMG531Idiopathic Thrombocytopenic Purpura

Aplastic anemiaLaunched

PII

Mogamulizumab KW0761

Leukemia/LymphomaCutaneous T-cell LymphomaPeripheral T-cellLymphoma

Adult T-cell Leukemia/LymphomaSolid Tumor

Asthma

LaunchedPIIIPIIPIIPIPI

Antithrombin Gamma KW3357

Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency

Disseminated Intravascular Coagulation,Congenital Antithrombin

LaunchedPIPI

Granisetron - Chemotheraphy induced Nausea and Vomiting Launched

Tivantinib ARQ197 Hepatocellular Cancer PIII

Benralizumab KHK4563 Asthma PIII

Brodalumab KHK4827 Psoriasis PIII

Istradefylline KW6002 Parkinson's Disease PIII

Mesalazine Z206 Ulcerative Colitis PIII

- ASKP1240 Organ Transplant Rejection PII

- BIW8962 Cancer PII


- KHK4577 Atopic Dermatitis PII

- KHK7580 Secondary Hyperparathyroidism PII

Bardoxolone Methyl RTA402 CKD in Patients with Type 2 Diabetes PII

- KRN23

X-linked Hypophosphatemic Rickets(XLH)inpediatricpatients

X-linked Hypophosphatemic Rickets/Osteomalacia(XLH)inadultpatients

X-linked Hypophosphatemic Rickets/Osteomalacia(XLH)inadultpatients

PII

PI

PI

- KHK2823 Cancer PI

- KHK2898 Cancer PI

- KHK4083 Autoimmune diseases PI

-KHK2804CEP37250

Cancer PI

- KHK6640 Alzheimer's Disease PI

Tivozanib KRN951 Cancer PI


RepresentativeRyu Deokhee

Headquarter Address9F, Kyungdong B/D, 1926 Nambusunhwan-ro, Gwanak-gu, Seoul, Korea


Research FocusCirculatory system, Digestive system



Webwww.kdpharma.co.kr

Contact PersonNam, Gwi Hyun



Kyung Dong Pharm. Co., Ltd. established a GMP factory in 1987 to manufacture medical products with good quality.

Since we were approved as a designated KGMP company in 1991, we have been producing more than 80 items including tablets, capsules, injections, and solutions.

We have approved BGMP manufacturer since 2001 and also have the cGMP and EU-GMP grade facilities for general finished product and API.

Company Profile

Kyung Dong Pharm. Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 151,893 158,599 175,500

R&D Expenditure 4,390 4,580 5,600

Capital 13,575 13,575 13,575

Financial Figures

Main Products


1. Clopidogrel bisulfate (API) - Japan -

2. Roxatidine acetate HCl (API) - Japan, China -

3. Aclovir Inj (Acyclovir) - Pakistan, Chile -

4. Ceftisone Inj.(Ceftriaxone sodium) -Pakistan, Yemen, Vietnam, Philippines, Afghanistan

-

5. Ducas Tab. (Tripotassium bismuth dicitrate) - Vietnam -

6. Rebamide Tab.(Rebamipide) - Philippines -

7. Cozoltec Tab. (Cetrizine HCl) - Pakistan, Vietnam, Cambodia -


Bucillamine (API) - Antirheumatic Process Validation

Imidafenacin (API) - Urinary antispasmodic Process Validation

Risperidone (API) - Antipsychotic Process Validation

Escitalopram (API) - Antidepressant R&D

Ambrisentan (API) - Pulmonary hypertension R&D

Pilsicainide (API) - Antiarrhythmic R&D

Istradefylline (API) - Antiparkinson R&D

Suplatast (API) - Antiallergic R&D

Clopidogrel Camsylate (Finished Product) - Antiplatelet KFDA Approved

Esomeprazole base (Finished Product) - Anti-peptic ulcer KFDA Approved

(Finished Product) KD3003 Anti-rheumatic Preclinical Research

(Finished Product) KD4001 Anti-diabetic Preclinical Research

Amlodipine+Valsartan+Rosuvastatin (Finished Product)

KD5001Anti-hypertensive and Anti-

hyperlipidemicClinical Research

Varenicline Besylate (Finished Product) KD8001 Smoking cessation treatment Clinical Research

Other

Competitive strong power of Products and Good profit structure by 1st generic development through R&D and patent research.


RepresentativeMr. Hee-Cheul Lee / CEO

Headquarter Address17F, Keumkang Tower B/D, 889-13, Dachi-dong, Gangnam-gu, Seoul, 135-918

Foundation DateJun 1, 1957

Research FocusVitamin & Human Placenta




Webhttp://www.kyungnampharm.co.krhttp://www.lemona.co.kr

KyungNam Pharmaceutical has been representing the domestic vitamin C market by its steady seller ‘Lemona’ which has been receiving constant love for 28 years since the first release in 1983. As proving its popularity, it has been awarded “Brand Award of the Year for four consecutive years hosted by the Korean Consumers’ Forum and shown 73 percent of overwhelming public support in vitamin C product field in 2011. In addition, KyungNam has been occupying the unrivaled No.1 title in the Human placenta market, which is the origin of the life energy.

Moreover, KyungNam has been leading the general medicines market through its product such as PM, a typical athlete‘s foot medicine, and Minol Troche, a sore throat drug.

Company Profile

Kyung Nam Pharm. Co, Ltd


Fiscal Year 2008 2009 2010

Sales 43,701 46,869 45,983

R&D Expenditure - - 337

Capital 11,192 14,692 15,350

Financial Figures

Main Products


1. Lemona pulvis (vitamin B,C) vitamin America, Hong Kong, Mongolia -

2. KN vitamin C Tab. (vitamin B,C) vitamin - -

3. Lemo vita C Tab. (vitamin B,C) vitamin America, Hong Kong, Mongolia -

4. Jahasaengryeok (Human Placenta) Tonic nutrition Hong Kong, Mongolia -

5. Plagensia inj. (Human Placenta)relieve menopausal

symptoms- -

6. PM Solution (Salicylic Acid) athlete's foot treatments - -

7. Minol troche (Cetypyridinium Chloride)

relieve Throat inflammation

- -


RepresentativeChani Jeong

Headquarter Address7F, Diplomatic center 2558, Nambusunhwan-ro, Seocho-gu, Seoul, Republic of Korea

Foundation DateMay 20th, 1976

Research FocusETC, OTC Drugs




Webhttp://www.medicakorea.com/

Contact PersonLee Won Jung

Contact Phone82-2-70-4018-8052 82-2-70-4018-8053

Contact [email protected]@medicakorea.com

Established Doing-IlPharmaceutical Co., Ltd., in 1976. Acquired and renamed Medica Korea in 2000

Manufacturing one hundredand twenty pharmaceutical products under the control of KGMP (Korea Good ManufacturePractice).

Focus Area : Skin Diseases

Target country : Philippines, Vietnam, Cambodia, Hongkong, Singapore, Myanma, etc.

Company Profile

Medica Korea Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 30,637 36,858 36,858


Capital 3,560 3,560 3,560

Financial Figures

Main Products


1. Nimegen Soft Cap.10/20mg (Isotretinoin 10,20mg)

Cystic acne and acne conglobata treatment

Singapore, Hong kong, Myanma,

Vietnam-

2. GREEN PAM Cap. (Thymomodulin 80mg)

Supplementary treatment of bacterial and viral infections.

Vietnam -

3. POINTY Cap. (Diacerhein 50mg)Treatment of osteoarthritis

diseaseVietnam -

4. Allutec Tab. (Cetirizine Hydrochloride 10mg)

Rhinitis, Conjunctivitis, Eczema, Dermatitis, etc

Hong kong, Cambodia

-


Nimegen Soft Cap. 10mg (Isotretinoin 10mg)

-Cystic acne and acne conglobata treatment

Approved

SALBUTRON SR Cap.4mg(Salbutamol sulfate 8mg)

-Asthmatic bronchitis, Chronic

bronchitis, emphysema disease

Approved

NEWBORN Tab. 25 I.U.(Kallidinogenase 25 I.U.)

-

Hypertension, Meniere’s disease, Buerger’s disease,

menopausal disorder, circulatory disturbance of

chorioretinal disease

Approved

MUCOSTEN INJ. 10%(Acetylcysteine 100mg/mL)

-Acute Chronic & Asthmatic

bronchiti diseaseApproved

CALDIOL Soft Cap.20(Calcifediol 20 )

-Chronic renal failure,

Metabolic bone diseaseApproved


RepresentativeChul-Soo, Shin (Mr.)

Headquarter Address27, Yongso 2-gil, Gwanghyewon-myeon, Jincheon-gun, Chungcheongbuk-do, South Korea

Foundation DateSeptember 16, 2003

Research FocusNutrition infusion therapy products

Total Staff87 employees


Webwww.medi-green.co.kr

Contact PersonSeong-Un, Jeong (Mr.)



MG Co., Ltd. is a pharmaceutical company that specializes in manufacturing parenteral & enteral nutrition solution to play a big role in nutrition infusion therapy and its related areas.

It is mandatory for patients to provide proper nutrition to treat the disease and recover their health, especially for: surgical patients who are incapable of taking nutrition, patients with hypoproteinemia and malnutrition, patients with wasting disease caused by burn or gash, and patients with immunosuppression.

With a long-term experience and accumulated technology, for the first time in Korea, we succeeded in localization of a 3-chamber bag product, MG TNA with 2-chamber bag products, MG COMBI, and Lipid LCT etc. Furthermore, we recently developed the new products, FOMS TNA and FOMS Lipid, which are the combination of fish oil, olive oil, MCT oil and soybean oil.

We, MG Co., Ltd., promise our effort and endeavor to provide the best quality products in nutrition therapy and always hold an outstanding position to take care of human health in the 21st century.

Company Profile

MG Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 14,480 17,623 20,220


Capital 9,873 11,111 18,670

Financial Figures

Main Products


1. MG TNA inj. IVH for NPO inpatients VietnamUnder registration in Iran,

Kazahstan, Syria, Thailand, Malaysia and Kenya

2. MG TNA-peri inj. IVH for NPO inpatientsMongolia, Vietnam,

Philippines, Myanmar

Under registration in Iran, Kazahstan, Syria, Thailand,

Malaysia and Kenya

3. MG Combi-peri inj. IVH for NPO inpatients MongoliaUnder registration in Syria,

Kazahstan

4. Lipid LCT inj. 10% / 20% Supply EFA & Calory Mongolia Under registration in Iran

5. FOMS TNA inj. IVH for NPO inpatients -Under registration in overseas

countries

6. FOMS TNA-peri inj. IVH for NPO inpatients -Under registration in overseas

countries

7. FOMS Lipid inj. 20% Supply EFA & Calory -Under registration in overseas

countries


Selenium for injection - Supply for Selenium Formulation

Zinc for injection - Supply for Zinc Formulation

TPN solution for pediatric patients -IVH for NPO pediatric

inpatientsReview the formular

Dextrose, Amino acids, Lipid(New formular for 3-chamber bag)

- IVH for NPO inpatients Review the formular

Dextrose, Amino acids, Lipid, Vitamins, Elements etc.

(The first 4-chamber bag product)- IVH for NPO inpatients Review the formular


RepresentativeJwa-Jin Kim

Headquarter Address703-ho, 1-dong, (Lotte Itcastle,) 98, Gasan digital 2-ro, Geumcheon-gu, Seoul, Korea

Foundation DateJuly 20th, 2011

Research FocusNovel drug



Webwww.mtspharm.com

Contact PersonYe Rin Kim



MOTHER'S PHARMACEUTICAL CO., LTD. is a manufacturing plant of tablets, hard capsules authorized from Korea Food & Drug Administration. We took over a pharmaceutical company, which had manufactured oriental medicine more than 35 years. We have even expanded our business areas to chemical medicine based on natural product research experience. We have been rapidly developing to become the best pharmaceutical company.

Company Profile

MOTHER'S PHARMACEUTICAL CO., LTD.


Fiscal Year 2015 2016 2017

Sales 16,898 24,234 33,000

R&D Expenditure 500 600 1,000

Capital 2,000 2,000 2,000

Financial Figures

Main Products


1. RAYBON Tab. (Angelica·Chaenomeles·Ledebouriella·Dipsacus·etc Soft Ext. 405.4mg)

Relaxation on Golgwan Georgian ETC

2. STOEM Tab. (Artemisia Asiatica 95% Ethanol ext. 60mg) Chronic gastritis, acute gastritis improvement ETC

3. RACETINEM Tab. (Ranatidine hydrochloride 84mg, Tripotassium dicitrato bismuthate 100mg, sucralfate hydrate 300mg)

The above-mentioned · duodenal ulcer, gastritis, Sol drip-Ellison syndrome, reflux esophagitis, pre-anesthesia medication (prevention of Mendelson's syndrome), postoperative ulcer, nonsteroidal anti-

inflammatory analgesia (NSAID)

ETC

4. ITANDOL Tab.(Titrated extract of zea mays L. Unsaponifiable fraction 35mg)

Gingivitis after periodontal treatment, secondary treatment of moderate periodontitis

OTC

5. URUQBAC Tab.(Anhydrous dibasic calcium phosphate 100mg, Coated ascorbic acid 10 4.17mg, Benfotiamine 50mg, Biotin 0.2mg, Calcium pantothenate 30mg, Cholecalciferol granule 4mg, Choline bitartrate 50mg, 0.1% Cyanocobalamin 50mg, Folic acid 0.4mg, inositol 50mg, Magnesium oxide 100mg, Nicotinamide 50mg, Pyridoxine hydrochloride 50mg, Riboflavin 50mg, Ubidecarenone 10mg, Ursodeoxycholic acid 30mg, y-oryzanol 5mg)

1. Supply of vitamin (D, B1, B2, B6, C) OTC

6. Etantan-Plus Cap. (Ascrobic acid 150mg, Carbazochrome 2mg, Dried vitamin E 50% 10mg, Lysozyme chloride 30mg)

Gingivitis after periodontal treatment, adjuvant treatment of gingivitis and moderate

periodontitisOTC

7. KERASIDIL Cap. (Calcium pantothenate 60mg, Keratin 20mg, L-cystine 20mg, Medicinal yeast 100mg, p-aminobenzoic acid 20mg, Thiamine nitrate 60mg)

1. Damaged hair, poor growth of infectious nails2. Assistive treatment of hair loss

OTC

8. Bicarine-M EntericCoated Tab. (Bisacodyl 7mg, Docusate sodium 20mg, Sennae folium Powder 100mg)

- Constipation- Relieving the following symptoms of

constipation: loss of appetite (loss of appetite), abdominal distension, intestinal fermentation,

hemorrhoids

OTC

9. Ranitis Tab. (Aluminum magnesium hydroxide 100mg, Aluminium magnesium silicate 125mg, Magnesium oxide 50mg, Ranitidine hydrochloride 31.5mg)

Stomach pain, heartburn, indigestion, nausea OTC

10. UruqbacClassic Tab. (Anhydrous dibasic calcium phosphate 100mg, Coated ascorbic acid 10 4.17mg, Benfotiamine 50mg, Biotin 0.2mg, Calcium pantothenate 30mg, Cholecalciferol granule mg, Choline bitartrate 50mg, Cyanocobalamin(1000) 50mg, Folic acid 0.4mg, Magnesium oxide 100mg, Nicotinamide 50mg, Pyridoxine hydrochloride 50mg, Riboflavin 50mg, Ubidecarenone 10mg, Ursodeoxycholic acid 10mg, Zine oxide 21.2mg, y-oryzanol 5mg)

1. Supply of vitamin D, B1, B2, B6, C 2. Supply of zinc

OTC


- MTS-F1 - Candidate

- MTS-N1 - Candidate


RepresentativeHang Myung Lee

Headquarter AddressMyung-In Bldg, 95, Banpo-daero, Seocho-gu, Seoul, Korea 06657

Foundation DateApril.1.1985

Research FocusNew Drugs Introduction, Incrementally Modified Drugs development, New technology export, Overseas CMO business




Webhttp://www.myunginph.co.kr

Contact PersonHee Soo Kim



Established in 1985, Myung In is a distributor as well as a contract manufacturer with exceptional expertise in the development of small molecule, conventional and specialized solid dosage forms including pellets and bi-layer tablets, and sterile products including liquid/lyophilized vial and liquid ampoule.

A research-driven pharmaceutical company, Myung In has ranked first among locals in the field of central nervous system in Korea. Myung In also collaborates with many global partners to successfully launched their products in Korea, getting them to be blockbusters.

Myung In will continue to expand and invest in facilities to provide high quality medicines to patients as well as to meet the growing market demand.

Focus Area : anti-thrombotic, anti-hypertensive, anti-psychotic, anti-depressant&bipolar disorder, anti-insomnia, ADHD, anti-convulsant, anti-parkinson, anti-dementia

Company Profile

Myung In Pharm. Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 140,000 148,000 159,000

R&D Expenditure 5,400 6,500 9,000

Capital 5,600 5,600 5,600

Financial Figures

Main Products


1. Igatan-F Cap. Gum disease - -

2. Disgren Cap. Anti-thrombosis China -

3. Silvercept Tab./OD Tab. Dementia - -

4. Q-Rokel Tab./XR Tab. Schizophrenia Peru -

5. Rispen Tab./OD Tab. Anti-psychotic - -

6. Superpirin Cap. Anti-thrombosis - -

7. Newpram Tab. Depression&Bipolar disorder - -

8. Zanapam Tab. Tranquilizer - -

9. Proctin Cap. Depression&Bipolar disorder Singapore -

10. Q-Pam Tab./Oral soln./Inj. Epilepsy - -


Mirtazapine 7.5mg - Depression Approved

Betahistine HCl - Vertigo(Off-label:Obesity) Approved

Levetiracetam Inj. - Epilepsy Approved

Paliperidone - SchizophreniaWaiting for approval from

MFDS

Aspirin/Clopidogrel (75mg/75mg) - Anti-thrombosisWaiting for approval from

MFDS



Disgren(Triflusal) Anti-thrombosis 1993.12.13

Narcaricin Tab.(Benzbromarone) Anti-gout 1995.03.27


RepresentativeMr. Lee, Kyu Huok / CEO

Headquarter AddressMyungmoon B/D, 946-18 Dogok-dong, Gangnam-gu, Seoul

Foundation DateSeptember, 1983

Research FocusMedicines, Bio-Product




Webwww.mmpharm.co.kr

In 1983, Myungmoon Pharm. Co., Ltd. was established for the improvement of national health. It is achieving remarkable development via research and development, production, and sales based on its founding principle: Advancement, Harmony, and Creation.

Myungmoon Pharm. Co., Ltd. is an acknowledged manufacturer to produce the finished medicines; Injection, Tablet, Capsule, Patches, Solution and Creams.

Nowadays, Myungmoon Pharm. Co., Ltd. produces more than 250 specialized and general medicines and has more than 400 specialized and generalmedicine licenses to be able to manufacture. Myungmoon Pharm. Co., Ltd. is focusing on our research and development efforts so that Myungmoon Pharm. Co., Ltd. is launching more than 20 new products every year.

Myungmoon Pharm. Co., Ltd. established the new plant for API in 2008. Myungmoon Pharm. Co., Ltd has Gabapentin(USP) and the other 8 API products now, however, Myungmoon Pharm. Co., Ltd. would have many new API products in the foreseeable future.

To gain a foothold on biomedicine products, outsourcing strategies are preceding the use of trusted clinical agency CRO and production agency CMO, and Myungmoon Pharm. Co., Ltd has already started to develop human growth hormones through a bio-venture corporation. Within 2 or 3 years, Myungmoon Pharm. Co., Ltd. should be launching bio-similar, including EPO and the processing of the complement of plants for biomedical products as well as the development of advanced medical bioethics, including monoclonal antibodies.

Myungmoon Pharm. Co., Ltd. is sharply developing to be a professional and global treatment company in the world.

Company Profile

Myung Moon Pharm. Co., Ltd.


Fiscal Year 2008 2009 2010

Sales 77,390 92,246 100,914

R&D Expenditure 1,401 1,741 1,789

Capital 5,100 5,293 5,500

Financial Figures

Main Products


1. Kimite Patch (Scopolamine 1.5mg) Motion sickness Vitenam, China, Hong-Kong -

2. Dobutamine Inj. (Dobutamine HCl 280.3mg/5ml)

Cardiac stimulants Vietnam, Pakistan, Nigeria -

3. Inopan Inj. (Dopamine HCl 200mg/5ml)

Cardiovascular drug Vietnam, Pakistan, Nigeria -

4. Ketocin Inj. (Ketorolac tromethamine 30mg/1ml)

Nonsteoidal Anti-inflammatory drug

Vietnam, Philippines, Rep. of Dominica

-

5. Bupivacaine HCL Heavy Inj. 0.5% (Bupivacaine HCL 21.12mg/4ml)

Local AnestheticsVietnam, Nigeria, Rep. of

Dominica-

6. Pyrinol Tab. (Pyridostigmine Bromide 60mg)

Parasympathomimetics Chile, Malaysia -

7. Levonia Tab. (Levonorgestrel 1.5mg)

Contraceptive Vietnam, Mexico -

8. Tipem Inj. (Imipenem 500mg, Cilastatin 500mg)

Antibiotics Vietnam -

9. Esgen Vaginal Cream (Estropipate 1.5mg/g)

Hormons Guatemala -

10. Neocoline Inj. 500mg (Citicoline 500mg/2ml)

parkinson diease Uzbekistan, Vietnam -


Sonatropin-PEG conjugate (Bio-Product) GROWTH Hormone Finished Process(Lab Scale)

Erythropoietin(Bio-Product) Erythrogenesis Finished Process(Lab Scale)

Flumanzenil Inj. 0.5mg Antidote for Midazolam Launching on April, 2012

Valsartan 160mg, 80mg Hypertension Launching on April, 2012

Lansoprazole 30mg Antipeptic ulcer drug Launching on August, 2012

Sildenafil 100mg Erectile dysfunction Launching on August, 2012

Raloxifene 60mg Osteoporosis Launching on July, 2013


RepresentativeBong Kil, Nam

Headquarter AddressA-7F, Samho Bldg, 83 Nonheyon-ro, Seocho-gu, Seoul 137-940, South Korea

Foundation DateMay 1st, 1999

Research Focus25




Webwww.pharmbio.co.kr

Contact PersonJun Sang, Nam



Pharmbio Korea Co., Ltd. is an emerging, innovative company established in 1999, specializing in registration, ex/importing, manufacturing, and marketing of innovative pharmaceutical products in Korea. It is one of the most influential companies in many therapeutic areas.

Focus Area : Urology, gastroenterology, neurosurgery, orthopedics, general surgery, immunology, etc.

Company Profile

Pharmbio Korea Co., Ltd


Fiscal Year 2012 2013 2014

Sales 32,700 39,300 44,200

R&D Expenditure 1,500 2,700 3,300

Capital 20,680 34,065 40,020

Financial Figures

Main Products


1. Picolight (Sodium Picosulfate, Magnesium Oxide(light), Citric Acid(anhydrous)/Powder)

Pre-colonoscopic preparation -Discussing out-licensing

in Vietnam, etc.

2. Urocitra-K (Potassium citrate/Tablet)

Uric acid lithiasis MyanmarDiscussing out-licensing

in Vietnam, etc.

3. Urocitra-C (Potassium Citrate, Citric Acid Hydrate/Powder)

Uric acid lithiasis -Discussing out-licensing

in Cambodia, etc.

4. Endonse (Pronase B/Powder) Pre-endoscopic preparation - -

5. Ribon (Risedronate Sodium Hydrate /Tablet)

Postmenopausal osteoporosis

-Discussing out-licensing in Singapore, Hong Kong,

etc.

6. Gagron (Pentasan Polysulfate Sodium /Calsule)

Interstitial Cystitis - -

7. Movilax (Polyethylene Glycol3350, Electrolytes/Powder)

Chronic constipation - -

8. Zinkistin (Zinc Histidine Dihydrate / Capsule)

Zinc deficiency - -

9. Acupan casule (Nefopam Hydrochloride / Capsule)

pain controller -Discussing out-licensing

in Nigeria, etc.


RepresentativeMr. Young Chin Chun

Headquarter Address21 Sinangbukro 4-gil, Sangnok-gu, Ansan-si, Gyeonggi-do, South Korea

Foundation DateDec, 2001

Research FocusDMARDS, DMOADS, NSAIDS



Webwww.pmgpharm.co.kr

Contact PersonKi-Tae Han



PMG Pharm has been a leading pharm in the market for treatments of rheumatoid arthritis, osteoarthritis, anti-osteoporosis and related diseases and its main business has been focused on the development of DMARDS, DMOADS and NSAIDs etc. At 13 Mar 2012, a Layla Tab has been registered as a new treatment for the osteoarthritis. Layla is consisted of 12 medicinal plants which has been recognised as traditional herbal medicines for arthrosis. PMG Pharm is ready to expand its business by licensing out Layla.

Company Profile

PMG Pharm


Fiscal Year 2015 2016 2017

Sales 29,131 32,695 38,000

R&D Expenditure 1,147 1,335 1,500

Capital 2,319 2,636 2,636

Financial Figures

Main Products


PMG1001 - Osteoarthritis In-vitro test


1. Layla Tab (12 Herbal extracts 405.4mg) Osteoarthritis - -

2. Rudia Cap 50mg (Diacerein) Osteoarthritis - -

3. Duroc Tab 100, 200, 300 400mg (Hydroxychloroquine sulfate)

Rheumatoid arthritis - -

4. Tarsin Cap 0.5, 1mg (Tacrolimus) Rheumatoid arthritis - -

5. Rheumakin Tab 10, 20mg (Leflunomide) Rheumatoid arthritis - -

6. Admin Forte Tab (Cholecalciferol, VitD 1000IU)

VitD deficiency - -

7. Indometa Cap 25mg (Indomethacin) NSAID - -

8. SynflexSafe Tab (Naproxen/Esomeprazole 500/20mg)

NSAID - -

9. Morix Cap 7.5mg (Meloxicam) NSAID - -

10. Laxib Cap 100, 200mg (Celecoxib) NSAID - -

11. Droban Tab 150mg (Ibandronate) anti-osteoporosis - -

12. Risena Tab 35, 150mg (Risedronate Na)

anti-osteoporosis - -



Layla Tab(12 Herbal extracts 405.4mg) Osteoarthritis 2012.03.13/Korea


RepresentativeMr. JeongSuk Lee / CEO

Headquarter AddressDanam B/D 22F, 120 Namdaemoonno 5-ga, Jung-gu, Seoul

Foundation DateMarch, 1974

Research FocusFinished drug, Herbal medicine




Webwww.richwood.net

Richwood Pharmaceutical Co., Ltd., a reliable CMO company with global standards in pharmaceutical manufacturing, has competitive advantages such as holding specialized formulation technologies using a 3-layer tablet machine and a GPCG series, a strategic partnership with CRO, and development pipelines of herbal medicine.

Company Profile

Richwood Pharmaceutical Co., Ltd.


Fiscal Year 2008 2009 2010

Sales 25,192 32,744 41,414


Capital 500 500 500

Financial Figures

Main Products


1. Acetracet Tab. (acetaminophen, tramadol HCl) Pain relief - -

2. Ebaco SR Cap. (pseudoephedrine, ebastin) Allergic rhinitis - -

3. Gli-M Tab. 2/500mg (glimepiride, metformin) Type II diabetes - -

4. Limaprost 0.17mg (limaprost)Buerger's disease, acquired

spinal canal stenosis- -

5. Cetirizine Tab. (cetirizine) Allergic rhinitis - -

6. Livaduet Tab. (atrovastatine,amlodipine besylate) Hypertension - -


Oxycodone hydrochloride Opioid analgesic Clinical trial


RepresentativeSeung-ho Han, Nam-gi Kim

Headquarter Address315 Yeongdong-daero, Gangnam-gu, Seoul, Korea

Foundation DateOct.1983

Research FocusPharmaceuticals, health functional food



Webhttp://www.rpskorea.com

Contact PersonHee Jeong Jang



- RP Bio. is CMO by OEM/ODM specializing in Soft Gelatine Capsules for pharmaceutical and health functional food formulations since 1983. Initially founded as a J/V between R.P. Scherer USA and Daewoong Pharmaceutical Co., Ltd. Korea. RP Corp. boasts high quality production as a Korean company to pass international audits.

* Infra

· KGMP approved Pharmaceutical Mfg. facility (finished dosage: Soft capsules)

· Two KGMP approved Health Functional Food Mfg. facilities (one for soft capsules and another for tablets, powders and granules)

Company Profile

RP Bio


Fiscal Year 2015 2016 2017

Sales - 26,013 70,000

R&D Expenditure - 250 300

Capital - 34,144 40,690

Financial Figures

Main Products


1. Ginsatine (Korea Ginseng 100mg and multivitamins etc.)

Korea Ginseng Multivitamin Vietnam, Cambodia Soft gels

2. Caldiol (Calcifediol hydrate 20mg) Vitamins Vietnam, Pakistan Soft gels

3. Ursa (Ursodeoxycholic acid 100mg) Hepatics China Soft gels

4. Provimin (Korea Ginseng 100mg, etc.) Vitamins Cambodia Soft gels

5. Livergold-F (Milk Thistle 100mg, etc.) Hepatics Myanmar Soft gels

6. Valix Vaginal (Nystatin 100kIU, etc.) Pessary Vietnam Soft gels

7. Nimegen (Isotretinoin 20mg) Acne Vietnam, Cambodia Soft gels

8. Tak-Sen (Naproxen 250mg) Pain Reliever - Soft gels

9. Whituben Q (Acetaminophen 180mg, etc.) Cold Medicine - Soft gels

10. Tobicom-S (L-Citrulline, etc.) Eye - Soft gels


Headquarter Address351, Hyoryeong-Ro, Seocho-gu,Seoul 137-877, Korea

Foundation Datein 1943

Total Staff384 Employees


Webwww.scd.co.kr

Contact PersonMr. Brian Kim



SamChunDang(SCD) Pharm. Co., Ltd. is the leading pharmaceutical company specialized in ophthalmic fields. We have acquired EU GMP certificate for sterile eye drops from UK MHRA(Medicines & Healthcare products Regulatory Agency). Since established in 1943, we have been providing a high quality pharmaceutical product for the purpose of providing healthier and happier lives for everyone.

We provide safety and convenience and also offer a wide range of choices with multi-dose and preservative-free single dose eye drops. We have been exporting pharmaceutical products to more than 25 overseas countries for more than 20 years and have been seeking to expand in to the global market with EU GMP certificated techology.

Company Profile

SamChunDang Pharm. Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 100,514 111,521 120,422

R&D Expenditure 4,357 5,158 9,480

Capital 10,619 11,000 11,053

Financial Figures

Main Products


1. Sodium Hyaluronate 0.1% Eye Drops Artificial Tears Vietnam, Myanmar -

2. Tobramycin 0.3% Dexamethasone 0.1% Eye Drops

AntibacterialMyanmar, Panama,

Cambodia, Hong Kong, Yemen

-

3. Fluorometholone 0.1% Eye Drops Anti-Inflammatory

Myanmar, Panama, Vietnam, Cambodia, China, Costa Rica,

Hong Kong

-

4. Mometasone furoate 0.05% Nasal Spray Nasal SprayHong Kong,

Myanmar, Vietnam, Ecuador, Cambodia

-


Confidential SCD311 Artificial Tears Formulation development

Confidential SCD212 analgesics DDI (Phase I complete)

Confidential SCD313 Artificial Tears Formulation development

Other

Submission of EU CTD (Decentralised Procedure) UK-MHRA has confirmed the dates for submission of Dossier and allocated the DCP number.

Allocated DCP number(s) together with the PL numbers : UK/H/5793/01/DC - Olopatadineeye drops 1mg/ml, PL 43063/0002 DECENTRALISED

After submission of EU CTD Dossierin Aug. 2014, MHRA (UK) inspection was successfully done in 1st week of Jan. 2015.

EU GMP Certificate from MHRA, U.K was generated on Mar. 9th,2015.

(Certificate No. : UK GMP 43778 Insp GMP 43778/10951938-0001)


RepresentativeJun Hur

Headquarter Address49 Dongwha gongdan-ro, Munmak-eup, Wonju-si, Gangwon-do

Foundation DateOct. 04, 1945

Research FocusRespiratory, ENT, Dermatology, Pediatrics, GI, and Orphan Diseases




Webwww.samapharm.co.kr

Contact PersonSoojin Lee



SAMA is Korea’s top leading company in Respiratory, ENT, Dermatology, and Pediatrics. Founded in 1945, it is one of the most financially sound companies with a long history of achievements and recognitions by the Korean government. It has a GMP-certified manufacturing plant, and it has been accredited by Japan’s Regulatory Authority (PMDA: Pharmaceuticals and Medical Agency) as an “Accredited Foreign Manufacturers”. SAMA has a central R&D center and nation-wide sales force.

SAMA has a strong track record of new business development and partnership with multinational companies, with some having lasted over 30 years. It has demonstrated capabilities in branding and marketing to achieve #1 brand recognition and equity.

SAMA is also active in its own in-house R&D activities, especially in Respiratory and GI fields. SAMA’s CitusTM(pranlukast) tablet for adults was developed with its proprietary patent technology, which dramatically lowered the dosage (112.5mg * 2cap. -> 50mg * 1tab.) SAMA also successfully completed a Phase II clinical trial for the new 4th generation LTRAs drug in collaboration with Mitsubishi Tanabe.

SAMA plans to expand into other fast growing therapeutic areas via licensing deals and its own R&D.

Focus Area : Respiratory, ENT, Dermatology, Pediatrics, GI, and Orphan diseases

Company Profile

SAMA PHARM CO.,LTD.


Fiscal Year 2015 2016 2017

Sales 59,658 65,876 61,800

R&D Expenditure 4,898 4,236 4,400

Capital 140,077 148,916 156,100

Financial Figures

Main Products


1. SETOPHENTM (Acetaminophen/ tablets ER tablets & Dry syrup & suspension)

NSAIDs (Fever, Pains, Headache,

Menstrual pain etc.)- -

2. CODENAL® (Dihydrocodeine, etc. / tablets & syrup)

Cough, sputum Hong Kong -

3. ATOCK® (Formoterol fumarate / tablets & dry syrup)

Acute & chronic, bronchitis, Bronchial asthma

- -

4. LIDOMEX® (Prednisolone valeroacetate / topical lotion & cream)

Eczema, Dermatitis, Prurigo, Psoriasis, etc.

- -

5. CITUSTM (Pranlukast hydrate / tablets, ispersible tablets & dry syrup)

Bronchial asthma, Perennial allergic rhinitis

- -

6. TANTUM® (Benzydamine HCl / gargle solution & nebulizer)

Gingivitis glossitis, Pharyngitis, Laryngitis,

Tonsillitis etc.- -

7. HEBRON® (Ivy leaves extract / tablets & syrup)

Chronic inflammatory bronchial disease, acute

inflammation of respiratory tract

- -

8. BEPORIN® (Bepotastin salicylate / tablets) Anti-histamines - -

9. GERD® (Sodium alginate / solution)Gastric ulcer, duodenal

ulcer, improvement of gastro esophageal reflux disease

- -

10. NOMA (Multivitamins, Minerals / gummies & chewable tablets)

Growth promotion, nutritional deficiency, supply for vitamins & minerals

- -

R&D Pipeline


SLIP SLIP Erectile dysfunction Launch

TDIQ TDIQ Erectile dysfunction Launch

PRIT PRITBronchial asthma,

Allergic rhinitisLaunch

SA09012 SA09012Bronchial Asthma,

Allergic rhinitisPhase 2

DRIT SA15001 Gastric ulcer, GERD Non-clinical study

PRIC SA16001Bronchial Asthma,

Allergic rhinitis Phase 1

HLIM SA16002 Bronchitis Phase 1


RepresentativeLee, Sae Young

Headquarter Address15F, A Tower, 11, Beobwon-ro 11-gil, Songpa-gu, Seoul, 05836, Republic of Korea

Foundation Date1973

Research FocusCirculatory System


Representative Phone82–2-928–0661~4

Webwww.samik.co.kr

Contact PersonKim, Yu Li



Since founded in 1973, Samik has focused on our ability to improve public health through the R&D and manufacture of a number of the over-the-counter drugs famous for excellent efficacy and good quality under the banner of "systemic approach to natural drugs".

“Aiming for the best technical capability in the field of solid dosage form”

Now, Samik will establish as Total Health Company in fact as well as in name by devoting itself to the development of new natural drugs, modified drug and to supplementing biomedicine pipeline, marketing its own best medicines globally in R&D and management as well as by continuing in development and manufacture of the therapeutic prescription only medicine based on excellent technology accumulated in the natural drug manufacture industry in the mean-time.

“Realizing Health improvement in harmony with nature”

Please give us your help and encouragement with interest and support continuously to us who are devoting ourselves to establish a welfare society in spite of our poor ability in contributing to Health of mankind under the banner of "realizing health improvement in harmony with nature."

Company Profile

Samik Pharm. Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 33,053 38,367 40,689


Capital 34,781 38,831 42,000

Financial Figures

Main Products


1. CEZAR TAB. (Losartan potassium 50/100mg) Hypertension - -

2. CEZAR PLUS TAB. (Losartan potassium 50mg, Hydrochlorothiazide 12.5mg)

Hypertension - -

3. TAMITRA TAB. (Acetaminophen 325mg, Tramadol Hydrochloride 37.5mg)

NSAIDsCambodia, Myanmar,

Vietnam-

4. NEWSOVOMIN SYR. (Dimenhydrinate 20mg, Anhydrous Caffeine 10mg, Pyridoxine Hydrochloride 2.5mg)

Dizziness, vomiting, headache caused by motion sickness.

Mongolia -

5. TMD CAP. (Thymomodulin 80mg) Bacterial and viral infections.Cambodia, Myanmar,

Vietnam-

6. BROJE TAB. (Bromelain 40mg, Crystallized trypsin 1mg)

Inflammation Cambodia, Vietnam -

7. BONOMAX TAB. (Alendronate 70mg) Osteoporosis Myanmar, Vietnam -

8. AMORIA CAP. (Meloxicam 7.5/15mg) NSAIDs Bolivia, Hong Kong -

R&D Pipeline


Chong Myung Tang - Brain Function Formulation Development

SIP-1101 SIP-1101 Liver Function Research

SIP-1102 SIP-1102 Allergic Rhinitis Formulation Development

SIP-1103 SIP-1103 Dementia, Brain Function Formulation Development

SIP-1104 SIP-1104 Hypertension Formulation Development


RepresentativeKang Huh

Headquarter Address155, Hyoryeong-ro, Seocho-gu, Seoul, Korea

Foundation Date07 OCT. 1947

Research FocusOphthalmology, Gastro-intestinal, Respiratory, Circulatory, Cardiovascular, Dermatology




Webwww.samil-pharm.com

Contact PersonShin-ku Kang



Company overview

· 1947 - The establishment of Samil Pharm. Co., Ltd.

· 1969 - Technical alliance with Boots Co. of the UK for Brufen

· 1985 - Korea stock exchange IPO (000520)

· 1985 - Completion of KGMP (Korean Good Manufacturing Practice) in Ansan

· 1987 - Establishment of Central R&D Center / Set up ophthalmic business division

· 2003 - Newly established Thea business division

· 2008 - Joint Venture contract with Allergan Inc, of USA

· 2011 - Joint Venture contract with Mon-samil LLC of Mongolia

· 2014 - $9 Million export contract with Iran

Export country : Hong Kong, Japan, Myanmar, Mongolia, Philippines, USA, Vietnam, Yemen

Subsidiary company : Samil H&T Co., Ltd., Samil Medical Co., Ltd. (detistry, medical device)

Focus Area : Ophthalmology, Gastro-intestinal, Respiratory, Circulatory, Cardiovascular, Dermatology

Company Profile

Samil Pharm. Co., Ltd.


Fiscal Year 2015 2016 2017

Sales - - -


Capital - - -

Financial Figures

Main Products


1. Ofloxacin 3mg/mL Ophthalmic Soln. & Oint.

Susceptible strains of the microorganisms

Asia, Mid-East under registration

(Asia, Mid-East, Europe)

2. Tobramycin 3mg/mL Ophthalmic Solution & Ointment


Asia, Mid-East under registration (Asia, Mid-East)

3. Polymyxin B sulfate 6,000IU, Neomycin sulfate 3mg (potency), Dexamethasone 1mg / Ophthalmic Suspension & Ointment

conjunctivitis, blepharitis, and keratitis

Asia, Mid-East under registration (Asia)

4. Levofloxacin 5mg/mL Ophthalmic Solution


Asia under registration (Asia, Mid-East)

5. Sodium Hyaluronate 1mg/mL Ophthalmic Solution

Sjogren's syndrome, Stevens-Johnson Syndrome, dry eye

syndrome, drug-induced, injury, contact lenses


6. Diclofenac sodium 1mg/mL Ophthalmic Solution

a nonsteroidal anti-inflammatory product

Asia, Mid-East under registration

(Mid-East)

7. Povidone 20mg/mL Ophthalmic Solution

a lubricant alleviating dry eyes Asia under registration

(Mid-East)

8. Acyclovir 30mg/g Ophthalmic Ointment

keratitis caused by herpes simplex virus


9. Fluorometholone 1mg/mL Ophthalmic suspension

corticosteroid-responsive inflammation of outer and anterior

segments of the globeAsia

under registration (Asia, Mid-East)

10. Losartan Potassium, HCTZ 50mg, 50/12.5mg, 100/12.5mg Tablets

hypertension Asia -


Trimebutine 1020100002507Stable pharmaceutical composition

comprising Trimebutine and prokinetic agent12 JAN. 2010

Limaprost alfadex 1020100068304Pharmaceutical composition in tablet form

for oral administration comprising Limaprost15 JUL. 2010

Sulglycotide 1020110013635

Multi layer pharmaceutical tablet with improved stability comprising Sulglycotide

and H2 antagonitsts and preparation method thereof

16 FEB. 2011

Telmisartan 1020120079809Pharmaceutical composition comprising Telmisartan with improved stability and

preparation method thereof23 JUL. 2012

Telmisartan & Hydrochlorothiazide 1020120114062Pharmaceutical composition comprising

Telmisartan and HCTZ15 OCT. 2012


RepresentativeSung-Woo Lee

Headquarter Address121 Wausan-Ro(Seogyo-dong), Mapo-Gu, Seoul, Korea

Foundation DateApr. 18. 1970

Research FocusAIDS, Dry eye, etc.



Webwww.samjinpharm.co.kr

Contact PersonBum-Kyu Shin



All human beings have the right to enjoy a healthy and happy life.

However, the complicated social structure of modern society and the development of material civilization cause the advent of new diseases.

In order to protect human health from these diseases and fundamentally get rid of diseases, Samjin Pharm Co., Ltd secures excellent personnel and latest equipment and continues to challenge the development of excellent pharmaceutical drug by utilizing advanced pharmaceutical information and technology.

Samjin pharm Co., Ltd always strives for a better future on the basis of dignity of human life and company philosophy.

The company pioneering a healthy life of people and challenging the prosperous future with mind of creation.

Focus Area : Cardiovascular system drugs, Analgesics & Antipyretics, etc.

Company Profile

Samjin Pharmaceutical Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 216,511 239,312 245,272

R&D Expenditure 15,748 17,437 19,932

Capital 13,900 13,900 13,900

Financial Figures

Main Products


1. PLATLESS (Clopidogrel / Tablet) Antithrombotics, AntiplateletSingapore, Cambodia, Philippines

-

2. GEWORIN Tablet Analgesics & Antipyretics

Philippines, Vietnam, Cambodia,

Mongolia, Uzbekistan

OTC

3. NEUSTATIN-A (Atorvastatin / Tablet) Antilipidemic Agents Philippines -

4. TRESTAN Capsule Appetite Stimulants - OTC

5. NEUTOIN (Donepezil / Tablet) Nootropics & Neurotonics - -

6.NEUSTATIN-R (Rosuvastatin /Tablet) Antilipidemic AgentsHong Kong, Philippines, Myanmar

-

7. BAMEDIN (Rebamipide/Tablet) AntiulcerantsCambodia, Guatemala

-

8. MAROBIVEN-A Inj. Antiinflammatory Enzymes - -

9. SYNERJET (Acetaminophen, Tramadol / Tablet) Analgesics & Antipyretics Philippines, Vietnam -

10.ARB-XG (Amlodipine, Valsartan / Tablet) Antihypertensive Agents Philippines, Vietnam -


- SJ-3366 AIDS Phase1/Preclinical

Rebamipide Prodrug SA001Dry eye syndrome, Oral

treatmentPhase II

- SJP002Dry eye syndrome, Eye drop

solutionPhase II

- SJP1601 Cancer Preclinical

- SJP1602 Cancer Biological test

Aptamer-drug conjugate SJP1604 Cancer Preclinical

- SJP1610 Cancer Biological test

- SJP1701Alzheimer's disease, Parkinson's disease

Biological test


RepresentativeTaeung Eom

Headquarter Address295 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Korea


Research Focusnovel drug delivery systems and medical devices



Webwww.samyangbiopharm.com

Contact PersonMr. Sung-Seup Shin



Samyang Biopharmaceuticals Corporation is focusing its efforts on healthcare as its core strategic business of the 21st century. Samyang Biopharmaceuticals Corporation is developing proprietary and unique core technologies for the development of world class novel drug delivery systems.

Focus Area : Oncology, GMP Manufacturing(APIs, Injections, Patches), DDS Technology

Company Profile

Samyang Biopharmaceuticals Corporation


Fiscal Year 2015 2016 2017

Sales 62,634 70,300 80,500

R&D Expenditure 7,700 8,400 8,890

Capital 208,939 220,788 230,000

Financial Figures

Main Products


1. Genexol® Inj. (Paclitaxel) Anti-CancerAsia, Europe, Middle East

-

2. Genexol-PM® Inj. (Paclitaxel) Anti-Cancer Africa, Asia -

3. Nanoxel®-M Inj. (Docetaxel) Anti-Cancer - -

4. Pemed® Inj. (Pemetrexed) Anti-Cancer Europe, Middle East -

5. Protezomib® Inj. (Bortezomib) Anti-Cancer - -

6. Lenalid® Tab. (Lenalidomide) Anti-Cancer - -

7. Palseron® Inj. (Palonosetron) Nausea and vomiting - -

8. Zolenic® Inj. (Zoledronic Acid) Bone metastasis Europe -

9. Rheumastop® Transdermal Patch (Diclofenac Diethylamine)

Rheumatoid arthritis Africa, Middle East -

10. Tulobuterol Transdermal Patch Asthma acute bronchitis - -

11. Fentaderm® Transdermal Patch (Fentanyl) Severe Pain - -

12. Rivastigmine Transdermal Patch Anti-Alzheimer - -

13. Paclitaxel (API) Anti-CancerAsia, Europe, Japan,

South America-

R&D Pipeline


PM(Polymeric Micelle)

Paclitaxel -

Cancer

Market

Docetaxel - Market

Temsirolimus - Preclinical

PNP(Polymeric Nano-

Particle)

Docetaxel -Cancer

Clinical

Sirolimus - Preclinical

Oral_CSDS Prednisolone - Ulcerative colitis Research

Oral_FDT Ramosetron - Vomiting Registration

Oral_BA - SYO-1644 Cancer Preclinical

SENS

siRNA

- Cancer ResearchmRNA

pDNA


RepresentativeMr. Jungho Kim

Headquarter Address21, Banpo-daero, Secho-gu, Seoul, 06710, Korea

Foundation Date1976 Aug.

Research FocusNCE, IMD, ODF



Webwww.seoulpharma.com

Contact PersonYongnam Jang


Contact [email protected]@seoulpharma.com

Seoul Pharma Co., Ltd., (the “SPC”) has engaged in manufacturing and distribution of pharmaceuticals since its establishment in 1976 and established the Centralized R&D Centre in 1997 for the purpose of R&D on new drug delivery technology.

SPC has produced more than 50 oral solid products mainly as Rx with such therapeutic categories as respiratory, infective, cardio-vascular, gastro-intestinal, endocrinal, anti-obesity, and so on.

In order to become a world-class pharmaceutical company, SPC has focused its R&D on the innovative and creative DDS technology such as special formulations development and as its result, SPC developed a new Platform technology, named as “SmartFilm® Technology”, to produce Orally Disintegrating Film(ODF) products. SPC has planned to penetrate the global market through SmartFilm® Technology with a new cGMP/EU-GMP plant was built in Osong city, especially targeting to the US, EU, and other regulatory markets. Through SmartFilm® Technology, SPC is willing to enter the global challenge for the market and be a Hidden Champion in the global pharmaceutical industry.

Company Profile

Seoul Pharma Co.,Ltd.


Fiscal Year 2015 2016 2017

Sales 44,731 45,920 46,652

R&D Expenditure 2,505 2,127 2,526

Capital 33,528 42,070 54,090

Financial Figures

Main Products


1. VULTIS® (Sildenafil citrate/ ODF) Erectile dysfunction -Lauched as Viagra L

in Korea

2. VULTEUM® (Tadalafil / ODF) Erectile dysfunction - -

3. ARTPEZIL® (Donepezil HCl / ODF) Dermentia - -

4. Diflu cap. (Fluconazole/capsule) Antifungal - -

5. Aliver susp. (I-leucine,I-isoleucine,I-valine) Hypoalbuminemia - -

6. Sebron cap./syrup (acetylcystein/cap./syrup) Mycolytics - -

7. Seoul Amlodipine Besylate tab. (amlodipine besylate/tablet)

Anti-Hypertension - -

R&D Pipeline


- SPC-702COPD agent

(W-peptide derivative)Preclinical

- SPX-601 prevention and curing arthritis Phase II a Clinical

Sildenafil citrate Vultis erectile dysfunction Launched May 2012

Donepezil HCl Artpezil DermentiaA Domestic Patent

Registration

- Aripiprazole ODF Schizophrenia MA completed

Tadalafil Vulteum Erectile dysfunction Launched Sep 2015

- SPO-1107 Anti-emetic Formulation Research

- SPO-1304 Antiviral Formulation Research

- SPO-1405 Obesity Formulation Research

- SPO-1401 Anti-emetic Formulation Research

- SPO-1406 Overactive bladder Formulation Research

Other

Our SmartFilm® technology, which is a DDS technology to produce Orally Disintegrating Film (ODF), results from our effort and devotion to develop the new technology under our confidence since 2009 that our future depends on how to secure platform technology and strengthen core competence.The SmartFilm® technology is differentiated from the existing platform one, because it is the globally leading technology to enable to load the higher dose of active pharmaceutical ingredients, secure the optimal manufacturing process of ODF and mask the bitter taste of medicines.We appreciate you for your continuous support and encouragement to us until our company becomes one of the global leading pharmaceutical companies through SmartFilm® technology.


RepresentativeJei Man Ryu

Headquarter Address161 Yeoksam-ro, Gangnam-gu, Seoul, 0646, Korea


Research FocusCV, CNS, surgical wound care, musculoskeletal, anti-infective


Representative Phone82-31-491-6191-2

Webwww.shinpoong.co.kr/eng

Contact PersonJ. S. Hong



Shin Poong Pharm. Co., Ltd is a R&D oriented multinational pharmaceutical company headquartered in Seoul, South Korea, with 7 manufacturing site worldwide with global partners in over 59 countries. Main focusing areas are CV, CNS, surgical wound care, musculoskeletal, and anti-infective.

Under the management philosophy of ‘for the health of the people’, Shin Poong Pharm. Co., Ltd. specializes in manufacturing remedy drugs with sincere efforts put into producing every single tablet of life-saving drugs ranging from ingredients to finished products based on our state-of-the-art manufacturing facilities and quality assurance system. We are committed to realizing the spirit of Shin Poong 3V (Vision, Venture and Victory) with top-notch competitiveness based on in-house ingredient synthesizing technologies obtained through rigorous R&D efforts and to further developing the company into the one that receives confidence from our customers and that contributes to promoting the wellbeing of human beings.

Company Profile

SHIN POONG PHARM. CO., LTD.


Fiscal Year 2015 2016 2017

Sales 185,478 182,276 -


Capital 23,790 27,593 -

Financial Figures

Main Products


1. Medicurtain Inj. Surgical adhesion barrier -Medical device with novel mode of action

2. Candeamlo Tab. Hypertension treatment - IMD, FDC

3. Ezerosu Tab. Hyperlipidemia treatment - IMD, FDC

4. Hyal Forte Inj. Osteoarthritis treatment - Leading product in Korea


SP-8008 - Anti-platelet (NCE) Preclinical

SP-8232 - Heart failure (NCE) Preclinical

SP-8356 - Atherosclerosis (NCE) Preclinical

FreeWink™ - Dermal/body filler (NME) Preclinical

SP-35454 -Osteoporosis/fracture healing

(NCE)Phase I

HyalOne™ - Osteoarthritis (NME) Phase I

SP-8203 - Acute ischemic stroke (NCE) Phase II

Pyramax Granule - FDC/Pediatric malaria (NCE) Phase III-IV



Pyramax Tab. FDC/Malaria (NCE)2011.08 / Korea

2012.02 / EU


RepresentativeHanki Kim

Headquarter AddressKorea Bio Park C - 4fl, 694-1, Sampyeong-dong, Bundang-gu, Seongnam, Geyeonggi-do, Korea 463-400

Foundation Date1955

Research FocusPain reliving and wound care etc.




Webhttp://global.sinsin.com

Contact PersonWoongjin Han



In the year 1959, few years after Korean war, SINSIN Pharmaceutical Company was established during the reconstruction of post-war period for the purpose of improving the national health.

Amidst the devastating conditions of the 1950’s SINSIN committed to the development of top professional staff, research and development of new products and to the improvement of the Korean pharmaceutical market. SINSIN’s efforts were successful in replacing the expensive Japanese Plaster and through superior quality management became the #1 Plaster company in Korea.

SINSIN began to export it’s products in 1971 and at present time it ships to over 30 different countries worldwide with trememdous success.

SINSIN has been given various awards including the Outstanding Company Award and the Presidential award. These awards have motivated SINSIN to work harder to promote national health, which is both our responsibility to society and our original goal as a leading pharmaceutical company.

From environmental concerns to national health SINSIN Pharmaceutical will continue to diligently work for the improvement of life.

Thank you for all of your support.

Focus Area : Pain reliving patches, Liniment, Aerosol, Wound care product.

Company Profile

SINSIN Pharmaceutical Cp., Ltd.


Fiscal Year 2012 2013 2014

Sales 9,376 8,704 8,631


Capital - - -

Financial Figures

Main Products


1. SINSINPAS-RXActive ingredient : Out of 1 sheet (10x14cm, 2,301.24mg)L-menthol 90.9mg, dl-camphor 34.1mg,Mentha oil 45.46mg, Methyl salicylate 90.90mg,Vanillyl Nonylamide 0.114mg

IndicationMuscular pain, Joint pain, Shoulder pain, backache, Bruise, Sprain

U.S.A, Aisan sounties.

Pain Relief Patch

2. SINSIN PAS Pain relief PatchActive ingredient : Out of 1 sheet (6.2x 4.1cm, 453.29mg)Methyl salicylate 29.98mg, Thymol 0.77mg, L-menthol 36.32mg,DL-camphor 15.63mg, Borneol 1.20mg

IndicationMuscular pain, Joint pain, Shoulder pain, backache, Bruise, Sprain

U.S.A, EU, Asian countries.

Pain Relief Patch

3. SINSIN CAPSICUM PATCHActive ingredient : Out of 1 sheet (13x18cm, 2,400mg)Capsicum extract 0.025%

IndicationMuscular pain, Joint pain, Shoulder pain,Neuralgia, Rheumatism, backache

U.S.A, Middle East, Asian countries.

Pain Relief Patch

4. ICE COLD PAIN RELIEF PATCHActive ingredients ( out of 8x12cm, 5.2g)• L-Menthol 5%

Indication• Muscular pain • Joint pain• Shoulder pain • backache• Bruise • Sprain

Exporting countryOver 15 countries including :• U.S.A

(CVS, Wal green)• Poland• U.K (Boots )• Asia• RussiaICE COLD PAIN RELIEF PATCHPAIN RELIEF HYDRO GEL PATCHCode :SSP 3405

Pain Relief Patch

5. KETOCLIN PLASTERActive ingredients (out of 10×7cm2, 0.7g )• Ketoprofen 30mg

Indication• Arthritis Deformans • Peri-arthritis of shoulder• Tendinitis • Peri-tendinitis• Myalgia

Exporting countryOver 10 countries including :• HK• Vietnam• Macao• Iran• Guatemala

Pain Relief Patch,

Transdermal Drug

Delivery System(TDDS).


RepresentativeIn-Serk Lee

Headquarter Address686 Sampyeong-dong, Bundang-gu, Seongnam-si 463-400, Gyeonggi-do, Korea


Research FocusNCE, Herbal, Biologics




Webwww.skchemicals.com

SK Chemicals is a member company of SK Group, the third largest company group in Korea.

Since founded in 1969, SK Chemicals has focused on the development of drug products targeting the diseases with unmet treatment needs in order to fulfill its vision; “Healthcare and Earthcare”.

The R&D area of SK Chemicals covers a broad range of product lines, including new chemical entities, new herbal extract drugs, reformulated generics, vaccines and blood products. Owing to its continuous efforts on R&D, SK Chemicals was able to develop three new chemical entities (NCEs), novel drug delivery system (DDS) flat foam technologies, recombinant DNA technology and in-house premium vaccines.

On the basis of this strong R&D capability together with its outstanding marketing operations, SK Chemicals was selected as a member of the Korea Innovative Pharmaceutical Company.

Company Profile

SK Chemicals Co., Ltd.


Fiscal Year 2008 2009 2010

Sales 258,952 303,383 350,270

R&D Expenditure 24,500 30,621 34,910

Capital - - -

Financial Figures

Main Products


1. OMED Tab. (Omeprazole) Gastric Ulcer EU -

2. SID710 Patch (Rivastigmine) Alzheimer's Disease EU -

3. SK Albumin Inj. 20% (Human Albumin) Albumin Deficiency

Egypt, India, China, Hong Kong,

Mongolia Dominican Republic

-

4. LIV-Gamma Inj. (Human IgG) IgG DeficiencyThailand, Peru, India,

Egypt-

5. Trast Patch (Piroxicam) ArthritisSaudi Arabia, China,

Philippines-

6. Ginexin Tab. (Ginko biloba) Blood Circulation Enhancer Saudi Arabia -

7. Joins Tab. Arthritis Australia -

8. SID530 Inj. (Docetaxel) Anti-cancer EU -

9. SID820 Cap. (Esomeprazole) Gastric Ulcer EU -

10. MvixS ODF (Mirodenafil) Erectile Dysfunction - -


NCE 401 Fibrosis Pre-clinical

NCE 403 Endometriosis Pre-clinical

HMP 301 Asthma Phase III

HMP 302 Alzheimer's Disease Phase III

HMP 304 Irritable Bowel Disease Phase II

NBP 606Prevention of infection caused by Pneumococcal

bacteriaPhase I

NBP 607 Prevention of infection caused by Influenza virus Phase I

New Active Substances Product (Ingredient) Use Approval Date/Country

SUNPLA (Heptaplatin) Anti-cancer 1999

JOINS (Herbal Extracts) Arthritis 2002

Mvix (Mirodenafil) Erectile Dysfunction 2007


RepresentativeKoh, Jae-Won (CEO)

Headquarter Address10, Beomjigi-ro 141beon-gil, Danwon-gu, Ansan-si


Research Focus973.783m2



Webwww.susungpharm.co.kr

Contact PersonPark, Chul-Seo



SS Pharm is a manufacturer of APIs.

And our facilities and operations conforms to PIC/S and WHO GMP.

Company Profile

SS Pharm.Co.,Ltd.


Fiscal Year 2015 2016 2017

Sales 7,669 8,659 9,500


Capital 2,030 2,030 2,030

Financial Figures

Main Products


1. Acetyl-L-Carnitine Hydrochloride Nootropics & Neurotonics - KDMF

2. Bethanechol Chloride Other Genito-Urinary - -

3. Benfotiamine Anti-oxidant - -

4. Caffeine and Sodium Benzoate Respiratory Stimulants - -

5. Celecoxib COX-2 inhibitor - -

6. Citrulline Malate Amino acids and derivatives - -

7. Clopidogrel Bisulfate Anti-thrombotic - KDMF

8. Doxofylline Anti-Asthmatics - -

9. IsotretinoinRetinoids, Anti-Acne

Preparations- -

10. Talniflumate Anti-imflammatory - KDMF

11. Cilnidipine Cardiovascular agent - -


Choline Alfoscerate - Nootropics & Neurotonics Under development

Nafamostat Mesylate - Anti-coagulantsExamined for Product license

by MFDS

R-Thioctic acid Tromethamine salt - diabetic neuropathyExamined for Product license

by MFDS

Epinastine Hydrochloride -Anti-histamines & anti-

allergicsUnder development


RepresentativeMr. Joo Hwan, YANG / CEO

Headquarter AddressJung-An B/D 6F, 435-5 Jangan 1dong, Dongdaemun-gu, Seoul

Foundation Date1973




Webwww.suheung.co.kr

Since Establishment in 1973, Suheung Capsule Co., Ltd have sought to produce only the highest quality capsules and thus grown to be one of the world's leading manufacturers and exporters of empty hard gelatin, fish and HPMC capsules.

Company Profile

Suheung Capsule. Co., Ltd.


Fiscal Year 2008 2009 2010

Sales 101,606 107,816 124,860


Capital 5,902 6,084 6,084

Financial Figures

Main Products


1. Empty hard gelatin capsules - more than 40 -

2. Empty hard fish capsules - more than 40 -

3. Empty hard HPMC capsules - more than 40 -


RepresentativeTae Young Lee

Headquarter Address8 Daesagwan-ro 31-gil, Yongsan-gu, Seoul

Foundation Date1978

Research FocusOphthalmology, Gastrointestinal agents, Contrast media, etc




Webwww.taejoon.co.kr

Contact PersonMr. Andy Lee



Taejoon Pharm., founded in 1978, is a global pharmaceutical company accomplished in exporting aseptic eye drops to Europe for the first time in Korea. In addition, we are the first specialized company to have technologies to make all three fields of contrast media products: X-ray, MRI, and CT. Taejoon Pharm's Yongin plant, which was built in October, 2005, became Korea's first EU-GMP certified plant to produce qualified pharmaceutical products that export to Europe.

Taejoon is implementing a marketing strategy, targeting countries of the world and continuously reinforcing pioneering movement by actively participating in internationally renowned academies and exhibitions. As a result, we were able to create a strong sales network among more than 50 countries, including 30 European countries. On this basis, we plan to strengthen the sales network with the goal of simultaneous release into the world in the event of global product launch. We expect to increase the company's brand value by establishing the sales network through localized sales marketing in particular countries, such as the U.S., China, Russia, and Europe.

Focus Area : Ophthalmology, Gastrointestinal agents, Contrast media, etc.

Company Profile

Taejoon Pharmaceutical

Summary

Fiscal Year 2012 2013 2014

Sales $95,043,027 $94,325,508 $90,905,789

R&D Expenditure $4,836,463 $6,355,765 $7,686,165

Capital $92,603,127 $101,850,598 $91,917,685

Financial Figures

Main Products

Product (Ingredient/Formulation) Use Exporting Countries Remark

Ophthalmic solution

1. Cyporin N ophthalmic solution (Cyclosporine)

The increase of tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca

-

2. MC Free ophthalmic solution(Sodium carboxymethylcellulose)

Dry eyes for the temporary relief of burning, irritation and discomfort

EU, USA

3. Hyaluni ophthalmic solution(Hyaluronic acid)

Bond and repair corneal epithelial cells, helps cure corneal injuries and retain and stabilize tears, dysfunction tear syndrome

- -

4. Taejoon Ultra ophthalmic solution(Polyethylene Glycol)

Temporary relief of irritation and burning due to dryness of the eye

USA -

5. Xalost Plus ophthalmic solution(Latanoprost + Timolol maleate)

Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

EU, Russia, China

6. Xalost ophthalmic solution (Lataonoprost)Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

EU, Russia, China -

7. Alpaday ophthalmic solution (Olopatadine HCl) Relief of allergic conjunctivitis - -

8. Fluvin ophthalmic solution(Fluorometholone)

Inflammatory diseases of the anterior/external segment of the eye (blepharitis, conjunctivitis, keratitis, etc)

- -

Gastrointestinal agents

9. Coolprep (PEG 3350) Preparation for colonoscopy -

10. Lamina G (Sodium Alginate)Hemostasis and remission of subjective symptom in gastric & duodenal ulcer, erosive gastritis

-

11. Gasocol Susp. (Simethicone)For elimination of gastric bubble for gastroendoscopy

- -

12. Colyte (PEG 3350) Preparation for colonoscopy - -

13. Colyte F (PEG 3350) Preparation for colonoscopy - -

Contrast Media

14. MRbester injection(Gadopentetate dimeglumine)

Contrast medium for cranial and spinal MRI/ whole body MRI

Asia

15. Iobrix injection (Iohexol)Myelography, angiography, urography, contrast enhancement of computerized tomography

Asia -

16. Radisense injection (Iopamidol)

Angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography), and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic (CECT) head and body imaging

Asia -


Product (Ingredient/Formulation) Use Exporting Countries Remark

17. Iversense injection (Ioversol)

For cerebral angiography and peripheral arteriography, contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography

- -

18. Visisense injection (Iodixadol)

1. Intra-arterial intra-arterial digital subtraction angiographyangiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebralarteriography

2. Intravenous CECT imaging of the head and body, excretoryurography, and peripheral venography.

- -

19. Solotop-HD (Barium sulfate)

Contrast enhanced x-rays or computed tomographic imaging (CAT scan, CT scan; a type of body scan that uses a computer to put together x-ray images to create cross-sectional or three dimensional pictures of the inside of the body) of the esophagus (tube that connects the mouth and stomach), stomach, and intestine

Asia -


Age-related Macular Degeneration(New Biological Entity)

- AMD Phase 2/3

Antibiotic product (New Chemical Entity)

- Bacterial conjunctivitis Pre-clinical

Dry eye product(New Chemical Entity)

- Dry eye Pre-clinical

Combination or Improved drugs - Ophthalmic/GI indications Phase 3 ~ Pre-clinical

RepresentativeChang Koo Lee

Headquarter Address123, Jeyakgongdan 3-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea

Foundation Date1957




Webhttp://www.taiguk.co.kr

Contact PersonYou Mi Kim



“Supply best quality pharmaceutical products to customer.” Since established in 1957, Tai Guk Pharm. Co., Ltd. has been manufacturing pharmaceutical products. We have focused on development of OTC products such a hydroquinone cream and professional and leading manufacturer of ointments(ointment, cream, gel) in Korea. We have largest plant in Korea for ointments at Buyeo and pushing to FDA approved Buyeo plant. We can also undertake contact manufacturing Tablet, Capsule, Internal & External liquid, and specially Ointments. We are export to USA and many other countries.

Focus Area : Ointment & Cream

Company Profile

Taiguk Pharm. co., Ltd.


Fiscal Year 2012 2013 2014

Sales 38,000 43,000 50,000


Capital 16,000 17,000 20,000

Financial Figures


Main Products


1. Highrosone Cream(Hydrocortisone / Cream)

Dermatitis Cambodia -

2. Paracool Cream(Methyl Salicylate, l-Menthol, dl-Camphor / Cream)

Pain Relief Vietnam -

3. Pramyxin Ointment(Bacitracin Zinc, Neomycin sulfate , Polymyxin B Sulfate, Pramoxine HCl / Ointment)

Antibiotics Hongkong -

4. Partygel Suspension(Almagate / Gel)

Hyperacid Vietnam -

5. Miobi soft cap.(Vitamin A and other ingredients / Capsule)

Multi Vitamin Ecuador -RepresentativeJI KYU WON

Headquarter Address5F, 32, Nonhyeon-ro 30-gil, Gangnam-gu, Seoul, Korea

Foundation Date1st. OCT. 1990

Research FocusFirst Generic & Slow release type drug




Webhttp://www.thera-gen.com

Contact PersonSun-Hee, Kim



THERAGEN ETEX CO., LTD. is a leading pharmaceutical company to develop innovative and personalized new drugs having a world class analysis technology of individual genome.

Excellent System : We have manufactured outstanding pharmaceuticals by controlling all lines at GMPs factory from manufacturing to quality controls in compliance with WHO/ICH Guideline.

Best Bio center : Our laboratory having the best analysis technology and excellent analysts of the genome in Korea. The first and the best results of studies to be recognized in the world - Whole genome mapping of woman, tigers and whales(the first in the world) - Commercialized personal genome analysis service(the first in Asia)

Innovative New drug : THERAGEN ETEX CO., LTD. has built databases and infrastructures to dvelop personalized pharmaceuticals by analysing individual's deases genes as the only pharmaceutical manufacturing facilities and genome analysis service in Korea.

Focus Area : E.N.T & Cardiovascular

Company Profile

THERAGEN ETEX CO., LTD.


Fiscal Year 2012 2013 2014

Sales 65,757 56,398 52,244

R&D Expenditure 5,710 3,914 2,815

Capital 13,627 13,887 13,887

Financial Figures


Main Products


1. ETEXCITICOLINE Tab. (Cilticoline 500mg)Memory disorder, Ischemic stroke

Vietnam -

2. CELEMIN Cap. 200mg (Celecoxib 200mg) NSAID Vietnam -

3. NEXON Tab. 20mg/40mg (Esomeprazole 20mg/40mg)

Gastritis Vietnam -

4. RABEZOLE 10mg/20mg (Rabeprazole 10mg/20mg)

Gastritis Vietnam -

5. EXPERA Tab. 5/80 (Amlodipine 5mg + Valsartan 80mg)

Hypertension Phillipine -

6. ATOSEN Tab. (Atorvastatin 10mg) Hyperlipidemia Vietnam -

7. ETEX ROSUVASTATIN Ca Tab. (Rosuvastatin Ca 5mg/10mg/20mg)

Hyperlipidemia Phillipine -

8. ZAKUTEX Dry syrup 156.25mg/5mL (Amoxiciliine hydrate 21.6248g + Diluted potassium calvulanate 10.8124g)

Chronic branchitis Myanmar -

9. ZAKUTEX Neo Dry syrup (Amoxiciliine hydrate 54.5454g + Diluted potassium calvulanate 7.8g)

Acute otitis media for children Vietnam -

10. CLAROCIN Tab. (Clarithromycin 250mg) Antibiotics Vietnam -

11. UMCKAMAX Syrup (Pelargonium sidoides 11%EtoH ext.17.16mg)

BronchitisLaryngopharyngitis

Vietnam -

12. CRANTOL Syrup (Amboroxol HCl 150mg + Clenbuterol HCl 0.1g)

Cough Nigeria -

13. CITLEN Solution (Citrulline maleate 1g) Fatigue recovery Vietnam -

14. ETEX CYCLOSERINE Cap. (Cycloserine 250mg) Tuberculosis Vietnam -

15. ZENTOX Tab. (Albendazole 400mg) AnthelminthicUzbekistanAzerbaijanKyrgyzstan

-

16. OEANZIL Vaginal Soft Cap. (Neomycin 35,000IU, Nystatin 10,000IU, Polymyxin B sulfate 35,000IU)

Vaginal infectionMyanmarCambodia

-

17. SIMTUM-TWO Tab. (Acetaminophen 325mg, Phenylphrine HCl 5mg Dextromethorphan hydrobromide 10mg, Chlorpheniramine maleate 2mg)

Cold Hongkong -

RepresentativeSung Jun Kim

Headquarter AddressWonwae B/D 5F, 26, Olympic-ro 43-gil, Songpa-gu, Seoul, Korea

Foundation DateNov. 1956

Research FocusInfectious disease




Webwww.ukp.co.kr

Contact PersonJeongsu Ock

Contact Phone82-2-489-3611(Ext.311)


Union Korea Pharma is pharma manufacturing company, certificated GMP compliance of tablet, capsule, injection(ample, vial) and cephalosporin powder from MFDS Korea.

We have exported to Vietnam, Cambodia, Philipine, Hongkong, Mongo, Peru, Chile, Bolivia, Yemen, Azerbaijan etc, and we had received Presidental Award by small and medium enterprise export support center in 2009.

Focus Area : Antibiotics(Cepha inj.), Cardiovascular, Degenerative Disease, Contrast media, Ophthalmology

Company Profile

Union Korea Pharma Co., Ltd.


Fiscal Year 2012 2013 2014

Sales 42,294 40,467 48,715


Capital 2,100 2,100 2,100

Financial Figures


Main Products


1. Unitiaxone Inj. (Ceftriaxone Sodium 1g)

Respiratory system infection, infection related otolaryngology renal and urinary tract infection, septicemia meningitis,

prophylactic of pre/post operation infection, osteoarthritis, skin and soft

tissue infection, cholecystitis, G.I. tract infection.

Vietnam, Philippines,Yemen

-

2. Uni-Infusion Inj. (L-Ornithine-L-Aspartate 500mg)

Hepatic dysfunction - Acute and chronic hepatitis, alcoholic liver disease; post

hepatitis convalescence, cirrhosis, along with hepatotoxic drugs.

Vietnam, Mongol -

3. Union Cefuroxime Sodium Inj. (Cefuroxime Sodium 750mg)

Acute or chronic bronchitis, bronchiectasis, bacterial pneumonia, pneumonial abscess, post-operational chest infection, sinusitis,

tonsilitis, pharyngitis, nephropyelitis, cystitis, cellulitis, eryspelas

Vietnam, Philippines -

4. Climycin Inj. (Clindamycin phosphate 600mg)

Infections caused by susceptible anaerobic bacteria

Vietnam, Philippines -

5. Unifenac Inj. (Diclofenac Sodium 75mg)

Fever and pain due to cold, headache, neurodynia, muscle ache, menstrual

cramps, rheumatoid arthritis, arthralgia, toothache

Vietnam -


Combined antibiotics with beta-lactamase

-bacterial infections (upper

respiratory tract infections).Phase III trial

RepresentativeYang Won Cheol

Headquarter Address621,Yeongdongdaero,Gangnam-gu, Seoul, Republic of Korea

Foundation Date2012

Research Focushypertension, diabetes mellitus, Hyperlipidemia



Webwww.whitels.co.kr

Contact PersonLee sang won



White Life Sciences Co., Ltd. was founded in 2012 as White Pharmaceuticals to create value for both clean and innovative companies through rapid change and innovation.

We strive to be “company that contributes to the right of everyone to the same level of health care.“

We launched a stomach medicine (“STOCURE“ Rebamipide) in October 2013. Since then, more than 200 items have been approved, including circulatory, respiratory, urinary, circulatory, and musculoskeletal, and more than 100 items were sold. Also we are establishing a foundation to become Korea's leading global company through partnership with multinational pharmaceutical companies.

In 2017, we changed our company name to White Life Sciences, we will do business not only in medicines but also in biotechnology, medical devices and cosmetics. We promise to listen to the voice of the patient for 365 days and 24 hours and to be a pharmaceutical company based on communication and trust based on customer's needs. We would like to extend my sincere gratitude to all those who have supported the White Life Sciences Co.,Ltd.,

Company Profile

WHITE LIFE SCIENCE


Fiscal Year 2015 2016 2017

Sales 11,467 11,677 14,384


Capital 3,370 4,203 4,203

Financial Figures


Main Products


1. Atrode Tab (atorvastatin calcium) Anti hypertension - -

2. Cholestop Tab (rosuvastatin calcium) Anti hypertension - -

3. Alforen soft Cap (choline alfoscerate 400mg) Anti psychotics - -

4. Itclor Cap (cefaclor) Anti biotic - -

5. Candino Cap (fluconazole) Anti fungal agent - -

6. Albid Tab(ranitidine HCl, sucralfate, tripotassium bismuth dicitrate)

Anti ulceratives - -

7. Sarpogrel Tab (sarpogrelate hydrochloride)peripheral circulatory

disturbance- -

8. Loxocool Tab (loxoprofen sodium) analgesic - -

9. Rabepezole Tab (rabeprazole sodium) Anti ulceratives - -

10. Valsapine Tab (amlodipine besylate, valsartan) Anti hypertension - -


Anti fungal agent WLS-001 Anti fungal agent Stability

Obesity treatment WLS-002 Obesity treatment Formulation development

analgesic WLS-003 analgesic Formulation development

Anti ulceratives WLS-004 Anti ulceratives Formulation Research

Anti hypertension WLS-005 Anti hypertension Formulation Research

RepresentativeWonbum Lee

Headquarter Address11, Beobwon-ro 6-gil, Songpa-gu, Seoul, Republic of Korea

Foundation DateJune 5, 1978

Research FocusCNS disorders & Neurodegenerative diseases, Age-related disorders and new areas of unmet medical needs



Webwww.whanin.com

Contact PersonSeunghoon Suh



WhanIn Pharm is Korea's No.1 CNS company. We provide the best psychotherapeutic solutions which includes Antipsychotics, Antidementia drugs, Antidepressants, Antiparkinson drugs, Antiepileptics, Anti-ADHD agents, Anxiolytics, and Alcoholism treatment.

Company Profile

WhanIn Pharm Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 145,397 141,376 72,805

R&D Expenditure 5,522 7,834 4,638

Capital 206,594 220,130 231,460

Financial Figures


Main Products


1. Quetapin tab. (Quetiapine) Antipsychotics Asia, Middle East -

2. Riperidon tab. (Risperidone) Antipsychotics Asia, Middle East -

3. Alpram tab. (Alprazolam) Anxiolytics & hypnotics Asia, Middle East -

4. WI Donepezil tab. (Donepezil Hydrochloride) Antidementia drugs Asia, Middle East -

5. U-Rantac tab./U-Rantac inj. (Ranitidine) Gastrointestinal drugs - -

6. Zyrepin tab. (Olanzapine) Antipsychotics Asia, Middle East -

7. Neuoxitam tab. (Oxiracetam) Nootropics - -

8. WI Acamprosate tab. (Acamprosate Calcium) Alcoholism treatment - -

9. Proiban tab./Proiban inj. (Ibandronate) Osteoporosis treatment - -

10. Zolpiram tab. (Zolpidem Tartrate) Anxiolytics &hypnotics - -


WIP-MO14 WIP-MO14 Dementia Clinical

WIB-801CE WIB-801CE Blood circulation Clinical

WIP-DT14 WIP-DT14 BPH Clinical

WIP-LG15 WIP-LG15 Lumbar Spinal Stenosis Preclinical

WIP-PX16 WIP-PX16 Schizophrenia Research

WIP-AX16 WIP-AX16 Schizophrenia Research

WIP-DX16 WIP-DX16 Dementia Research

WIP-LX16 WIP-LX16 Anti-Epileptic Research

WIP-DF17 WIP-DF17 Depression Research

WIN-1601 WIN-1601 Memory impairment Research


Other


NEPONID (Nemonapride) Antipsychotics Jan. 1994 / Republic of Korea

WhanIn provides you with best quality products with Bioequivalance study. We hope that we would make long and sincere relationship with you.

Headquarter Address827 Shindong-ri, Chunpo-myeon, Iksan-si, Jeonrabuk-do

Foundation DateMay, 1934

Research FocusSave all livings from distress and sichness




Webwww.wonpharm.co.kr

Founded by Winkwang University on the basis of Bohwadang, a pharmacy established in 1934 under the slogan"Save all living things from distress and sickness" Wonpharm Co., Ltd. manufactures over 180 medicines, lncluing Gyeongokgo under strict quality control, and over 20 health foods, incluing Wonkwang Bohwaokgo Bohwaokgo and Hyosam Forte, at its KGMP-certified factory equipped with clean facilities.

Wonpharm CO., Ltd., which has been designated as cooperative business for research in pharrmaceutical resources as well as the practice factory for Pharmacy College, Wonkwang University, devotes itself to technical development for a society free from disease.

tit has aiso established a solid educational industrial research system with research system with medical College, Oriental Medical Center of Wonkwang University.

Company Profile

Won Kwang Pharm. Co., Ltd

Summary

Fiscal Year 2008 2009 2010

Sales 2,790,000,000 3,125,000,000 3,567,000,000

R&D Expenditure 4,500 3,600 3,200

Capital 3,000,000,000 3,000,000,000 3,000,000,000

Financial Figures


Main Products


1. Bohwa Kyungokgo - - -

2. Bohwa Sohap won - - -

3.Woohwang chungsimwon Suspension liquid - - -

BoHwa KyungOkKo is composed of Korean Ginseng Hoelen, Rehmannia juice, and sweet honey based on the prescription of the korean traditional medical book known as Dong Eui Bo Kam (UNESCO recognizes as a world legacy of the record). This product is well recognized as a restorative enforcing the vitality of whole organs, and also as elimination fatigues, exhaustion followed by weariness. Because of the special properties that had no any interferences against any foods, this product has been used by the ancient royal family and the nobles. Especially this product improves the growth df children and the recovery from weariness due to illness of stress.

RepresentativeNam-Hyun Ryu

Headquarter Address10th Fl., Korea Fire Officials Credit Union Bldg., 274 Songpa-daero, Songpa-gu, Seoul, Korea, 05719

Foundation Date26.Oct. 1957

Research FocusETC, OTC Drugs, Cosmetics, Food supplements


Representative Phone82-2-80-080-4211

Webhttp://wooridulpharm.com/main.do

Contact PersonChul-Hee Choi



WOORIDUL PHARMACEUTICAL LTD. was established in 1957, where it researched, produced and sold pharmaceutical products. Manufacturing plant is currently located in Hyang Nam Industrial complex in Gyeong gi province, which has GMP qualified manufacturing facilities with highly hygienic manufacturing environment and high technology. Thus, the plant can produce pharmaceutical products that will satisfy in both quality and quantity. In 1990, after initial public offering, our company has not only continuously grown but also has been designated as one of growing export companies.

Our company also invests on researching new drugs and Incrementally Modified Drugs. With continuous producing and researching based on Platform, R&D Power, our company researches on safe and high-performance cosmetic products.

Company Profile

WOORIDUL PHARMACEUTICAL LTD.


Fiscal Year 2015 2016 2017

Sales 60,405 71,546 79,846


Capital 29,106 36,835 47,047

Financial Figures


Main Products


1. NEPHRIS-S Tab. (Ononidis radix extract 100mg, Orthosiphon folium extract 100mg, Solidaginis extract 200mg)

Adjunctive treatment of acute ∙ choronic nephritis, cystitis, bladder and kidney stones

CAMBODIA

2. NEPHRIS Soft Cap. (Ononidis radix extract 30mg, Orthosiphon extract 100mg, Uvae ursi extract 80mg)

1. Seasonal and perennial allergic rhinitis2. Chronic idiopathic urticaria3. Dermatitis and eczema accompanied with itchiness, eczema

MONGOLIA

3. CETINZAL Tab. (Levocetirizine HCl 5mg)

1. Seasonal and perennial allergic rhinitis2. Chronic idiopathic urticaria3. Dermatitis and eczema accompanied with itchiness, eczema

CAMBODIA

4. PRENEW Cap. (Pregabalin 75mg, 150mg)

1. Treatment of peripheral and central neuropathic pain in adults2. Epilepsy: Adjuvant for partial seizures with or without

secondary systemic symptoms in adults3. Treatment of fibromyalgia

-

5. POTALION Tab. (Bepotastine besilate 10mg)

Allergic rhinitis, chronic urticaria, pruritus associated with skin diseases(eczema, dermatitis, skin pruritus, prurigo)

-

6. VARDIPINE Tab. 5/80mg, 10/160mg, 5/160mg

(Amlodipine/Valsartan)

Treatment for essential hypertension that is not controlled properly with monotherapy using amlodipine or valsartan

-

7. NEULOS Cap. (Gabapentin 100mg, 300mg)

Epilepsy, neuropathic pain -

8. LOXORON Tab. (Loxoprofen 60mg)

1. Chronic rheumatoid arthritis, osteoarthrosis, low back pain2. Acute upper respiratory inflammation

-

9. LIVATIN Tab. (Atorvastatin 10mg, 20mg)

1. Hyperlipidemia2. Reduce risks of myocardial infarction, stroke, revascularization,

chronic angina-

10. WOORIDUL RANITIDINE HCl Tab. (Ranitidine 75mg, 150mg)

Gastro-duodenal ulcer, Zollinger-Ellison syndrome, reflux esophagitis etc.

-


Confidential WRDP001 Central Nervous System Drugs Non-clinical

Confidential WRDP002 Anti-Histamines Non-clinical

Confidential WRDP003Antipyretic, Analgesic, Anti-

Inflammatory DrugsNon-clinical

Confidential WRDP004 Anti-Diabetics Non-clinical

Confidential WRDP005 Anti-Diabetics Non-clinical

Confidential WRDP006 Anti-Atherosclerotics Non-clinical

Confidential WRDN001Antipyretic, Analgesic, Anti-

Inflammatory DrugsResearch

Confidential WRDN002 Anti-Peptic Ulcer Drugs Research

RepresentativeMr. Woo-Pyoung Yoo

Foundation DateDec. 23, 1981

Research FocusNew Drug & IMD




Webwww.yypharm.co.kr

Contact PersonMr. Choi



Yooyoung has established a foothold for growth through consistent increasing sales, and we are growing as a leading pharmaceutical company in Korea by fulfilling our medium and long term mission.

Focus Area : Arthritis, Anti-Thrombosis, Mixed-Dylipidemia, etc.

Company Profile

YOOYOUNG PHARMACEUTICAL


Fiscal Year 2012 2013 2014

Sales 74,169 75,372 85,651

R&D Expenditure 3,535 2,640 3,418

Capital 3,000 3,000 3,000

Financial Figures


Main Products


1. Ati InjectionArthritis, Scapular

periarthritis

Poland, Syria, UAE, Russia, Vietnam,

Japan

CTD Dossier Available

2. Atri Plus InjectionArthritis, Scapular

periarthritisPoland, UAE, Russia,

MalaysiaCTD Dossier

Available

3. Cnoxane Injection LMWH : Anti-CoagulantRussia, Syria,

Philiphine, VietnamCTD Dossier

Available

4. Asasulfan Tablet Ulcerative colitis Japan -


Stem cell Neuronata-R ALS On Market

IMD/DDS Artis-FR Gastic ulcer Registration

Monoclonal Antibody YYB101 Anti-cancer Phase 1

IMD/DDS YY1201 OA Phase 1

IMD/New combination YYC301 Neuropathic Pain Preclinical

IMD/Release control YYD601 GERD Preclinical

IMD/New HA filter YYD701 Dermal Filler Preclinical

Fusion Protein YYB102 Anti-cancer Discovery

RepresentativeJunghee Lee

Headquarter Address74, Noryangjin-ro, Dongjak -gu, Seoul, Korea

Foundation DateDec. 1926

Research FocusCancer, Metabolic disease



Webwww.yuhan.co.kr

Contact PersonK. C. Lee



Founded in 1926 with the mission of supporting South Korea by enhancing the quality of life for all Korean people, Yuhan has been providing high quality medicines for the last 91 years as one of the leading pharmaceutical companies in South Korea.

API and Intermediate

Yuhan provides the custom-tailored contract services in research, development, and manufacturing of APIs, key intermediates, and RSMs at two sites under cGMP, approved by FDA(US), EDQM(EU), TGA(Australia), PMDA(Japan) and MFDS(Korea), to the global pharmaceutical companies with excellent quality. And Yuhan offers one-stop services from process development through commercial manufacturing.

Finished product

Yuhan is supplying various categories of high quality pharmaceutical finished products including cardiovascular, metabolic, respiratory, antibiotic, anticancer products and OTC products to both domestic and overseas markets. In terms of Antiphlamine Lotion(anti-inflammatory agent) and Yumangel suspension(antacid), they are all market leaders in the relevant market of Korea and Vietnam.

R&D

Yuhan is focusing its R&D capabilities on developing innovative small molecule and biological medicines, especially in the therapeutic areas of cancer and metabolic diseases. Its advanced drug-delivery technology also supports the development of incrementally modified drugs (IMDs) such as fixed-dose combination and controlled release drugs.

Company Profile

Yuhan Corporation


Fiscal Year 2015 2016 2017

Sales 1,120,937 1,312,018 1,451,988

R&D Expenditure 71,543 85,191 101,609

Capital 1,285,767 1,390,818 1,487,991

Financial Figures


Main Products


1. CMO (New Drug APIs) HIV USA, Europe -

2. CMO (New Drug APIs) HCV USA, Europe, Asia -

3. CMO (New Drug API) Rheumatoid Europe -

4. CMO (New Drug APIs) ß-lactamase inhibitor Europe -

5. Levofloxacin (Generic API) Antibiotic Canada, Japan -

6. Cilostazol (Generic API) Anti-platelet Japan -

7. Newfactan (Finished product)Neonatal RespiratoryDistress Syndrome

ASIA, Middle EastBovine lungsurfactant

8. Antiphlamine S Lotion (Finished product) Lotion type of

Anti-inflammatory agentASIA -

9. Duowell tab. (Finished product) Hypertension, Hyperlipidemia Under registration

Fixed Dose Combination drug of Telmisartan &

Rosuvastatin10. Nazacare Nasal Spray Sol. 140dose &

60dose (Finished product)Allergic rhinitis Nasal polyps Under registration -


- YHP1604 Hypertension/Dyslipidemia Phase 3

- YHP1701 Hypertension/Dyslipidemia Phase 3

- YHP14755 Dyslipidemia/Diabetes Phase 3

- YH22162 Hypertension Phase 3

- YHD1119 Neuropathic pain Phase 3

- YH23537 Peridontitis/Arthritis Phase 2

- YH26153 Peri-implantitis Phase 1

- YH12852 Postoperative ileus Phase 1

- YH25448 Cancer Phase 1/2

- YH26136 Dyslipidemia/Thrombosis Preclinical

- YH25724 NASH Preclinical

- YH24931 Cancer Preclinical


Other


Revanex (Revaprazan) Duodenal Ulcer, Gastric Ulcer, Gastritis Sep. 2005 / Korea

1. Yuhan is a leading pharmaceutical company in Korea with generating more than KRW 1.4trillion in sales. 2. Yuhan has come out on top at the Korea's Most Admired Companies Awards in its industry category for 14 consecutive years. 3. Yuhan is strictly abiding by Compliance Program.

Representativer. Seungpil Yu, Ph.D. / CEO

Headquarter AddressHyein Building, 200 Jangchungdan-ro, Jung-gu, Seoul, Korea

Foundation Date1941

Research FocusNew Drug, Botanical Drug


Representative Phone82–2–2253-6600

Webwww.yuyu.co.kr

Contact PersonBrian Jung



Yuyu Pharma Inc, established in 1941, is a company that sales, markets and manufactures pharmaceutical products in Korea and has developed its business through not only in-house developed new drugs but also various partnerships with global companies such as Sanofi-Aventis, Pfizer, GSK and Novartis by incensing in their original products for the Korean market.

Yuyu Pharma has focused on how to serve the aging population, as people are living longer and searching for ways to live a healthier life. This has led us to be a specialist in the fields of neurology, osteoporosis, cardiovascular and nephrology. Yuyu’s treatment in these areas has proven to be fruitful and we will continue to focus on these therapeutic categories. In order to expand the business, we are also expanding our presence in the field of gastrointestinal diseases and antibiotics.

Also, Yuyu has completed new state-of-art factory in 2006. The factory designed in accordance with cGMP and EU GMP. Tablets, capsules and cream are manufactured with advanced equipment under cGMP compliance.

We would like to have an opportunity for the business relationship with your company who is dealing with imported finished pharmaceutical products.

Company Profile

Yuyu Pharma., Inc.


Fiscal Year 2015 2016 2017

Sales 69,743 71,579 53,518

R&D Expenditure 1,245 2,246 2,000

Capital 7,835 7,835 7,835

Financial Figures


Main Products


1. Dusta soft capsule (Dutasteride) BPH&Alopecia Mongolia -

2. Bonky soft capsule (Calcitriol) Osteoporosis Malaysia, Cambodia -

3. Bonky Injection (Calcitriol) Hypocalcemia Malaysia, Azerbaijan -

4. Yupan-C tablet Vitamin-C Mongolia, Syria -

5. Yupan-C pop Vitamin-C Mongolia -

6. Maxmarvil tablet (Alendronate, Calcitriol) Osteoporosis Thailand, Myanmar -

7. Yuachoo Day&Night (DL-Methylepadrine) Cold Mongolia -

8. Veonplus Gel (Heparin Sodium)Colorless transparent &

smooth gelRussia -

9. Barosofen soft capsule (Dexibuprofen) Anti-inflammatory Mongolia -


YY-102 YY-102 Dry eye Preclinical

YY-201 YY-201 Benign prostatic hyperplasia Phase 1

YY-312 YY-312 Obesity NDA

Tanamin Tab. - Circulatory Improvement Launched

Maxmarvil Tab. - Osteoporosis Launched

Marvil W plus Tab. - Osteoporosis Launched

Marvil M Tab. - Osteoporosis Launched

Newmacor soft capsule - Hyperlipidemia Launched

Dustar (6oblong) - Benign prostatic hyperplasia Launched

Dustar (2oval) - Benign prostatic hyperplasia Launched

Foundation Date1997

Research FocusContract Research Organization



Webwww.cnrres.com

Contact PersonSong, Yunseok



We, the most representative Contract Research Organization in Korea, has performed over 1,200 clinical trials projects for drugs and medical devices since it was built in 1997, and there are about 300 employees including professional medical doctors and experienced clinical specialists. Moreover, We have secured its position as a leading CRO since it was awarded <South Korea Clinical Research Organization of the year>(2008, Frost & Sullivan Awards).

Besides, C&R Research Ltd. Inc. has run various subsidiary companies such as Quality Assurance expert company (C&R QA), pharmacometric analysis center (Q-fitter) and education institution approved by MFDS (C&R Academy) to offer multi-directional and professional clinical trial total solutions, and expanded global influences through Chinese branch in Beijing, and C&R Healthcare Global in Singapore.

Company Profile

C&R Research Inc.


Fiscal Year 2015 2016 2017

Sales 20,273 23,348 29,360


Capital (1,541) (1,422) 2,840

Financial Figures


Other

C&R Subsidiaries

[C&R ACADEMY]

C&R Academy was founded in May 2010 aimed at being a clinical trial training center in Northeast Asia, offering a wide range of training programs related clinical trials.

Now C&R Academy provides professional, comprehensive and practical “hand-on” clinical research training and continuous education programs to researchers (PI) and research nurses (CRC) as well as CRA, PM, CRM to improve the quality of clinical trials.

Training programs of C&R Academy is consists of Fundamental Course, Basic Course, Monitoring Practice, Clinical Project Management, GCP Training, Oncology Clinical Trial, Early Phase Study, Introduction to Clinical Trial and so on. All training programs can expect the effect of intensive training workshop conducted in the form of a small two-way communication.

In addition, since 2011, C&R Academy introduced LMS (Learning Management System) and have been strived to improve the validation and quality of educational services for all C&R Academy as ISO9001 certified company. C&R Academy will to be oriented to international standards of clinical training services continuously.

[C&R QA]

C&R QA Inc., founded in Aug 2014, is the first company specialized in quality assurance of clinical trials in South Korea.

C&R QA is established for the purpose of enhancing the professionalism of the quality assurance work of clinical trials independently from C&R Research that had provided quality assurance services such as audits in a variety of therapeutic areas, education and preparation for government authority inspection. As the importance of quality assurance of clinical trials has been increasingly emphasized, C&R QA is aiming to provide quality assurance services of clinical trials to customers with credibility.

All auditors of C&R QA have a membership of RQA (Research Quality Assurance) and Auditor certificates, especially lead auditors have a certificate of ‘Registered Quality Assurance Professional’ by SQA(Society of Quality Assurance).

C&R QA will continue to devote itself to be the best partner for customers in the field of quality assurance of clinical trials by ensuring that the clinical trial is performed and the data are generated, documented (recorded), and reported in compliance with Good Clinical Practice (GCP) and the applicable regulatory requirement(s).

[Q-fitter]

Q-fitter Inc. is dedicated to help customer through the drug development process. Main job is to perform a high quality pharmacometric analysis-the use of modeling and simulation that quantifies drug, disease and trial information to support efficient drug development and regulatory decisions- and provide clinical services to support the management of early phase clinical trials.

[C&R Healthcare Global]

C&R Healthcare Global provides business platform that supports bio-healthcare industries in advancing to global market. Based on accumulated clinical development experience and global network of leading CRO ‘C&R Research’. C&R Healthcare Global will fulfill the platform through incubation, matching the investment manufacture, and distribution to maximize corporate value.

RepresentativeJoong Myung Cho, Ph.D.

Headquarter Address5th F. Bldg.A, Korea Bio Park, 700 Daewangpangyoro, Bundanggu, Seongnamsi, Gyeonggido, 13488 Korea


Research FocusDiscovery, R&D and commercialization of novel therapeutics



Webwww.cgxinc.com

Contact PersonSteven Kim



CrystalGenomics, Inc. is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in California, and it is publicly traded on the KOSDAQ exchange.

CrystalGenomics currently has one product on the market and is developing two additional novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation COX-2 inhibitor for the treatment of signs and symptoms of osteoarthritis. The first clinical stage program is CG400549, a novel targeted antibiotic for MRSA where its phase 2a skin infection study in the US has been completed with a positive outcome of 100% clinical cure rate. The second program is CG200745, an epigenetic anti-cancer therapeutic for various types of solid and liquid tumors and currently, two clinical studies are ongoing for pancreatic cancer and MDS.

The Company's therapeutic candidates are discovered and developed through its proprietary discovery platform technology which employs integrated technologies of the SPS™ (technology for structure determination), the SCP™ (technology for the generation of lead compounds) and the SDF™(technology used for lead optimization) technologies.

By leveraging its capabilities and the know-how in novel drug discovery and development, CrystalGenomics will continue to strive in making significant contributions to improve human health.

Company Profile

CrystalGenomics, Inc.


Fiscal Year 2015 2016 2017

Sales 6,136 14,525 14,685

R&D Expenditure 6,102 7,066 7,000

Capital 73,639 83,265 97,258

Financial Figures


Main Products


1. Acelex® (polmacoxib) Osteoarthritis

Currently none;Turkey, Lebanon, Saudi Arabia, Kuwait, UAE: 2018~2019 (projected)

Dong-A ST: commercial partner for Korea.

TR-Pharm: commercial partner for Turkey &

MENA region


HDAC inhibitor (NCE) CG200745 Pancreatic cancer Phase 2 in progress

HDAC inhibitor (NCE) CG200745myelodysplastic syndrome

(MDS)Phase 1b in progress

HDAC inhibitor (NCE) CG200745 Acute myeloid leukemia (AML) IND preparation

FabI inhibitor (NCE)Polmacoxib & Tramadol (FDC with NCE)

CG400549MRSA & other serious staph

infections

Phase 2a completed;IND preparation with newly

formulated drug product

BTK/Flt3 inhibitor (NCE) CG100650 Various acute & chronic pain IND submitted

BTK/Flt3 inhibitor (NCE)CG026806 (CG'806)

AML, MCL, CLLPreclinical (Out-licensed to

Aptose Bioscienses in 2016)



Acelex® (polmacoxib) Osteoarthritis Feb. 2015 / Korea

RepresentativeHunsik, Wang

Headquarter Address#714 Jungang Induspia V, 137, Sagimakgol-ro, Jungwon-gu, Seongnam, Gyeonggi-do, Korea

Foundation DateAug, 2002

Research FocusIMD(Incrementally Modified Drugs)



Webhttp://www.glpt.co.kr

Contact PersonJun Sang Park

Contact Phone82-31-739-5220 (#324)


GL PharmTech (GLPT) has focused on developing improved versions of the currently marketed pharmaceutical products with reduced side effects, greater therapeutic efficacy and better patient compliance using our proprietary drug formulation and delivery technologies since 2002.

We have provided more than 50 pharmaceutical companies in Korea with value-added drug formulations and delivery technologies for generic and improved version of marketed drug.

We are now transitioning from a being a technology transfer-based operation to being a specialty pharmaceutical company capable of developing and delivering new product lines by ourselves from 2010. We are doing this based on intensive investment in various clinical studies of products currently in our pipelines and using our already-established drug delivery platform technologies.

Technology - GLARS(Geometrically Long Absorption Regulated System)

Conventional sustained release drug delivery systems such as ALZA’s OROS (Osmotic Release Oral System) and Skyepharma’s Geomatrix, have enjoyed great success in the field of a drug dosage form reformulation. Although these systems extend the drug release up to 24 or 48 hours, the simple extension of drug release time would be meaningless because a practical absorption site of overall drugs is generally limited to a small intestine consider the total transit time along the small intestine with absorption will be only 4 to 6 hrs. This means that relatively large amounts of the incorporated drug would pass out without a sufficient practical absorption.

Company Profile

GL PharmTech


Fiscal Year 2014 2015 2016

Sales 7,301 6,475 4,636

R&D Expenditure 1,158 1,034 1,130

Capital 1,162 2,323 3,022

Financial Figures


Main Products


1. G-soren Tab. (Artemisiae Argyi Folium Isopropanol ext.(20 -> 1))

Gastritis - -

2. GL1203(Tamsulosin) Benign Prostatic Hyperplasia - -

3. GL1204(Felodipine ER) Hypertension - -

4. GL1314(Ramipril) Hypertension - -

5. GL1317(Pantoprazole) Gastric ulcer - -

6. GL1319(Nifedipine SR) Hypertension - -

7. GL1320(Doxazosin XL) Benign Prostatic Hyperplasia - -

To overcome the shortcomings of the currently existing sustained release drug delivery technologies we have recently developed a novel drug delivery system to enable a drug to be dissolved irrespective of the surrounding environment and further absorbed up to colon. We coined this “Geometrically Long Absorption Regulated System (GLARS)”.

Basically, this system is a triple-layered tablet, comprised of upper and lower layers that swell and draw a sufficient amount of water, plus a highly water-soluble middle layer that rapidly draw water into the tablet core simultaneously.

As the middle layer induces a rapid water draw into the tablet core, the penetrated water also diffuses to the upper and lower layers, which makes the tablet to rapidly swell and controls drug release. At virtually the same time, the swollen upper and lower layers form to surround a lateral side of the middle layer, which can, in turn, further control drug release. This relatively rigid swollen matrix structure makes drug release not affected by surrounding mechanical flux, which can provide relatively consistent in vivo drug release irrespective of degree of gastrointestinal motility.

The water drawn into the tablet (about 3 to 5 times the weight of the tablet itself) functions as an additional media which enables additional and later drug release out of the dosage form. This serves to overcome the shortage of surrounding media that has been reported to be one of the key reasons for mal-absorption of a drug in colon.


IMD

Pregabalin QD GLA5PR Pain Phase III

Risedronate + Vitamin D3

Effervescent tabletGLE1RCW Osteoporosis Phase I

Paroxetine CR GLE3PA Vasomotor Symptoms Phase III

Generic

Ropinirole XL GL1901 Parkinson's disease Bioequivalence test

Mirabegron PR GLG1MI Overactive bladder Bioequivalence test


8. GL1405(Paroxetine CR) Depression - -

9. GL1502(Limaprost) Buerger's disease - -

10. GL1505(Tolterodine LA) Benign Prostatic Hyperplasia - -

11. GL1507(Rabeprazole) Gastric ulcer - -

12. GL1606(Tramadol plus acetaminophen) Pain - -

13. GL1608(Atorvastatin) Hyperlipidemia - -

14. GL1712(Tacrolimus) Immunosuppressant - -

15. GL2803(Gimepiride plus Metformin XL) Diabetes - -


RepresentativeHyun-Soo Kim, Seong-Lae Kim

Headquarter Address7th Floor, Ssangbong B/L, Unju-ro 874, Gangnam-gu, Seoul Korea

Foundation Date1968. 8. 20 (Listing: 1988.5.20)

Research FocusStem Cell



Webhttp://www.pharmicell.com

Contact PersonSungpill Park



Since its establishment in 2002, Pharmicell has devoted to developing stem cell drugs to benefit more people with desperate needs and successfully developed the world’s first stem cell drug on July 1st, 2011, marking a new era in the world history of cell treatment. The path for innovation and challenge pioneered by Pharmicell to become the world first, has set Korean Standards in the area of stem cell drugs and has changed the spectrum of the overseas stem cell industry beyond the boundary of Korea. In addition, Pharmicell has emerged as the global leader of biopharmaceutical raw materials development and is recognized for its technology with our exporting performance of raw medicine to prominent global pharmaceutical companies. Moreover, Pharmicell strives further to develop the next generation of new drugs based on the management value of fusion and challenge. Pharmicell will take the lead for Korea to become the outstanding leader of biopharmaceutical industries of the world through continuous R&D and ultimately create value for a healthy and happy human life.

Company Profile

Pharmicell Co., Ltd.


Fiscal Year 2015 2016 2017

Sales 25,176 27,839 25,197

R&D Expenditure 2,597 4,941 4,029

Capital 28,617 29,191 29,204

Financial Figures

RepresentativeMr. Ok-nam PARK/ CEO

Headquarter Address8-1207 Woorim Lion's Valley, Digital 3rd Complex, 371-28 Gasan-dong, Geumcheon-gu, Seoul 153-786

Foundation Date1998




WebWWW.MEDIHELPLINE.NET

Since its foundation in Feb.1998, Medi Help Line has conducted average annual number of 150 RA projects for new drugs, innovative drugs, medical devices and quasi-drugs for 13 years and has a well-established business partnership with many domestic and international companies based on the performance of the strategic consulting services as well as RA outsourcing services, accumulated database of the various projects and communication know-how with the KFDA.

We provide a real Total Package Service from the consulting service for research and development strategy to the outsourcing services including KFDA IND/NDA, HIRA listing and KGMP.

Company Profile

Medi Help line


Fiscal Year 2008 2009 2010

Sales 1,558 1,338 1,590


Capital 50 - -

Financial Figures


2 0 1 8 D I R E C T O RY O F K O R E A N P H A R M A C E U T I C A L I N D U S T RY

KPBMA Member Company List

Main Products


1. Cellgram-AMI Acute myocardial infarction - World first stem cell drug


Cellgram-LC - Liver CirrhosisExpected to be launched

in May 2018

Cellgram-ED - Impotence Phase 1

Cellgram-IS - Acute cerebral infarction Phase 3

Cellgram-SCI - Spinal cord injury Phase 2/3

Cellgram-CLI - Critical lower limb ischemia Phase 1


No Company Phone Fax Address Homepage

26 Corestem Inc. 82-2-497-3711 82-2-6349-8666 24, Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea www.corestem.com

27 Crown Pharm. Co., Ltd. 82-31-443-3922 82-31-443-3921 218-7 Anyang7-dong Manan-gu, Anyang si, Gyeonggi-Do

www. crownpharm.co.kr

28 Crystal Life Sciences. 82-31-628-2900 82-31-628-2901Koreabiopark A, 5F, 700, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do

www.crystallifescience.com

29 CTCBIO, Inc 82-2-70-4033-0200 82-2-449-6966 CTC Building, 13 Jungdaero 40 gil, Songpa-gu, Seoul www.ctcbio.com

30 C-Tri 82-31-557-0001 82-31-557-6622 778-1 Ilpae-dong, Namyangju-si, Gyeonggi-do www.c-tri.co.kr

31 Dae Woo Pharm. Ind. Co., Ltd. 82-51-204-3831 82-51-202-3397 153 Dadaero, Saha-gu, Busan www. daewoopharm.com

32 Daebong LS 82-32-712-8800 82-32-817-8808 122B-9L, 692-8, Gojan-dong, Namdong-gu, Incheon

www. daebongls.co.kr

33 Daehwa Pharm. Co., Ltd. 82-33-342-5140 82-33-342-0576 308 Masan-ri, Heongseong-gun, Gangwon-do www.dhpharm.co.kr

34 Daewon Pharm. Co., Ltd. 82-2-2204-7000 82-2-498-9108 229-3 Yongdap-dong, Seongdong-gu, Seoul www. daewonpharm.com

35 Daewoong Pharm. Co., Ltd. 82-2-550-8800 82-2-550-3530 163-3 Samsung-dong, Gangnam-gu, Seoul www. daewoong.co.kr

36 Dai Han Pharm. Co., Ltd. 82-2-2678-8445 82-2-2671-9636 8-3 Yangpyeong-dong 4-ga, Yeongdeungpo-gu, Seoul www.daihan.com

37 Daiichi Sankyo Korea Co.,Ltd. 82-2-3453-3300 82-2-3452-9756 Posco West 3F, Daechi4-dong, Kangnam-gu, Seoul

www. daiichisankyo.co.kr

38 Dalim Biotech Co., Ltd. 82-31-535-6091 82-31-535-6093 907-5 Sangsan-ri, Hyangnam-eup, Hwaseong-si, Geonggi-do

www. dalimmedical.co.kr

39 DHP Korea Co., Ltd. 82-43-239-3303 82-43-239-3308 491 Mansu-ri, Gangwoe-myeon, Cheonggwon-gun, Chungcheongbuk-do www.dhpkorea.co.kr

40 Dong In Dang Pharm. Co., Ltd. 82-31-319-1990 82-31-319-1995 Shiwah Complex 1 Ra No.603,1248-8 Jungwang-dong, Siheung-si, Gyeonggi-do

www. dongin-dang.co.kr

41 Dong Koo Pharm. Co., Ltd. 82-2-2688-5421 82-2-2681-1880 195-2 Gocheok 2-dong, Guro-gu, Seoul www.dongkoo.co.kr

42 Dong Kook Pharm. Co., Ltd. 82-2-2191-9900 82-2-566-8542 997-8 Daechi 3-dong, Gangnam-gu, Seoul www.dkpharm.co.kr

43 Dong Kwang Pharm. Co., Ltd. 82-2-776-7641 82-2-777-4874 Daeyeongak tower 12F, 25-5 Chungmuro 1-ga, Jung-gu, Seoul

www. dkpco.co.kr

44 Dong Wha Pharm. Ind. Co., Ltd. 82-2-2021-9300 82-2-778-2336 5 Sunwha-dong, Jung-gu, Seoul www. dong-wha.co.kr

45 Dong-A Pharmaceutical 82-2-920-8112 - 64 Cheonhodaero, Dongdaemun-gu, Seoul en.dapharm.com

46 Dong-A ST 82-2-920-8111 - 64 Cheonhodaero, Dongdaemun-gu, Seoul en.donga-st.com/

47 Dongsung Pharm. Co., Ltd. 82-2-6911-3600 82-50-5191-69081 703-14 Banghak-dong, Dobong-gu, Seoul www.dongsung-pharm.co.kr

48 Eisai Korea Inc. 82-2-3451-5500 82-2-3451-5599 Revessant B/D 10F, 147-17Samseong-dong, Gangnam-gu, Seoul www.eisaikorea.com

49 Elyson Pharmaceutical Co. Ltd. 82-2-6342-7001 82-2-6342-7003 2F Kyungpung Building, 788-26 Yeoksam-dong, Gangnam-gu, Seoul www.elyson.co.kr

50 Estech Pharma Co., Ltd. 82-2-3471-2078 82-2-3471-2079 Daekwan B/D 5F, 15-1 Yangjae-dong, Seocho-gu, Seoul

www. estechpharma.com

51 Ferring Pharm. Korea Co.,Ltd. 82-2-534-2761 82-2-534-2956 Songwon B/D 7F, 59-5 Banpo-dong, Seocho-gu, Seoul www.ferring.co.kr


1 Aestura Corporation - - 100 Cheonggyecheon-ro, Jung-gu, Seoul www.aestura.com/

2 Ahn-Gook Pharm. Co., Ltd. 82-2-3289-4200 82-2-847-8867 993-75 Daelim-dong, Yeongdeungpo-gu, Seoul www.ahn-gook.com

3 Aju Pharm Co., Ltd. 82-2-2630-0700 82-2-2636-7519 413-13 Shindolim-dong, Guro-gu, Seoul www. asiapharm.co.kr

4 Alpha Pharm. Co., Ltd. 82-54-552-5381 82-2-54-552-5385 662 Jinjeong-ri, Sanyang-myeon, Mungyeong-si, Gyeongsangbuk-do

www. alphapharm.co.kr

5 Alvogen Korea. Co., Ltd. 82-2-2047-7700 82-2-443-0589 13F. TWO IFC Bldg. 10 Gukjegeumyung-ro, Yeongdeungpo-gu, Seoul, Korea

www. alvogenkorea.com

6 Antrogen. Co., Ltd. 82-2-2104-0391 82-2-2104-0393(Namsung Plaza, Gasan-dong) 405, 130, Digital-ro, Geumcheon-gu, Seoul, 08589, Korea

www.antrogen.com

7 Aprogen Pharmaceuticals 82-31-625-4045 - 545, Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do

www. aprogen-pharm.com

8 Arlico.co.Ltd. 82-2-520-6943 82-2-3474-3281 Alico Building, 70-5 Yangjae-dong, Seocho-gu, Seoul www.arlico.co.kr

9 ASTELLAS Pharm Korea, Inc 82-2-3448-0504 82-2-3448-0510 GumHa B/D 6F 41-2 Chungdam-dong, Gangnam-gu, Seoul

www. astellas.com/kr

10 B. Braun Korea. Co., Ltd 82-2-3459-7800 82-2-3453-3060 Posco center 13F, 892 Daechi-dong, Gangnam-gu, Seoul www.bbraun.co.kr

11 Baxter Inc. 82-2-6262-7100 82-2-6272-7101 KNTO B/D 5F,10 Da-dong, Jung-gu, Seoul www.baxter.co.kr

12 Bc world pharm. Co.,Ltd. 82-2-2182-0403 82-2-574-5064 Kyung B/D .Gaepo-dong 1184-8 , Gangnam-gu, Seoul www.bcwp.co.kr

13 Binex Co., Ltd. 82-6710-7235 82-2-6710-7299 Ilshin B/D, Dohwa-dong 541, Mapo-gu, Seoul www.bi-nex.com

14 Bolak. Co., Ltd. 82-31-352-6455 82-31-352-4341 307-1 Songsan-ri, Yanggam-myeion, Hwaseong-si, Gyeonggi-do www.bolak.co.kr

15 Boryung Pharm. Co., Ltd. 82-2-708-8000 82-2-708-8439 Boryung B/D, 66-21 Wonnam-dong, Jongno-gu, Seoul www.boryung.co.kr

16 Bukwang Pharm. Co., Ltd. 82-2-828-8114 82-2-828-8029 398-1 Daebang-dong, Dongjak-gu, Seoul www.bukwang.co.kr

17 Celltrion Pharm. Inc 82-32-850-5000 82-32-850-4309 13-6, Songdo-dong, Yeonsu-gu, Incheon www.celltrionph.com

18 Chemtros Co., Ltd 82-31-491-0653 82-31-491-0881 7 Neungan-ro, Danwon-gu, Ansan-si, Gyeonggi-do www.chemtros.com

19 Cho-a Pharm. Co., Ltd. 82-2-2166-4000 82-2-2166-4111 Ace Techno Town 1F, 55-7 Moonrae-dong 3 ga,Youngduengpo-gu, Seoul www.choa.co.kr

20 Chodang Pharm. Co., Ltd. 82-2-869-0181 82-2-869-1192 44 Guro 5-dong, Guro-gu, Seoul www.chodang.com

21 Chong Kun Dang Pharm. Corp. 82-2-2194-0300 82-2-2194-0369 Chong Kun Dang B/D 368, Chungjeongno 3-ga, Seodaemun-gu, Seoul www.ckdpharm.com

22 Chunhedang Pharm. Co., Ltd. 82-31-675-5561 82-31-676-6320 246-47 Dodang-dong, Wonmi-gu, Pucheon-si, Gyeonggi-Do -

23 CJ Healthcare 82-2-6740-2119 - CJ Cheiljedang Center, 330, Dongho-ro, Jung-gu, Seoul 100-400, Korea www.cjp.co.kr/

24 CMG Pharmaceutical CO.,Ltd. 82-2-3453-8816 82-2-3453-8819 7F MJL Building, 204-5 Nonhyun-dong, Gangnam-gu, Seoul

www. cmgpharma.co.kr

25 Cmic CMO Korea Co.,Ltd. 82-32-678-5771 82-32-675-3385 157-3 Dodang-dong, Wonmi-gu, Pucheon-si, Gyeonggi-Do www.cmic-cmo.co.kr

Regular Members(2018. 4)



77 Huniz. Co., Ltd. 82-51-831-1030 82-51-831-1040 1529-4, Songjeong-dong, Gangseo-gu, Busan www.huniz.kr

78 Huons Co., Ltd 82-31-854-4700 82-31-6455-0740C-901 PangyoInoBelly, 621 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do

www.huons.com

79 Hutecs Korea Co., Ltd 82-31-377-7900 82-31-377-7911 555-2 Yeongchun-ri, Dongtan-myeon, Hwaseong-si, Gyeonggi-do www.hutecs.co.kr

80 Hyundai Pharm. Ind. Co., Ltd. 82-2-2600-3813 82-2-2693-7628 Hyungai pharm B/D, 204-4 Nonhyeon-dong, Gangnam-gu, Seoul

www. hyundaipharm.co.kr

81 Icure Pharm. Inc. 82-31-776-3776 82-31-776-3770Room 1305 Technopark Techcentre, 190-1 Sangdaewon-dong, Jungwon-gu, Seongnam-si

www.icure.co.kr

82 Ik-Su Pharm. Co., Ltd. 82-2-416-1112 82-2-416-1118 Iksoo B/D, Amsa-dong 488-20, Kangdong-gu, Seoul www.iksu.co.kr

83 Il Dong Pharm. Co., Ltd. 82-2-526-3114 82-2-526-3030 60 Yangjae-dong, Seocho-gu, Seoul www.ildong.com

84 Ilsung Pharm Co., Ltd. 82-2-3271-8800 82-2-2701-6335 44-7 Wonhyoro1-ga, Yongsan-gu, Seoul www.ilsung-ph.co.kr

85 Ilwha Co., Ltd. 82-31-550-0100 82-31-550-0105 437 Sutaek1-dong, Guri-si, Gyeonggi-Do www.ilhwa.co.kr

86 Il-Yang Pharm. Co., Ltd. 82-2-570-3700 82-2-570-3708 544-5, Dogok-dong, Gangnam-gu, Seoul www.ilyang.co.kr

87 Inist Bio Pharmaceutical. Co., Ltd. 82-31-370-7300 82-31-354-1539 34-40, Jaeyakgongdan 2-gil, Hyangnam-

eup, Hwaseong-si, Gyeonggi-dowww.inist.co.kr/inistbio

88 Inist ST Co., Ltd. 82-31-669-9520 82-31-737-4198701, 2nd Geumgang High-Tech 159, Sagimakgolro, Joongwon-gu, Seongnam-si, Gyeonggi-do

www. inist.co.kr/inistst

89 Isu Abxis Co., Ltd. 82-2-2227-8888 82-2-2227-8887 Yeonse medical school 6F, Sinchon-dong 134, Seodaemoon-gu, Seoul www.abxis.com

90 Janssen Korea Ltd. 82-2- 2094-4500 82-2- 538-5632 25F LG Yongsan Tower B/D, 191 Hangang-ro 2ga , Yongsan-gu, Seoul

www. janssenkorea.com

91 Je Il Pharm. Co., Ltd. 82-53-583-6226 82-53-583-5775 Daechun-dong 739, Dalseo-gu, Daegu city www.jeilphar.co.kr

92 Jeil Pharm. Co., Ltd. 82-2-549-7451 82-2-549-4045 343, Sapyeong-daero, Seocho-gu, Seoul www.jeilpharm.co.kr

93 Jin Yang Pharm. Co., Ltd. 82-2-3470-0300 82-2-3470-0390 1532-9 Seocho-dong, Seocho-gu, Seoul www. jinyangpharm.com

94 JW Pharmaceutical 82-2-840-6777 82-2-841-1213 698 Shindaebang-dong, Dongjak-gu, Seoul www. jw-pharma.co.kr

95 JW Shinyak 82-2-2109-3300 82-2-2109-3388 3F 13cha Daeryung Techno Tower, Gasan-dong, Geumcheon-gu, Seoul

www. jw-shinyak.co.kr

96 KMS Pharm Co., Ltd. 82-31-215-5456 82-31-215-5925 492-12, Maetan 3-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do www.kmspharm.com

97 Kolmar Korea 82-41-862-1057 82-41-862-7637 170-7 Seojeong-ri, Jeonui-myeon, Yeongi-gun, Chungcheongnam-do www.kolmar.co.kr

98 Kolmar pharma 82-43-640-0088 82-43-640-0007 93 Biovalley 2-ro, Jecheon-si, Chungcheongbuk-do www.kolmar.co.kr

99 Kolon Life Science Inc. 82-2-3677-4150 - Floor 7, Kolon Tower annex, Kolon 13, Gwachun-si, Gyunggi-do www.kolonls.co.kr

100 Kolon Pharma 82-2-2120-8300 82-2-2120-8301 6F Annex to Kolon Tower, 1-22 Byeoryang-dong, Gwacheon-si, Gyeonggi-do

www. kolonpharm.co.kr

101 Korea Atomic Energy Research Institute 82-42-868-4641 82-42-868-2106

Advanced Reactor Development Institute, Daedeok-daero 989-11, Yuseong-gu, Daejeon

www.kaeri.re.kr


52 Firson Co., Ltd. 82-2-1833-8200 82-41-566-8321 47, Baekseokgongdan 1-ro, Seobuk-gu, Cheonan-si, Chungcheongnam-do, Korea www.firson.co.kr

53 Fresenius Kabi Korea Ltd. 82-2-3484-0900 82-2-3484-0957 SaemaeulUndong B/D 3F, 1008-4 Daechi-dong, Gangnam-gu, Seoul

www. fresenius-kabi.com

54 Fresenius medical care korea co.,Ltd 82-2-2112-8800 82-2-2112-8804 Landmarktower 7F, 837-36 yeoksam-dong,

Gangnam-gu, Seoulwww. fmc-korea.co.kr

55 Galderma Korea Ltd. 82-2-6717-2000 82-2-6717-2001 Bando B/D 7F, 48-1 Banpo-dong, Seocho-gu, Seoul

www.galdermakorea.com

56 GlaxoSmithKline Korea 82-2-709-4116 82-2-796-4710 LS Youngsan tower 9F, 92, Hangang-daero, Yongsan-gu, Seoul www.gsk-korea.co.kr

57 GlaxoSmithKline Korea Consumer Healthcare 82-2-709-4305 82-2-798-0985 LS Youngsan tower 9F, 92, Hangang-daero,

Yongsan-gu, Seoul www.gsk-korea.co.kr

58 Green Pharm. Co., Ltd. 82-2-842-1301 82-2-842-1302 2F, 4159 Shingil 6-dong, Yeoungdeungpo-gu, Seoul -

59 Greencross Corporation 82-31-260-9300 82-31-260-9413 303 Bojeong-dogn, Giheung-gu, Yongin-si, Gyeonggi-do

www. greencross.com

60 Greencross Cell 82-2-2101-0600 82-2-2101-0601 4&6th floor, 278, Beotkkot-ro, Geumcheon-gu, Seoul, 08511, Korea

www. greencrosscell.com

61 Greencross WellBeing 82-31-629-8600 82-31-629-86017th Floor, Dodam bldg B-dong, 246 Hwangsaeul-ro, Bundang-gu, Seongnam, Gyeonggi-do

www. greencrosswb.com

62 Guju Pharm. Co., Ltd. 82-2-2672-1122 82-2-2679-7569 94-119 Yeoungdeungpo-dong 2-ga, Yeongdeungpo-gu, Seoul www.gujup.co.kr

63 Hamsoa Pharm. Co., Ltd. 82-2-2176-2180 82-2-3443-0825 8F Joil Building 62 Nonhyeon-dong, Gangnam-gu, Seoul

www. hamsoapharm.com

64 Han Kook Korus Pharm. Co., Ltd. 82-33-264-5771 82-33-264-5774 1181 Geodu-ri, Dongnae-myeon, Chuncheon-si, Gangwon-do

www. koruspharm.co.kr

65 Hana Pharm. Co., Ltd. 82-2-577-7667 82-2-577-6003 Rocket B/D 6~7F, 747-29 Yeogsam-dong, Gangnam-gu, Seoul www.hanaph.co.kr

66 Hanall Bio Pharm. Co., Ltd. 82-2-2204-1928 82-2-2414-7474 Jamsil I-Space 6F, 11-10 Shinchon-dong, Songpa-gu, Seoul www.hanall.co.kr

67 Handok Pharm. Co., Ltd. 82-2-527-0114 82-2-527-5001 132 Teheran-ro, Gangnam-gu, Seoul www.handok.co.kr

68 Hankooksinyak Pharm. Co., Ltd. 82-41-740-8900 82-41-740-8849 805-15 Jungsan-ri, Yangchon-myeon, Nonsan-si, Chungcheongnam-do www.hsp.co.kr

69 Hanlim Pharm. Co., Ltd. 82-2-3489-6000 82-2-3489-6101 1656-10 Seocho-dong, Seocho-gu, Seoul www.hanlim.com

70 Hanmi Pharm. Co., Ltd. 82-2-410-9114 82-2-410-9259 Hanmi Tower, 45 Bangi-dong, Songpa-gu, Seoul www.hanmi.co.kr

71 Hanpoong Pharm. Co., Ltd. 82-2-586-5211 82-2-583-8584 981-52 Banbae-dong, Seocho-gu, Seoul www.hanpoong.co.kr

72 HanseoChem 82-31-682-8655 82-31-682-8656 41 Poseunggongdan-ro, Poseung-eup, Pyeongtaek-si, Kyeonggi-do

www. hanseochem.co.kr

73 Hansol Pharm. Co., Ltd. 82-43-881-6333 82-43-881-6332Chungpyeong-gil 2-11 (Docheong-lee 33-32), Geumwang-eup, Eumsung-gun, Choongcheongbook-Do

www. hansolpharm.com

74 Hanwha Pharma. Co., Ltd. 82-2-959-3161 82-2-959-3621 261 Seokkwan 2-dong, Seongbuk-gu, Seoul www.hwpharm.com

75 Hawon Pharm. Co. 82-2-554-2012 82-2-554-4557 788-1 Yeogsam-dong, Gangnam-gu, Seoul www. hawonpharm.co.kr

76 Humedix. Co., Ltd. 82-70-7492-5600 82-31-420-5650 Room 502 Anyang-megavalley, 268 Hagui-ro, Dongan-gu, Anyang-si, Gyeonggi-do humedix.com



127 Myung In Pharm. Co., Ltd. 82-2-587-9060 82-2-585-0352 Myungin B/D, 1539-9 Seocho-dong, Seocho-gu, Seoul

www. myunginph.co.kr

128 Myung Moon Pharm. Co., Ltd. 82-2-6711-2000 82-2-572-5137 Myungmoon B/D, 946-18 Dogok-dong, Gangnam-gu, Seoul www.mmpharm.co.kr

129 Nelson Korea Pharm Co.,Ltd. 82-2-588-0941 82-2-588-0170 Nelson B/D 3F, Seocho-dong 1462-17, Seocho-gu, Seoul

www. nelsonkorea.co.kr

130 Nensys Co., Ltd. 82-31-232-5285 82-31-234-4410 836 Seryu3-dong, Gwonsun-gu, Suwon-si, Gyeonggi-Do www.nensys.co.kr

131 Newgenpharm Inc. 82-2-580-5900 82-2-580-5999 BK Tower 11F, 942-2 Daechi 2, Gangnam-gu, Seoul

www. newgenpharm.com

132 Ono Pharma Korea Co., LTD. 82-2-928-8423 82-2-925-2151 13F, The-K twin towers B, 50 Jong-ro 1-gil, Jongno-gu, Seoul www.ono.co.jp/eng/

133 PharmaResearch Products Co., Ltd. 82-31-8039-1500 - 74, Pangyo-ro 255beon-gil, Bundang-gu,

Seongnam-si, Gyeonggi-dowww. pr-products.co.kr

134 Pharmbio Korea Co., Ltd 82-2-587-2551 82-2-587-2552 7F Samhomulsan Building A, 275-1 Yangjae-dong, Seocho-gu, Seoul www.pharmbio.co.kr

135 Pharvis Bio Tech Korea Corp. 82-2-579-6262 82-2-579-0880 517-9 Doggok-dong, Gangnam-gu, Seoul www.pharvis.co.kr

136 PMG PHARM Co., Ltd 82-31-439-5470 82-31-405-5471 726-4 Bugok-dong, Sanrok-gu, Ansan-si, Gyeonggi-do

www. pmgpharm.co.kr

137 Reyon Pharm. Co., Ltd. 82-2-793-5557 82-2-798-7538 38-6 Dongbinggo-dong, Yongsan-gu, Seoul www. reyonpharm.co.kr

138 Richwood Trading Co., Ltd. 82-2-757-3071 82-2-3789-6993 Danam B/D 22F, 120 Namdaemoonno 5-ga, Jung-gu, Seoul www.richwood.net

139 RP BIO. Co., Ltd 82-2-568-0051 82-2-554-0871 163-3 Samsung-dong, Gangnam-gu, Seoul www.rpskorea.com

140 Sae Han Pharm. Co., Ltd. 82-2-533-7417 82-2-553-7416 Samoh B/D 4F, Yeoksam1-dong 751-10, Kangnam-gu, Seoul www.shpharm.co.kr

141 Sam Chun Dang Pharm. Co., Ltd. 82-2-2046-1100 82-2-2046-1101 Seocho-dong 1606-1, Seocho-gu, Seoul www.scd.co.kr

142 SamA Pharm. Co., Ltd. 82-2-2056-7200 82-2-2056-7300 Sama B/D, 80-18 Cheongdam-dong, Gangnam-gu, Seoul

www. samapharm.co.kr

143 Samik Pharm. Co., Ltd. 82-2-928-0661 82-2-924-3749 Dongbo B/D 4F, 1253 Sungin-dong, Jongno-gu, Seoul www.samik.co.kr

144 Samil Pharm. Co., Ltd. 82-2-520-0300 82-2-588-5924 990-1 Bangbae1-dong, Seocho-gu, Seoul www. samil-pharm.com

145 Samjin Pharm. Co., Ltd. 82-2-3140-0605 82-2-338-8032 338-8 Seokyo-dong, Mapo-gu, Seoul www. samjinpharm.co.kr

146 Samnam Pharm. Co., Ltd. 82-41-754-3771 82-41-752-0086 99-1 Sang-ri, Geumsan-eup, Geumsan-gun, Chuncheongnam-do

www. samnam51.com

147 Samsung Pharm. Ind. Co., Ltd. 82-2-3408-4500 82-2-3408-4702 614-4 Junggok-dong, Gwangjin-gu, Seoul www.sspharm.co.kr

148 Samyang Biopharm. Corp. 82-2-740-7116 82-2-743-6626 263 Yeonji-dong, Jongno-gu, Seoulwww.samyangbiopharm.co.kr

149 Samyang Chemical Co., Ltd. 82-2-3488-5592 82-2-521-3100 1500-10 Seocho 3-dong, Seocho-gu, Seoul www. samyangchem.com

150 SANDOZ Korea Co., Ltd 82-2-768-9300 82-2-753-1287 Yonsei severance B/D 18F, 84-11 Namdaemonn-ro 5ga, Junggu, Seoul www.sandoz.com

151 Santen Pharm. Korea Co., Ltd. 82-2-754-1434 82-2-754-2929 1678-4 Seocho-dong, Seocho-gu, Seoul -

152 Seoul Pharma co. Ltd. 82-31-497-1931 82-31-431-0715 Kyungje-ro 59, Siheung-si, Gyeonggi-do www.seoulpharma.com


102 Korea Global Pharm. Co., Ltd. 82-41-951-4300 82-41-951-4344 417-4, Seokchon-ri, Jongcheon-myeon, Seocheon-gun, Chungcheongnam-do

www. globalpharm.co.kr

103 Korea Kowa Company Ltd. 82-2-6930-4800 82-2-6930-4808 7F Gookmin-1 B/D, 302 Yeongdong-daero, Gangnam-gu, Seoul

www. kowakorea.com

104 Korea mcnulty. Co., Ltd. 82-31-378-1460 82-31-378-1468 713-2, Jung-ri, Dongtan-myeon, Hwaseong-si, Gyeonggi-do

www. koreamcnulty.co.kr

105 Korea Otsuka Pharm. Co., Ltd. 82-2-3287-9000 82-2-3287-9019 770-9 Yeoksam-dong, Gangnam-gu, Seoul www.otsuka.co.kr

106 Korea Pharma Co., Ltd. 82-2-558-1277 82-2-558-1677 Baeklim B/D 8F, 823-33 Yeogsam-dong, Gangnam-gu, Seoul

www. koreapharma.co.kr

107 Korea Prime Pharm. Co., Ltd. 82-62-233-1110 82-62-233-3298 Daein Building, 158-3 Daein-dong, Dong-gu, Gwangu

www. koreaprime.co.kr

108 Korea United Pharm. Inc. 82-2-512-9981 82-2-548-4599 154-8 Nonhyun-dong, Gangnam-gu, Seoul www.kup.co.kr

109 Korea Vaccine Co., Ltd. 82-2-443-1961 82-2-443-4484 Doowon B/D, 87-3 Garak-dong, Songpa-gu, Seoul

www. koreavaccine.com

110 Korean Drug Co., Ltd. 82-2-529-6100 82-2-529-6114 423-2 Dogok-dong, Gangnam-gu, Seoul www.nicepharma.com

111 Kuhnil Pharm. Co., Ltd. 82-2-714-0091 82-2-719-0493 Osong B/D 27-11Jeong-dong, Jung-gu, Seoul www.kuhnil.com

112 Kukbo Science Co., Ltd. 82-43-264-7765~8 82-43-267-7769 49 Sandan-ro, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do

www. kukboscience.co.kr

113 Kukje Pharm. Ind. Co., Ltd. 82-31-781-9081 82-31-781-6040 513-2 Yatap-dong, Bundang-gu, Seongnam-si, Gyeonggi-do

www. kukjepharm.co.kr

114 Kwang Dong Pharm. Co., Ltd. 82-2-6006-7777 82-2-6006-7024 1577-4 Seocho-dong, Seocho-gu, Seoul www.ekdp.com

115 Kyongbo Pharm. Co., Ltd. 82-41-545-0456 82-41-546-8427 345-6 Silok-dong, Asan-si, Chuncheongnam-do www.kbpharma.co.kr

116 Kyowa Hakko Kirin Korea Co. Ltd. 82-2-3471-4921 82-2-3471-4322 5F Poonglim Building, 823 Yeoksam-dong,

Gangnam-gu, Seoulwww.kyowa-kirin-korea.com

117 Kyung Dong Pharm. Co., Ltd. 82-2-576-6121 82-2-577-5195 1659-5 Inheon-dong, Gwanak-gu, Seoul www.kdpharma.co.kr

118 Kyung Nam Pharm. Co., Ltd. 82-2- 3490-5105 82-2- 3490-5129 889-13 Daechi-dong ,Gangnam-gu, Seoulwww.kyungnampharm.co.kr

119 LG Chem 82-2-3773-1114 82-2-6924-3051 LG Gwangwamoon Building, 92 Sinmun-ro 2ga, jongno-gu, Seoul www.lgchem.com

120 Medicakorea Co., Ltd. 82-70-4018-8000 82-2585-9689 3, 8F Medica Building, 1489-2 Seocho 3 dong, Seocho-gu, Seoul

www. medicakorea.com

121 Meditox 82-2-3471-8319 82-2-3476-8372626 Teheran-ro, Gangnam-gu, Seoul, Republic of Korea (Medytox Building, Daechi-dong)

www.medytox.com

122 MG Co., Ltd. 82-2-2057-1002 82-2-2057-1003 Yangjae B/D, Yangjae-dong 261, Seocho-gu, Seoul

www. medi-green.co.kr

123 Mirae Pharma. Korea 82-2-583-9077 82-2-583-7421 174 Saimdang-ro, Seocho-gu, Seoulwww.miraepharmkorea.co.kr

124 Mitsubishi Tanabe Pharma Korea Co., Ltd 82-2-579-0121 82-2-579-0125 R902 9F Yookyung Building, 239-1

Nonhyeon-dong, Gangnam-gu, Seoulwww.mt-pharma-korea.com

125 Mother's Pharmaceutical co., Ltd 82-2-2026-8890 82-2-2026-8094 1-702 Gasandigital 2-ro, Geumcheon-gu, Seoul

www. motherspharm.com

126 Mundipharma Korea 82-2-568-5689 82-2-568-5634 541 Namdaemoon-ro 5, Jung-gu, Seoul www. mundipharma.co.kr



1 Abnoba Korea Co.,Ltd 82-2-6340-5114 82-2-6340-5588 Room1704 Ace High-end Tower2, 222-14 Guro3-dong, Guro-gu, Seoul www.krabnoba.com

2 BioLeaders 82-42-934-7671 82-42-934-7670 13 Techno8-ro, Yuseong-gu, Daejeon, Korea

www. bioleaders.co.kr

3 Biosolution Co., Ltd. 82-2-3446-8884 82-2-3445-1380 R519 Seoul Technopark, 172 Gongneung 2-dong, Nowon-gu, Seoul

www. biosolutions.co.kr

4 BL&H Co., Ltd. 82-2-3282-4710 82-2-3281-9081 Daerung Techno Town 17th, 25 Gasan Digital 1-ro, Geumcheon-gu, Seoul www.blnh.co.kr

5 CellBion Co., Ltd. 82-2-743-3311 82-2-743-33996th Floor, Seoul National University Cancer Research Institute 101, Daehak-ro, Jongno-gu, Seoul

www.cellbion.co.kr

6 Central Medical Service 82-10-4070-2417 82-2-3394-5165 793 Cheonho-daero, Gwangjin-Gu, Seoul www.cmscorea.co.kr

7 CorePharmBio 82-2-927-8220 -5F, Garosu Bldg., 103, Bokjeong-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do, 13112

www. corepharmbio.com

8 C&R Research 82-2-6251-1500 82-2-6251-1504 3F Leeyangwon Building, 63-7 Kyungwoon-dong, Jongno-gu, Seoul www.cnrres.co.kr

9 Crystalgenomics 82-31-628-2700 82-31-628-27015F, Tower A, Korea Bio Park 700, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Cyeonggi-do

www.crystalgenomics.com

10 Daegu-Gyeongbuk Medical Innovation Foundation 82-53-790-5113 82-53-790-5119 2387 dalgubeol-daero, Suseong-gu, Daegu www.

medivalley.re.kr

11 DreamCIS Inc. 82-2010-4500 82-2-720-5385 R1010 Jeokseon-Hyundai Building, 80 Jeokseon-dong, Jongno-gu, Seoul www.dreamcis.com

12 Genexine Co.,Ltd. 82-31-628-3200 82-31-628-3229B-4F Korea Bio Park, 694-1, Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do

www.genexine.com

13 Glpharmtech.corp. 82-31-739-5220~3 82-31-739-5224R714 Chungang Induspia 5th, Sangdaewon-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do

www.glpt.co.kr

14 Korea Institute of Toxicology 82-42-610-8250 82-42-610-8085 141 Gajeong-ro, Yuseong-gu, Daejeon 305-343 www.kitox.re.kr

15 Medi help line 82-2-2026-0707 82-2-2026-0708 R1207 Woorim Lions Building B, 371-28 Gasan-dong, Geumcheon-gu, Seoul

www. medihelpline.co.kr

16 PHARMICELL Co.,Ltd 82-2-3496-0114 82-2- 3496-0159 12F Chungho Building, 120 Dosandae-ro, Gangnam-gu, Seoul

www. pharmicell.com

17 Samsung Bioepis Co., Ltd 82-32-455-3114 82-32-455-6119 107, Cheomdan-daero, Yeonsu-gu, Incheon www.samsungbioepis.com

18 SK Bioland 82-41-564-8615 82-564-8619394 Songjeong-ri, Byungcheon-myeon, Dongnam-gu, Cheonan-si, Chungcheongnam-do

www. biolandkorea.com


178 Yuyu Pharma, Inc. 82-2-2253-6600 82-2-2253-6200 Yu Yu B/D, 358-9 Shindang-dong, Jung-gu, Seoul www.yuyu.co.kr

Associated Members(2018. 4)


153 Shin Poong Pharm. Co., Ltd. 82-2-2189-3426 82-2-2189-3439 748-31 Yeoksam-dong, Gangnam-gu, Seoul www. shinpoong.co.kr

154 Sinil Pharm. Co., Ltd. 82-2-2211-6700 82-2-2212-6539 Sinil B/D, 315-18 Jangan 2-dong ,Dongdaemun-gu, Seoul www.sinilpharm.com

155 Sinsin Pharm. Co., Ltd. 82-31-491-6151 82-31-491-6153 776-6 Wonsi-dong, Danwon-gu, Gyeonggi-do www.sinsin.com

156 SK Chemicals Life Science 82-2-2008-2008 82-2-2008-2009 686 Sampyung-dong, Bundang-gu, Seongnam-si, Gyeonggi-do

www. skchemicals.com

157 SS Pharm Co.,Ltd 82-31-491-6311 82-31-491-4797 533-2 Bongkok-ri, Banpo-myun, Gongju-si, Chungchungnam-do

www. susungpharm.co.kr

158 Suheung Capsule. Co., Ltd. 82-2-2210-8116 82-2-2217-2357 435-5 Jangan 3-dong, Dongdaemun-gu, Seoul www.suheung.co.kr

159 Sungwon Adcock Pharm. Co., Ltd. 82-2-3665-2872 82-2-3665-2874 Room 302 Gayang-technotown, 1487

Gayang 3-dong, Gangseo-gu, Seoul www.swpharm.com

160 Taejoon Pharm. Co., Ltd. 82-2-798-6601 82-2-795-8873 657-87 Hannam-dong, Yongsan-gu, Seoul www.taejoon.co.kr

161 Taiguk Pharm. Co., Ltd. 82-80-3474-7761 82-2-3472-5501 Seowoo B/D 6F, Yeoksam-dong 837-12, Kangnam-gu, Seoul www.taiguk.co.kr

162 Takeda Pharmaceuticals Korea Co., Ltd. 82-2-3484-0800 82-2-3484-0808 12F KT&G Cosmodaechi Tower, 945-10

Daechi-dong, Gangnam-gu, Seoulwww. takeda-asia.com

163 TDSPHARM Co., Ltd. 82-31-8018-7337 - C-403 ,253, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do www.tdspharm.com

164 Teva-Handok. Co., Ltd. 82-2-521-5501 82-2-527-5510 132 Teheran-ro, Gangnam-gu, Seoul www. teva-hahdok.co.kr

165 Theragen Etex Pharm. Inc. 82-2- 3463-7111 82-2- 3463-8111 Kyunghee B/D 5F, 517-5 Dogok-dong, Gangnam-gu, Seoul www.etexpharm.com

166 UK Chemipharm Co., Ltd. 82-31-310-1983 82-31-310-1985 R38 6F Asandigital Park, 1123 Shingil-dong, Danwon-gu, Ansan-si, Kyunggi-do

www. ukchemipharm.com

167 Unimed Pharm. Inc. 82-2-2240-5100 82-2-2240-5115 Unimed B/D, 250-8 Jamsilbon-dong, Songpa-gu, Seoul www.unimed.co.kr

168 Union Korea Pharm. Co., Ltd. 82-2-489-3611 82-2-487-3611 Wonwae B/D 5F, 389-1 Poongnap 2-dong, Songpa-gu, Seoul www.ukp.co.kr

169 Whan In Pharm. Co., Ltd. 82-2-405-3000 82-2-404-2518 84-1 Munjeong-dong, Songpa-gu, Seoul www.whanin.com

170 White Global Pharmaceutical Corp. 82-2-541-4884 82-2-541-8448 621, Yeongdong-daero, Gangnam-gu, Seoul www.whpharma.com

171 Won Kwang Pharm. Co., Ltd 82-63-832-3114 82-63-833-4114 827 Shindong-ri, Chunpo-myeon, Iksan-si, Jeonrabuk-do

www. wonpharm.co.kr

172 Wooridul Pharmaceutical Ltd. 82-2-582-4211 82-2-582-566610F, Korea Fire Officials Credit Union Building, 274, Songpa-daero, Songpa-gu, Seoul

www.wooridulpharm.com

173 Yoo Young Pharm. Co., Ltd. 82-2-6207-6114 82-2-6207-6135 915-9 Bandbae 1-dong, Seocho-gu, Seoul www.yypharm.co.kr

174 Young Poong Pharm. Co., Ltd. 82-2-823-3251 82-2-821-2913 402-1 Daebang-dong, Dongjak-gu, Seoul www.yppharm.co.kr

175 Yuhan Corp. 82-2-828-0181 82-2-828-0300 49-6 Daebang-dong, Dongjak-gu, Seoul www.yuhan.co.kr

176 Yuil Pharm Tech. Co., Ltd. 82-43-537-2161 82-43-537-2163 365-1 Shinwon-ri, Iwol-myeon, Jincheon-gun, Chungcheongbuk-do www.yuilpharm.co.kr

177 Yungjin Pharm. Co., Ltd. 82-2-2041-8200 82-2-2041-8219 451-20 Chonho 3-dong, Gangdong-gu, Seoul www.yungjin.co.kr


MEMO MEMO


MEMO MEMO


MEMO


Documents

2018 DIRECTORY OF KOREAN PHARMACEUTICAL … · capabilities of Korean drug manufacturers, and has improved export conditions, including inspection exemptions of local drug manufacturing